,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,422,1,5,,17405462,4583,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
1,429,1,5,,17405462,4583,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
2,429,1,5,,17405462,4583,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
3,436,2,1,,17405462,4583,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
4,547,1,4,,17405462,4583,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
5,694,1,1,,17405462,4583,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
6,732,1,2,,17405462,4583,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
7,781,1,1,,11533038,4583,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
8,782,1,2,,11533038,4583,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
9,782,1,2,,11533038,4583,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
10,875,1,2,,26747609,4583,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
11,875,1,2,,26747610,4583,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
12,880,2,1,,11533038,4583,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
13,880,2,1,,11533038,4583,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
14,880,2,1,,26747609,4583,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
15,880,2,1,,26747609,4583,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
16,880,2,1,,26747610,4583,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
17,880,2,1,,26747610,4583,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
18,880,2,1,,50106760,4583,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
19,880,2,1,,50106760,4583,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
20,881,2,2,,26747609,4583,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
21,881,2,2,,26747610,4583,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
22,884,1,2,,26747609,4583,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
23,884,1,2,,26747610,4583,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
24,885,1,2,,26747609,4583,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
25,885,1,2,,26747610,4583,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
26,887,1,2,,26747609,4583,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
27,887,1,2,,26747610,4583,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
28,889,1,3,,26747609,4583,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
29,889,1,3,,26747610,4583,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
30,892,1,2,,26747609,4583,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
31,892,1,2,,26747610,4583,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
32,893,1,2,,26747609,4583,Active,122921310.0,,10.0,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
33,893,1,2,,26747609,4583,Active,122921311.0,,10.0,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
34,893,1,2,,26747610,4583,Active,122921310.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
35,893,1,2,,26747610,4583,Active,122921311.0,,25.1189,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
36,894,2,1,,26747609,4583,Inconclusive,31542939.0,3248.0,3.1623,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
37,894,2,1,,26747610,4583,Inconclusive,31542939.0,3248.0,25.1189,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
38,894,2,1,,50106760,4583,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
39,900,1,3,,26747609,4583,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
40,900,1,3,,26747610,4583,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
41,902,1,2,,26747609,4583,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
42,902,1,2,,26747610,4583,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
43,910,1,2,,26747609,4583,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
44,910,1,2,,26747610,4583,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
45,923,1,2,,26747609,4583,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
46,923,1,2,,26747610,4583,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
47,924,1,2,,26747609,4583,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
48,924,1,2,,26747610,4583,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
49,927,1,3,,26747609,4583,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
50,927,1,3,,26747610,4583,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
51,930,1,2,,26747609,4583,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
52,930,1,2,,26747610,4583,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
53,940,1,2,,11533038,4583,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
54,940,1,2,,17405462,4583,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
55,940,1,2,,26612280,4583,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
56,995,1,2,,26747609,4583,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
57,995,1,2,,26747610,4583,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
58,1021,1,1,,11533038,4583,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
59,1022,1,1,,11533038,4583,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
60,1030,2,1,,26747609,4583,Inconclusive,30582681.0,216.0,25.1189,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
61,1030,2,1,,26747610,4583,Inconclusive,30582681.0,216.0,31.6228,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
62,1030,2,1,,50106760,4583,Inconclusive,30582681.0,216.0,19.9526,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
63,1085,1,1,,11533038,4583,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
64,1236,1,1,,11533038,4583,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
65,1274,1,2,,11533038,4583,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
66,1276,1,1,,11533038,4583,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
67,1285,1,1,,11533038,4583,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
68,1332,1,1,,49699069,4583,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
69,1376,1,2,,11533038,4583,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
70,1379,1,2,,26747609,4583,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
71,1379,1,2,,26747610,4583,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
72,1379,1,2,,50106760,4583,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
73,1385,2,2,,11533038,4583,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
74,1422,1,1,,11533038,4583,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
75,1422,1,1,,17405462,4583,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
76,1422,1,1,,26612280,4583,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
77,1452,1,1,,26747609,4583,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
78,1452,1,1,,26747610,4583,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
79,1454,1,1,,11533038,4583,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
80,1454,1,1,,26747609,4583,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
81,1454,1,1,,26747610,4583,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
82,1454,1,1,,50106760,4583,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
83,1457,1,1,,26747609,4583,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
84,1457,1,1,,26747610,4583,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
85,1457,1,1,,50106760,4583,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
86,1458,1,1,,26747609,4583,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
87,1458,1,1,,26747610,4583,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
88,1458,1,1,,50106760,4583,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
89,1459,1,1,,50106760,4583,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
90,1460,1,3,,11533038,4583,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
91,1460,1,3,,26747609,4583,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
92,1460,1,3,,26747610,4583,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
93,1460,1,3,,50106760,4583,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
94,1461,1,2,,11533038,4583,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
95,1461,1,2,,50106760,4583,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
96,1463,1,1,,11533038,4583,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
97,1463,1,1,,26747609,4583,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
98,1463,1,1,,26747610,4583,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
99,1463,1,1,,50106760,4583,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
100,1465,1,1,,11533038,4583,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
101,1466,1,2,,11533038,4583,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
102,1467,1,3,,11533038,4583,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
103,1467,1,3,,26747609,4583,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
104,1467,1,3,,26747610,4583,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
105,1467,1,3,,50106760,4583,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
106,1468,1,1,,11533038,4583,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
107,1468,1,1,,26747609,4583,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
108,1468,1,1,,26747610,4583,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
109,1468,1,1,,50106760,4583,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
110,1469,1,1,,11533038,4583,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
111,1469,1,1,,26747609,4583,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
112,1469,1,1,,26747610,4583,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
113,1469,1,1,,50106760,4583,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
114,1471,2,1,,26747609,4583,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
115,1471,2,1,,26747610,4583,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
116,1476,2,1,,26747609,4583,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
117,1476,2,1,,26747610,4583,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
118,1476,2,1,,50106760,4583,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
119,1477,1,1,,11533038,4583,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
120,1477,1,1,,26747609,4583,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
121,1477,1,1,,26747610,4583,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
122,1477,1,1,,50106760,4583,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
123,1478,2,1,,26747609,4583,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
124,1478,2,1,,26747610,4583,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
125,1478,2,1,,50106760,4583,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
126,1479,1,2,,11533038,4583,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
127,1479,1,2,,26747609,4583,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
128,1479,1,2,,26747610,4583,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
129,1479,1,2,,50106760,4583,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
130,1487,1,1,,11533038,4583,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
131,1487,1,1,,50106760,4583,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
132,1490,2,1,,11533038,4583,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
133,1490,2,1,,26747609,4583,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
134,1490,2,1,,26747610,4583,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
135,1511,1,3,,11533038,4583,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
136,1519,1,3,,26747609,4583,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
137,1519,1,3,,26747610,4583,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
138,1519,1,3,,50106760,4583,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
139,1529,1,1,,11533038,4583,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
140,1530,1,1,,11533038,4583,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
141,1531,1,1,,11533038,4583,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
142,1532,1,1,,11533038,4583,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
143,1554,1,1,,11533038,4583,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
144,1580,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
145,1581,1,1,,8149812,4583,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
146,1582,1,1,,8149812,4583,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
147,1583,1,1,,8149812,4583,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
148,1584,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
149,1585,1,1,,8149812,4583,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
150,1586,1,1,,8149812,4583,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
151,1587,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
152,1588,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
153,1589,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
154,1590,1,1,,8149812,4583,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
155,1593,1,1,,8149812,4583,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
156,1594,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
157,1595,1,1,,8149812,4583,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
158,1596,1,1,,8149812,4583,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
159,1597,1,1,,8149812,4583,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
160,1598,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
161,1599,1,1,,8149812,4583,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
162,1600,1,1,,8149812,4583,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
163,1601,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
164,1602,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
165,1603,1,1,,8149812,4583,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
166,1604,1,1,,8149812,4583,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
167,1605,1,1,,8149812,4583,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
168,1606,1,1,,8149812,4583,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
169,1607,1,1,,8149812,4583,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
170,1608,1,1,,8149812,4583,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
171,1609,1,1,,8149812,4583,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
172,1610,1,1,,8149812,4583,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
173,1612,1,1,,8149812,4583,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
174,1613,1,1,,8149812,4583,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
175,1614,1,1,,8149812,4583,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
176,1616,1,1,,8149812,4583,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
177,1621,1,2,,11533038,4583,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
178,1626,1,2,,11533038,4583,Inconclusive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
179,1631,3,1,,11533038,4583,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
180,1634,3,1,,11533038,4583,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
181,1662,1,2,,11533038,4583,Active,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
182,1663,1,2,,11533038,4583,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
183,1672,1,3,,11533038,4583,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
184,1705,1,2,,50106760,4583,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
185,1707,1,3,,50106760,4583,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
186,1708,1,3,,50106760,4583,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
187,1721,1,2,,11533038,4583,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
188,1722,1,2,,11533038,4583,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
189,1766,1,1,,11533038,4583,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
190,1766,1,1,,11533038,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
191,1766,1,1,,26747609,4583,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
192,1766,1,1,,26747609,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
193,1766,1,1,,26747610,4583,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
194,1766,1,1,,26747610,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
195,1766,1,1,,50106760,4583,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
196,1766,1,1,,50106760,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
197,1768,1,1,,11533038,4583,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
198,1768,1,1,,11533038,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
199,1768,1,1,,26747609,4583,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
200,1768,1,1,,26747609,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
201,1768,1,1,,26747610,4583,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
202,1768,1,1,,26747610,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
203,1768,1,1,,50106760,4583,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
204,1768,1,1,,50106760,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
205,1813,1,2,,11533038,4583,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
206,1814,1,2,,11533038,4583,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
207,1815,1,1,,50106760,4583,Inconclusive,,,10.0,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
208,1816,1,1,,50106760,4583,Inconclusive,,,8.9125,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
209,1828,2,1,,50106760,4583,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
210,1832,2,1,,11533038,4583,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
211,1850,2,1,,56423109,4583,Active,,,0.31,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
212,1862,1,4,,11533038,4583,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
213,1863,2,1,,56423109,4583,Active,,,0.39,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
214,1865,1,1,,11533038,4583,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
215,1865,1,1,,26747609,4583,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
216,1865,1,1,,26747610,4583,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
217,1865,1,1,,50106760,4583,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
218,1867,1,4,,11533038,4583,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
219,1868,1,4,,11533038,4583,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
220,1870,1,4,,11533038,4583,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
221,1873,1,4,,11533038,4583,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
222,1875,2,1,,11533038,4583,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
223,1876,1,1,,50106760,4583,Inconclusive,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
224,1877,1,1,,50106760,4583,Inconclusive,,,8.9125,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
225,1882,1,1,,50106760,4583,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
226,1883,1,1,,50106760,4583,Active,,,14.1254,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
227,1885,2,1,,11533038,4583,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
228,1886,1,1,,50106760,4583,Inconclusive,,,10.0,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
229,1887,1,4,,11533038,4583,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
230,1899,1,3,,56423109,4583,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
231,1900,1,1,,11533038,4583,Active,,,3.033,EC50,Luminescence Microorganism-Based Dose Confirmation HTS to Identify Compounds Cytotoxic to SK(-)GAS Group A Streptococcus,Confirmatory,,
232,1902,1,1,,11533038,4583,Active,15675770.0,901648.0,3.694,EC50,Luminescence Microorganism-Based Dose Confirmation HTS to Identify Inhibitors of Streptokinase Promotor Activity,Confirmatory,,
233,1903,2,3,,56423109,4583,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
234,1906,1,3,,56423109,4583,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
235,1910,1,2,,11533038,4583,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
236,1914,1,2,,11533038,4583,Inconclusive,15675770.0,901648.0,,EC50,Absorbance Microorganism-Based Dose Response HTS to Identify Inhibitors of Streptokinase Expression,Confirmatory,,
237,1915,1,2,,11533038,4583,Active,,,4.106,EC50,Luminescence Microorganism-Based Dose Response HTS to Identify Compounds Cytotoxic to Streptococcus,Confirmatory,,
238,1947,1,2,,56423109,4583,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
239,1948,1,1,,26747609,4583,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
240,1948,1,1,,26747610,4583,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
241,1948,1,1,,50106760,4583,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
242,1950,1,3,,56423109,4583,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
243,1956,1,1,,11533038,4583,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
244,1962,1,2,,56423109,4583,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
245,1967,1,1,,85231170,4583,Inactive,4505907.0,5376.0,,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
246,1974,1,2,,56423109,4583,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
247,1979,1,1,,11533038,4583,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
248,1981,2,1,,56423109,4583,Active,,,0.56,IC50,A screen for inhibitors of the PhoP regulon in Salmonella Typhimurium using a modified counterscreen.,Confirmatory,,
249,1985,2,1,,56423109,4583,Active,,,0.23,IC50,A screen for inhibitors of the PhoP regulon in Salmonella Typhi using a modified counterscreen,Confirmatory,,
250,1987,1,2,,56423109,4583,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
251,2016,1,3,,56423109,4583,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
252,2023,1,3,,56423109,4583,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
253,2025,1,3,,56423109,4583,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
254,2029,1,3,,56423109,4583,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
255,2052,2,1,,56423109,4583,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
256,2057,1,2,,56423109,4583,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
257,2066,1,4,,56423109,4583,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
258,2094,1,2,,11533038,4583,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
259,2094,1,2,,11533038,4583,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
260,2094,1,2,,11533038,4583,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
261,2097,1,2,,11533038,4583,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
262,2098,1,1,,11533038,4583,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
263,2099,1,1,,11533038,4583,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
264,2100,1,1,,11533038,4583,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
265,2101,1,1,,11533038,4583,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
266,2101,1,1,,26747609,4583,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
267,2101,1,1,,26747610,4583,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
268,2101,1,1,,50106760,4583,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
269,2107,1,1,,11533038,4583,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
270,2107,1,1,,26747609,4583,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
271,2107,1,1,,26747610,4583,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
272,2107,1,1,,50106760,4583,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
273,2112,1,1,,11533038,4583,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
274,2112,1,1,,26747609,4583,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
275,2112,1,1,,26747610,4583,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
276,2112,1,1,,50106760,4583,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
277,2129,1,2,,56423109,4583,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
278,2130,1,3,,56423109,4583,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
279,2147,1,1,,11533038,4583,Inconclusive,221046486.0,,3.1623,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
280,2147,1,1,,26747609,4583,Inconclusive,221046486.0,,22.3872,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
281,2147,1,1,,26747610,4583,Inconclusive,221046486.0,,28.1838,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
282,2147,1,1,,50106760,4583,Inconclusive,221046486.0,,15.8489,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
283,2156,2,2,,11533038,4583,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
284,2174,1,3,,56423109,4583,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
285,2177,1,3,,56423109,4583,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
286,2216,1,3,,11533038,4583,Inconclusive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
287,2221,1,2,,11533038,4583,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
288,2227,1,2,,11533038,4583,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
289,2234,1,2,,56423109,4583,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
290,2235,1,2,,56423109,4583,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
291,2237,1,2,,11533038,4583,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
292,2239,1,2,,11533038,4583,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
293,2240,1,1,,85788436,4583,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
294,2241,1,1,,85788436,4583,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
295,2242,1,1,,11533038,4583,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
296,2247,1,2,,11533038,4583,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
297,2252,1,1,,56423109,4583,Inactive,,,,EC50,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen,Confirmatory,,
298,2253,1,1,,56423109,4583,Inactive,,,,EC50,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhimurium identified in the primary screen,Confirmatory,,
299,2275,1,1,,85788436,4583,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
300,2280,2,3,,56423109,4583,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
301,2288,1,1,,11533038,4583,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
302,2289,1,1,,11533038,4583,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
303,2300,1,3,,56423109,4583,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
304,2313,1,1,,85788436,4583,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
305,2314,1,2,,11533038,4583,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
306,2314,1,2,,11533038,4583,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
307,2315,1,2,,11533038,4583,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
308,2315,1,2,,11533038,4583,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
309,2322,1,1,,85788436,4583,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
310,2323,1,1,,50106760,4583,Inactive,254220970.0,,31.6228,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
311,2326,1,1,,11533038,4583,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
312,2326,1,1,,50106760,4583,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
313,2330,1,1,,85788436,4583,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
314,2353,1,3,,50106760,4583,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
315,2364,1,2,,50106760,4583,Inactive,4557365.0,641.0,,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
316,2380,1,2,,56423109,4583,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
317,2384,1,1,,56423109,4583,Active,,,1.73,IC50,A counter screen for small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
318,2391,1,1,,56423109,4583,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
319,2401,1,2,,56423109,4583,Active,,,0.8,IC50,A Counter Screen to identiry small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
320,2435,1,2,,56423109,4583,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
321,2445,1,2,,56423109,4583,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
322,2451,1,2,,11533038,4583,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
323,2451,1,2,,26747609,4583,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
324,2451,1,2,,26747610,4583,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
325,2451,1,2,,50106760,4583,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
326,2462,1,1,,56423109,4583,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
327,2462,1,1,,56423109,4583,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
328,2472,1,2,,11533038,4583,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
329,2472,1,2,,26747609,4583,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
330,2472,1,2,,26747610,4583,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
331,2517,2,1,,11533038,4583,Inactive,6980812.0,,112.20200000000001,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
332,2517,2,1,,26747609,4583,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
333,2517,2,1,,26747610,4583,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
334,2517,2,1,,50106760,4583,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
335,2517,2,1,,144204254,4583,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
336,2520,1,4,,56423109,4583,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
337,2521,1,3,,56423109,4583,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
338,2523,1,1,,11533038,4583,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
339,2524,1,2,,56423109,4583,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
340,2528,1,2,,11533038,4583,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
341,2528,1,2,,26747609,4583,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
342,2528,1,2,,26747610,4583,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
343,2528,1,2,,50106760,4583,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
344,2540,1,2,,56423109,4583,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
345,2544,1,2,,56423109,4583,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
346,2546,1,1,,11533038,4583,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
347,2546,1,1,,26747609,4583,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
348,2546,1,1,,26747610,4583,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
349,2549,1,1,,11533038,4583,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
350,2549,1,1,,26747609,4583,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
351,2549,1,1,,26747610,4583,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
352,2549,1,1,,50106760,4583,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
353,2550,1,3,,11533038,4583,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
354,2551,1,1,,11533038,4583,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
355,2551,1,1,,26747609,4583,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
356,2551,1,1,,26747610,4583,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
357,2553,1,2,,11533038,4583,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
358,2557,1,3,,56423109,4583,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
359,2563,1,1,,11533038,4583,Active,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
360,2599,1,2,,56423109,4583,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
361,2606,1,2,,56423109,4583,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
362,2629,1,1,,56423109,4583,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
363,2642,1,2,,11533038,4583,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
364,2648,1,2,,11533038,4583,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
365,2650,2,1,,56423109,4583,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
366,2660,1,1,,90341488,4583,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
367,2661,1,1,,56423109,4583,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
368,2662,2,1,,11533038,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
369,2662,2,1,,85231170,4583,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
370,2666,1,1,,90341488,4583,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
371,2667,1,1,,90341488,4583,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
372,2668,1,1,,90341488,4583,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
373,2674,1,1,,11533038,4583,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
374,2675,1,1,,11533038,4583,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
375,2675,1,1,,50106760,4583,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
376,2676,1,2,,11533038,4583,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
377,2685,1,1,,11533038,4583,Inconclusive,,,1.1582,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
378,2690,1,2,,56423109,4583,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
379,2706,1,1,,11533038,4583,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
380,2716,1,1,,56423109,4583,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
381,2717,1,2,,56423109,4583,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
382,2718,1,1,,56423109,4583,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
383,2732,1,1,,11533038,4583,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
384,2732,1,1,,17405462,4583,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
385,2751,2,2,,56423109,4583,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
386,2774,1,3,,92304364,4583,Inactive,,,,,LOPAC Circadian Assay,Screening,,
387,2796,1,4,,56423109,4583,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
388,2797,1,2,,56423109,4583,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
389,2805,2,2,,56423109,4583,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
390,2806,2,2,,56423109,4583,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
391,2825,1,2,,56423109,4583,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
392,9222,6,2,,103163813,4583,Unspecified,,,,,Activity against Acinetobacter calcoaceticus (AC54),Other,2163456.0,
393,17991,3,3,,103163813,4583,Unspecified,,,,,Bioavailability,Other,12873497.0,
394,28851,5,2,,103163813,4583,Unspecified,,,,,The compound was evaluated for the solubility in water at 25 degrees Centigrade,Other,8388467.0,
395,28899,4,1,,103163813,4583,Unspecified,,,,,Calculated partition coefficient (clogP),Other,8388467.0,
396,30399,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Acinetobacter calcoaceticus No.4,Other,9873632.0,
397,30407,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Acinetobacter calcoaceticus 15473 strain.,Other,,
398,30416,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the acinetobacter sp. CMX 669 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
399,38471,6,2,,103163813,4583,Unspecified,,,,,Activity against Bacillus subtilis (ATCC 6633),Other,2163456.0,
400,40786,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Bacillus subtilis ATCC 6633 strain.,Other,,
401,40925,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Bacillus subtilis ATCC 6633 by agar dilution method,Other,8410985.0,
402,41268,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Bacteroides fragilis (ATCC 25285),Other,2842501.0,
403,43924,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Burkholderia cepacia 23,Other,9873632.0,
404,51918,7,2,,103163813,4583,Unspecified,,,,,Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity),Other,1469702.0,
405,52922,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Citrobacter diversus 2046E strain.,Other,,
406,52937,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Citrobacter freundii KP-29,Other,9873632.0,
407,52938,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Citrobacter freundii No.7,Other,9873632.0,
408,53311,6,2,,103163813,4583,Unspecified,,,,,Inhibitory effect on DNA gyrase supercoiling activity from Escherichia coli K-12 C600,Other,2163456.0,
409,53321,6,5,,103163813,4583,Unspecified,,,,,Inhibition of DNA gyrase supercoiling in Escherichia coli.,Other,9871636.0,
410,63896,6,2,,103163813,4583,Unspecified,,,,,Activity against Enterobacter aerogenes (ATCC 13048),Other,2163456.0,
411,64252,6,2,,103163813,4583,Unspecified,,,,,Activity against Escherichia coli (K-12 C600),Other,2163456.0,
412,64253,6,2,,103163813,4583,Unspecified,,,,,Activity against Escherichia coli (KC-14),Other,2163456.0,
413,64884,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro for antibacterial activity against Escherichia coli (KC-14),Other,8230101.0,
414,64885,6,2,,103163813,4583,Unspecified,,,,,Tested for inhibitory activity against DNA gyrase supercoiling in Escherichia coli (KL-16),Other,8230101.0,
415,64889,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro for antibacterial activity agains Escherichia coli (NIHJ JC-2),Other,8230101.0,
416,65203,6,2,,103163813,4583,Unspecified,,,,,Minimum inhibitory concentration against Escherichia coli KC14 strain,Other,8388467.0,
417,65221,6,2,,103163813,4583,Unspecified,,,,,Minimum inhibition concentration against Escherichia coli NIHJ JC-2 strain,Other,8388467.0,
418,65376,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro for antibacterial activity agains Enterococcus faecalis (IID 682),Other,8230101.0,
419,65384,6,2,,103163813,4583,Unspecified,,,,,Minimum inhibition concentration against Enterococcus faecalis LS-101 strain,Other,8388467.0,
420,67215,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Enterococcus faecalis 1373,Other,9873632.0,
421,67217,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against gram-positive Ef Enterococcus faecalis IID 682.,Other,8126698.0,
422,67219,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Enterococcus faecalis IID682 (Ef),Other,8064806.0,
423,67422,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against E. Faecalis IID682,Other,8410974.0,
424,67531,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Entero. cloacae,Other,3172136.0,
425,67545,8,1,,103163813,4583,Unspecified,,,,,Activity against Enterobacter aerogenes,Other,12873497.0,
426,67549,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the enterobacter aerogenes ATCC 13048 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
427,67755,5,3,,103163813,4583,Unspecified,,,,,Minimum inhibitory concentration in vitro against Enterococcus faecalis LS-101,Other,,
428,68013,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterobacter cloacae MA2646,Other,3346869.0,
429,68172,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Enterobacter cloacae Nek39,Other,9873632.0,
430,68183,6,2,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Enterobacter cloacae HA 2646,Other,2374153.0,
431,68191,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Enterobacter cloacae 963,Other,2342057.0,
432,68201,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against clinical isolates of Enterobacter cloacae 041 (gram negative) by agar dilution assay.,Other,3820216.0,
433,68372,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Enterobacter cloacae 1194E strain.,Other,,
434,68373,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Enterobacter cloacae p99 strain.,Other,,
435,68846,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Escherichia coli KC-14,Other,8410974.0,
436,68848,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Escherichia coli NIHJ JC-2,Other,8410974.0,
437,68849,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Escherichia coli (ATCC 1-25922),Other,2842501.0,
438,68865,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Escherichia coli 10536 strain,Other,,
439,68866,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Escherichia coli 3190Y strain.,Other,,
440,68867,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Escherichia coli 851E strain.,Other,,
441,68868,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Escherichia coli TEM5 3739E strain.,Other,,
442,68869,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Escherichia coli TEM9 2639E strain.,Other,,
443,68976,6,2,,103163813,4583,Unspecified,,,,,Minimum concentration of the drug needed to produce linear DNA at an intensity relative to oxolinic acid(at 10 ug/mL),Other,3172136.0,
444,69479,8,1,,103163813,4583,Active,,,,,Minimum inhibitory concentration against Escherichia coli ATCC 25922,Other,12729630.0,
445,69619,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli H560,Other,3346869.0,
446,69626,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli Vogel,Other,3346869.0,
447,69641,5,3,,103163813,4583,Unspecified,,,,,Minimum inhibitory concentration in vitro against Escherichia coli NIHJ JC-2,Other,,
448,69782,6,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli (H560),Other,3005575.0,
449,69784,6,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli (vogel),Other,3005575.0,
450,69799,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Escherichia coli KL-16 in the absence of polymyxin B nonapeptide (PBMN) at 0 ug/mL,Other,,
451,69800,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Escherichia coli KL-16 in the presence of polymyxin B nonapeptide (PBMN) at 1 ug/mL,Other,,
452,69801,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Escherichia coli-ss in the absence of polymyxin B nonapeptide (PBMN) at 0 ug/mL,Other,,
453,69802,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Escherichia coli-ss in the presence of polymyxin B nonapeptide (PBMN) at 1 ug/mL,Other,,
454,69826,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Escherichia coli NIHJ JC-2 by agar dilution method,Other,8410985.0,
455,69951,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the Escherichia coli H560 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
456,69952,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the Escherichia coli JUHL by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
457,70426,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Escherichia coli CSH2/RE45,Other,9873632.0,
458,70427,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Escherichia coli CSH2/RK1,Other,9873632.0,
459,70428,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Escherichia coli ML4707,Other,9873632.0,
460,70429,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Escherichia coli NIHJ JC-2,Other,9873632.0,
461,70564,6,2,,103163813,4583,Unspecified,,,,,"Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-negative Ec(K), Escherichia coli KC-14.",Other,8126698.0,
462,70566,6,2,,103163813,4583,Unspecified,,,,,"Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-negative Ec(N), Escherichia coli NIHJ JC-2.",Other,8126698.0,
463,70570,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Escherichia coli H560,Other,3007757.0,
464,70571,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Escherichia coli vogel,Other,3007757.0,
465,70575,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Escherichia coli KC-14 (Ec(K)),Other,8064806.0,
466,70576,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Escherichia coli NIHJ JC-2 (Ec(N)),Other,8064806.0,
467,70721,6,2,,103163813,4583,Unspecified,,,,,Evaluated for minimum concentration needed to produce linear DNA at an intensity relative to oxolinic acid at 10 mg/mL. by gyrase mediated cleavage of DNA in Escherichia coli 560.,Other,2374153.0,
468,70735,6,2,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Escherichia coli Vogel,Other,2374153.0,
469,70770,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Escherichia coli H560,Other,3172136.0,
470,70781,7,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli NIH JC-2,Other,1335082.0,
471,70804,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Escherichia coli vogel,Other,3172136.0,
472,70860,6,3,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Escherichia cloacae HA 2646,Other,3007757.0,
473,70926,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli P-5101,Other,2342057.0,
474,70947,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against clinical isolates of Escherichia coli 15 (gram negative) by agar dilution assay.,Other,3820216.0,
475,71070,5,1,,103163813,4583,Unspecified,,,,,Concentration required to produce linear DNA from closed circular DNA by the denaturation of the drug-gyrase-DNA complex,Other,3346869.0,
476,71793,3,6,,103163813,4583,Unspecified,,,,,Percentage of GABA-induced chloride currents with 10 e-5 M 4-biphenylacetic acid,Other,8388467.0,
477,71794,3,6,,103163813,4583,Unspecified,,,,,Percentage of GABA-induced chloride currents with 10e-4 M 4-biphenylacetic acid,Other,8388467.0,
478,71795,3,6,,103163813,4583,Unspecified,,,,,Percentage of GABA-induced chloride currents with compound alone at 10 e-4 M,Other,8388467.0,
479,71980,9,2,,103163813,4583,Active,,,11.0,IC50,Inhibition of [3H]muscimol binding to GABA A receptor 4-biphenylacetic acid at 10 e-4 M,Confirmatory,8388467.0,
480,71981,9,2,,103163813,4583,Unspecified,,,100.0,IC50,Inhibition of [3H]muscimol binding to GABA A receptor with compound alone at 10 e-4 M,Confirmatory,8388467.0,
481,74727,7,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against five Gram-negative bacteria,Other,1469702.0,
482,74853,7,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against five Gram-positive bacteria targeting topoisomerase II (DNA gyrase B GyrB),Other,1469702.0,
483,78545,6,5,,103163813,4583,Unspecified,,,,,Concentration facilitating 50% of the maximum of the cleavable complex,Other,,
484,78688,6,5,,103163813,4583,Unspecified,,,,,Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay,Other,3005575.0,
485,78692,6,5,,103163813,4583,Unspecified,,,,,50% inhibitory concentration against DNA-gyrase,Other,3346869.0,
486,78695,6,4,,103163813,4583,Unspecified,,,,,Gyrase inhibitory activity against Escherichia coli,Other,2842501.0,
487,78696,6,6,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity was determined as inhibitory concentration causing 50% DNA-gyrase supercoiling inhibition (SCI),Other,,
488,78705,5,1,,103163813,4583,Unspecified,,,,,Inhibition constant against DNA Gyrase isolated from Escherichia coli,Other,2824776.0,
489,78707,6,4,,103163813,4583,Unspecified,,,,,MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay,Other,3005575.0,
490,78709,5,1,,103163813,4583,Unspecified,,,,,Inhibition of DNA gyrase of Escherichia coli H560 cells,Other,3007757.0,
491,78715,5,1,,103163813,4583,Unspecified,,,,,Inhibition constant against DNA Gyrase isolated from Micrococcus luteus,Other,2824776.0,
492,94051,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Klebsiella pneumoniae PCI-602 by agar dilution method,Other,8410985.0,
493,94137,6,2,,103163813,4583,Unspecified,,,,,Activity against Klebsiella pneumoniae (PCI-602),Other,2163456.0,
494,94363,7,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Klebsiella pneumoniae K-1966,Other,1335082.0,
495,95540,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro for antibacterial activity against Klebsiella pneumoniae (B54),Other,8230101.0,
496,95724,6,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Klebsiella aerogenes 1076E strain.,Other,,
497,95725,6,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Klebsiella aerogenes 1082E strain.,Other,,
498,95735,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Klebsiella oxytoca GN 10650,Other,9873632.0,
499,95885,6,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumonia (MGH-2),Other,3005575.0,
500,95891,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Klebsiella pneumonia,Other,3172136.0,
501,95916,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae MGH-2,Other,3346869.0,
502,96075,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the klebsiella pneumoniae 8045 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
503,96098,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Klebsiella pneumoniae KC-1,Other,9873632.0,
504,96099,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Klebsiella pneumoniae No.42,Other,9873632.0,
505,96228,6,2,,103163813,4583,Unspecified,,,,,"Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-negative Kp, Klebsiella pneumoniae B54.",Other,8126698.0,
506,96229,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Klebsiella pneumoniae MGH-2,Other,3007757.0,
507,96230,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Klebsiella pneumoniae B54 (Kp),Other,8064806.0,
508,96239,6,2,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Klebsiella pneumoniae MGH-2,Other,2374153.0,
509,96249,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Klebsiella pneumoniae 13,Other,2342057.0,
510,96264,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against clinical isolates of Klebsiella pneumoniae-4 (gram negative) by agar dilution assay.,Other,3820216.0,
511,96421,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Klebsiella pneumoniae B54,Other,8410974.0,
512,105366,6,2,,103163813,4583,Unspecified,,,200.0,CC50,Concentration required to reduce the viability of mock-infected MT-4 cells by 50%,Confirmatory,10397494.0,
513,110152,3,3,,103163813,4583,Unspecified,,,,,Percentage of mice with convulsion (400 mg/kg fenbufen),Other,8388467.0,
514,110153,3,3,,103163813,4583,Unspecified,,,,,Percentage of mice with convulsion with compound alone at 400 mg/kg,Other,8388467.0,
515,114659,6,2,,103163813,4583,Unspecified,,,,,Compound was evaluated for oral efficacy on systemic infections in mice by Escherichia coli KC-14,Other,1335082.0,
516,114660,6,2,,103163813,4583,Unspecified,,,,,Compound was evaluated for oral Pseudomonas aeruginosa E-2,Other,1335082.0,
517,117674,7,1,,103163813,4583,Unspecified,,,,,"Median protective dose against Escherichia coli, determined in acute, lethal systemic infection in female charles river CD-1 mice (po)",Other,3346869.0,
518,117675,3,3,,103163813,4583,Unspecified,,,,,"Median protective dose against Escherichia coli, determined in acute, lethal systemic infection in female charles river CD-1 mice (sc)",Other,3346869.0,
519,122920,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the micrococcus luteus 9341 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
520,122923,6,2,,103163813,4583,Unspecified,,,,,"Minimum inhibitory concentration against gram-positive MI, Micrococcus luteus ATCC 9341.",Other,8126698.0,
521,122925,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Micrococcus luteus ATCC 9341 (MI),Other,8064806.0,
522,123085,7,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Micrococcus luteus ATCC 9341,Other,1335082.0,
523,125769,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Micrococcus luteus ATCC 9341 strain.,Other,,
524,127505,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against glucose nonfermenter Moraxella bovis P-7101,Other,2342057.0,
525,128018,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for Therapeutic effects on systemic infections on mice by peroral administration,Other,8064806.0,
526,131001,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for oral efficacy on systemic infections caused by Escherichia coli KC-14 in mice,Other,8126698.0,
527,131003,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for oral efficacy on systemic infections caused by Staphylococcus aureus IID803 in mice,Other,8126698.0,
528,131005,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for oral efficacy on systemic infections on mice by peroral administration,Other,8064806.0,
529,131400,6,2,,103163813,4583,Unspecified,,,,,Oral efficacy against Pseudomonas aeruginosa 12 on Systemic Infections in Mice,Other,2342057.0,
530,131401,6,2,,103163813,4583,Unspecified,,,,,Oral efficacy against Streptococcus pyogenes A65 on Systemic Infections in Mice,Other,2342057.0,
531,131700,4,2,,103163813,4583,Unspecified,,,,,Effective dose against Escherichia coli KC14 strain in mouse,Other,8388467.0,
532,131701,4,2,,103163813,4583,Unspecified,,,,,Effective dose against Staphylococcus aureus smith strain in mouse,Other,8388467.0,
533,133807,3,3,,103163813,4583,Unspecified,,,,,Compound was evaluated for protective dose against Streptococcus pneumoniae SV-1 lethal infection following sc administration,Other,3007757.0,
534,133810,3,3,,103163813,4583,Unspecified,,,,,Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following peroral administration in mouse,Other,3007757.0,
535,133812,3,3,,103163813,4583,Unspecified,,,,,Compound was evaluated for protective dose against the Escherichia coli vogel lethal infection following sc administration in mouse,Other,3007757.0,
536,133813,3,3,,103163813,4583,Unspecified,,,,,Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following po administration in mouse,Other,3007757.0,
537,133815,3,3,,103163813,4583,Unspecified,,,,,Compound was evaluated for protective dose against the Streptococcus aureus UC-76 lethal infection following sc administration in mouse,Other,3007757.0,
538,133817,3,3,,103163813,4583,Unspecified,,,,,Compound was evaluated for protective dose against the Streptococcus pneumoniae SV-1 lethal infection following po administration,Other,3007757.0,
539,133953,3,3,,103163813,4583,Unspecified,,,,,In vivo antibacterial activity against Escherichia coli (Vogel) in mice administered perorally,Other,2842501.0,
540,133954,3,3,,103163813,4583,Unspecified,,,,,In vivo antibacterial activity against Escherichia coli (Vogel) in mice administered subcutaneously,Other,2842501.0,
541,133979,3,4,,103163813,4583,Unspecified,,,,,In vivo protective dose (PD50) in mice against Escherichia coli Vogel when administered perorally,Other,3172136.0,
542,133980,3,4,,103163813,4583,Unspecified,,,,,In vivo protective dose (PD50) in mice against Escherichia coli Vogel when administered subcutaneously,Other,3172136.0,
543,135327,6,1,,103163813,4583,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
544,143107,7,1,,103163813,4583,Active,,,3.0,MIC50,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis ATCC 27294 by 50%,Confirmatory,10397494.0,
545,143108,7,1,,103163813,4583,Active,,,2.0,MIC50,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis clinical isolate 1104 by 50%,Confirmatory,10397494.0,
546,143121,7,2,,103163813,4583,Active,,,,,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis ATCC 27294 by 90%,Other,10397494.0,
547,143122,7,2,,103163813,4583,Active,,,,,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium tuberculosis clinical isolate 1104 by 90%,Other,10397494.0,
548,143859,7,1,,103163813,4583,Active,,,1.5,MIC50,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium avium complex (MAC) ATCC 49601 by 50%,Confirmatory,10397494.0,
549,143862,7,2,,103163813,4583,Active,,,,,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium avium complex (MAC) ATCC 49601 by 90%,Other,10397494.0,
550,144017,7,1,,103163813,4583,Active,,,2.0,MIC50,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium fortuitum (clinical isolate) by 50%,Confirmatory,10397494.0,
551,144019,7,2,,103163813,4583,Active,,,,,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium fortuitum (clinical isolate) by 90%,Other,10397494.0,
552,144565,7,1,,103163813,4583,Active,,,2.0,MIC50,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium smegmatis ATCC 19420 by 50%,Confirmatory,10397494.0,
553,144567,7,2,,103163813,4583,Active,,,,,Minimum inhibitory concentration required in vitro to reduce the number of viable of Mycobacterium smegmatis ATCC 19420 by 90%,Other,10397494.0,
554,151057,6,2,,103163813,4583,Unspecified,,,,,Activity against Pseudomonas aeruginosa (E-2),Other,2163456.0,
555,151194,6,2,,103163813,4583,Unspecified,,,,,Activity against Pseudomonas cepacia (IID-1341),Other,2163456.0,
556,151530,6,2,,103163813,4583,Unspecified,,,,,Tested in vivo against Pseudomonas aeruginosa E-2 in mice after peroral dose of drug with 0.5% sodium carboxy methyl cellulose,Other,8410985.0,
557,151535,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Pseudomonas aeruginosa E-2 by agar dilution method,Other,8410985.0,
558,151536,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Pseudomonas aeruginosa IFO3445 by agar dilution method,Other,8410985.0,
559,151670,6,2,,103163813,4583,Unspecified,,,,,Minimum inhibition concentration against Pseudomonas aeruginosa U-31 strain,Other,8388467.0,
560,161281,10,5,,103163813,4583,Unspecified,7531135.0,3757.0,1412.54,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
561,162740,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Proteus mirabilis JY-10,Other,9873632.0,
562,162775,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Pseudomonas aeruginosa (ATCC 27853),Other,2842501.0,
563,162776,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Pseudomonas aeruginosa E-2,Other,8410974.0,
564,162777,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Pseudomonas aeruginosa IFO 3445,Other,8410974.0,
565,162786,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Pseudomonas aeruginosa 1012E strain.,Other,,
566,162787,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Pseudomonas aeruginosa 10145 strain.,Other,,
567,162792,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Pseudomonas aeruginosa,Other,3172136.0,
568,162914,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against clinical isolates of Proteus morganii 27 (gram negative) by agar dilution assay.,Other,3820216.0,
569,163048,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Proteus rettgeri,Other,3172136.0,
570,163227,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Proteus vulgaris KS-134,Other,9873632.0,
571,163228,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Proteus vulgaris No.33,Other,9873632.0,
572,163554,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Proteus vulgaris OX-19 by agar dilution method,Other,8410985.0,
573,163732,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Providencia rettgeri M1771,Other,3346869.0,
574,163738,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Providencia rettgeri H1771,Other,3007757.0,
575,163785,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro for antibacterial activity against Pseudomonas aeruginosa (E-2),Other,8230101.0,
576,163786,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro for antibacterial activity against Pseudomonas aeruginosa (IFO 3445),Other,8230101.0,
577,163961,7,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Pseudomonas aeruginosa E-2,Other,1335082.0,
578,164245,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa UI-18,Other,3346869.0,
579,164264,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Pseudomonas maltophilia 1057 in the presence of polymyxin B nonapeptide (PBMN) at 0 ug/mL,Other,,
580,164265,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Pseudomonas maltophilia 1057 in the presence of polymyxin B nonapeptide (PBMN) at 1 ug/mL,Other,,
581,164268,6,2,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Pseudomonas rettgeri H1771,Other,2374153.0,
582,164385,6,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa (UI-18),Other,3005575.0,
583,164395,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the Pseudomonas aeruginosa K 799/61 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
584,164396,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the Pseudomonas aeruginosa K 799/WT by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
585,164565,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa AK109,Other,9873632.0,
586,164701,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa K-13,Other,9873632.0,
587,164702,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa KP-254,Other,9873632.0,
588,164703,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Pseudomonas aeruginosa PAO1,Other,9873632.0,
589,164704,6,2,,103163813,4583,Unspecified,,,,,"In vitro minimum inhibitory concentration against gram-negative Pa(E), Pseudomonas aeruginosa E-2.",Other,8126698.0,
590,164706,6,2,,103163813,4583,Unspecified,,,,,"In vitro minimum inhibitory concentration against gram-negative Pa(I), Pseudomonas aeruginosa IFO 3445.",Other,8126698.0,
591,164709,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Pseudomonas aeruginosa UI-18,Other,3007757.0,
592,164712,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Pseudomonas aeruginosa E-2 (Pa(E)),Other,8064806.0,
593,164713,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-negative microorganism Pseudomonas aeruginosa IFO 3445 (Pa(I)),Other,8064806.0,
594,164873,6,2,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Pseudomonas aeruginosa UI-18,Other,2374153.0,
595,165048,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Pseudomonas aeruginosa IFO 3445,Other,2342057.0,
596,165055,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against clinical isolates of Pseudomonas aeruginosa 2437 (gram negative) by agar dilution assay.,Other,3820216.0,
597,197875,6,2,,103163813,4583,Unspecified,,,,,Minimum inhibition concentration against Staphylococcus aureus FDA209P strain,Other,8388467.0,
598,197994,6,2,,103163813,4583,Unspecified,,,,,Activity against Staphylococcus aureus (FDA207PJC-1),Other,2163456.0,
599,197995,6,2,,103163813,4583,Unspecified,,,,,Activity against Staphylococcus aureus (IID 803),Other,2163456.0,
600,198018,6,2,,103163813,4583,Unspecified,,,,,Activity against Staphylococcus epidermidis (IAM 1296),Other,2163456.0,
601,198023,6,2,,103163813,4583,Unspecified,,,,,Activity against Streptococcus faecalis (IID 682),Other,2163456.0,
602,198342,6,2,,103163813,4583,Unspecified,,,,,Tested in vivo against Staphylococcus aureus IID803 in mice after peroral dose of drug with 0.5% sodium carboxy methyl cellulose,Other,8410985.0,
603,198343,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Staphylococcus aureus FDA209P JC-1 by agar dilution method,Other,8410985.0,
604,198344,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Staphylococcus aureus IID803 by agar dilution method,Other,8410985.0,
605,200334,7,1,,103163813,4583,Active,,,,,Minimum bactericidal concentration required in vitro against Salmonella,Other,10397494.0,
606,200345,8,1,,103163813,4583,Active,,,,,Minimum inhibitory concentration required in vitro against Salmonella,Other,10397494.0,
607,200869,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Salmonella Typhimurium IID 971,Other,8410974.0,
608,200870,6,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Salmonella Typhimurium 14028 strain.,Other,,
609,200878,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Salmonella Typhimurium 701 in the absence of polymyxin B nonapeptide (PBMN) at 0 ug/mL,Other,,
610,200879,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Salmonella Typhimurium 701 in the presence of polymyxin B nonapeptide (PBMN) at 1 ug/mL,Other,,
611,200881,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Salmonella Typhimurium IID971 by agar dilution method,Other,8410985.0,
612,201406,6,2,,103163813,4583,Unspecified,,,,,Minimum inhibitory concentration against Staphylococcus aureus Smith,Other,8388467.0,
613,202106,6,2,,103163813,4583,Unspecified,,,,,Minimum inhibition concentration against Streptococcus pneumoniae Type I strain,Other,8388467.0,
614,203037,7,1,,103163813,4583,Active,,,,,Minimum bactericidal concentration required in vitro against Shigella,Other,10397494.0,
615,203039,8,1,,103163813,4583,Active,,,,,Minimum inhibitory concentration required in vitro against Shigella,Other,10397494.0,
616,203167,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Serratia marcescens IAM1184 by agar dilution method,Other,8410985.0,
617,203190,7,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Shigella flexneri 2a EW-10,Other,1335082.0,
618,203276,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the Staphylococcus aureus 45 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
619,203277,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the Staphylococcus aureus ATCC 6538 P by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
620,203278,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the Staphylococcus epidermis 3519 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
621,203317,7,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Serratia marcescens IFO 3736,Other,1335082.0,
622,203326,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Serratia marcescens S-9,Other,2342057.0,
623,205389,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram negative Serratia marcescens No.16-2,Other,9873632.0,
624,205546,8,1,,103163813,4583,Active,,,,,Minimum inhibitory concentration (MIC) against Staphylococcus aureus ATCC 13709,Other,12729630.0,
625,205596,6,2,,103163813,4583,Unspecified,,,,,"In vitro minimum inhibitory concentration against gram-positive Se, Staphylococcus epidermidis IAM 1296.",Other,8126698.0,
626,205650,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus aureus FDA 209P JC-1,Other,9873632.0,
627,205651,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus aureus JS-1,Other,9873632.0,
628,205652,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus aureus KP-90-3,Other,9873632.0,
629,205653,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus aureus smith,Other,9873632.0,
630,205663,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for in vitro antibacterial activity (minimum inhibition concentration) against gram-positive Sa (F) Staphylococcus aureus FDA 209P JC-1,Other,8126698.0,
631,205665,6,2,,103163813,4583,Unspecified,,,,,"In vitro minimum inhibitory concentration against gram-positive Sa (I), Staphylococcus aureus IID803.",Other,8126698.0,
632,205805,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus aureus IID 803 (Sa(I)),Other,8064806.0,
633,205806,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus aureus FDA 209P JC-1 (Sa(F)),Other,8064806.0,
634,205845,5,3,,103163813,4583,Unspecified,,,,,Minimum inhibitory concentration in vitro against Staphylococcus aureus FDA 209P,Other,,
635,205846,5,3,,103163813,4583,Unspecified,,,,,Minimum inhibitory concentration vitro against Staphylococcus aureus No.88,Other,,
636,205881,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Staphylococcus epidermidis IAM 1296,Other,8410974.0,
637,205908,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Staphylococcus epidermidis strain OC2603,Other,,
638,205924,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the faecium ATCC 8043 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
639,205964,6,2,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus aureus H228,Other,2374153.0,
640,205965,6,2,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus aureus UC-76,Other,2374153.0,
641,206009,8,1,,103163813,4583,Active,,,,,Minimum inhibitory concentration required in vitro against Staphylococcus aureus,Other,10397494.0,
642,206034,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro against Staphylococcus epidermidis IAM12896 by agar dilution method,Other,8410985.0,
643,206159,6,3,,103163813,4583,Unspecified,,,,,Tested for antibacterial activity as minimum inhibitory concentration against Staphylococcus aureus strain OC6538,Other,,
644,206174,6,2,,103163813,4583,Unspecified,,,,,Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus,Other,8064806.0,
645,206197,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro for antibacterial activity against Staphylococcus epidermidis (IAM 1296),Other,8230101.0,
646,206216,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for its minimal inhibitory constant against Gram-positive microorganism Staphylococcus epidermidis IAM 1296 (Se),Other,8064806.0,
647,206232,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Staphylococcus epidermis 178 strain.,Other,,
648,206233,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Staphylococcus epidermis 887E strain.,Other,,
649,206283,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus 209P JC-1,Other,2342057.0,
650,206284,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus 50774,Other,2342057.0,
651,206368,6,3,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus faecalis MGH-2,Other,2374153.0,
652,206370,6,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Streptococcus faecalis (ATCC 29212),Other,2842501.0,
653,206437,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against clinical isolates of Staphylococcus aureus 18773 (gram-positive) by agar dilution assay.,Other,3820216.0,
654,206632,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for the in vitro antibacterial activity (minimum inhibitory concentration) against 50% of clinical isolates of methicillin-resistant Staphylococcus aureus (MIC range),Other,8126698.0,
655,206643,6,2,,103163813,4583,Unspecified,,,,,Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus,Other,8064806.0,
656,206652,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for the in vitro antibacterial activity (minimum inhibitory concentration) against 90% of clinical isolates of methicillin-resistant Staphylococcus aureus (MIC range),Other,8126698.0,
657,206684,6,2,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus pneumoniae SV-1,Other,2374153.0,
658,206794,6,2,,103163813,4583,Unspecified,,,,,Tested for in vitro for antibacterial activity against 16 clinical isolated of methicillin-resistant Staphylococcus aureus,Other,8064806.0,
659,206812,6,3,,103163813,4583,Unspecified,,,,,Evaluated for minimum inhibitory concentration against gram-negative bacteria Staphylococcus pyogenes C203,Other,2374153.0,
660,206825,7,2,,103163813,4583,Unspecified,,,,,Compound was tested for antibacterial activity against gram positive Staphylococcus pyogenes cook,Other,9873632.0,
661,206854,7,1,,103163813,4583,Active,,,,,Minimum bactericidal concentration required in vitro against Staphylococcus aureus,Other,10397494.0,
662,206877,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus H-228,Other,3346869.0,
663,206890,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus UC76,Other,3346869.0,
664,207175,6,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus (H228),Other,3005575.0,
665,207201,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Staphylococcus aureus (ATCC 29213),Other,2842501.0,
666,207206,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Staphylococcus aureus FDA 209P JC-1,Other,8410974.0,
667,207207,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Staphylococcus aureus IID 803,Other,8410974.0,
668,207258,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro for antibacterial activity against Staphylococcus aureus (FDA 209P JC-1),Other,8230101.0,
669,207260,6,2,,103163813,4583,Unspecified,,,,,Tested in vitro for antibacterial activity against Staphylococcus aureus (IID 803),Other,8230101.0,
670,207364,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Staphylococcus aureus 241 strain.,Other,,
671,207365,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Staphylococcus aureus 6538p strain.,Other,,
672,207366,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Staphylococcus aureus 77 strain.,Other,,
673,207367,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Staphylococcus aureus giorgio strain.,Other,,
674,207384,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Staphylococcus aureus (resistant),Other,3172136.0,
675,207385,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Staphylococcus aureus (sensitive),Other,3172136.0,
676,207390,7,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus 209P JC-1,Other,1335082.0,
677,208131,6,2,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration against Streptococcus pneumoniae (ATCC 6301),Other,2842501.0,
678,208315,5,3,,103163813,4583,Unspecified,,,,,Minimum inhibitory concentration in vitro against Streptococcus pneumoniae Type III,Other,,
679,208735,7,1,,103163813,4583,Active,,,,,Minimum bactericidal concentration required in vitro against Streptococcus D,Other,10397494.0,
680,208737,8,1,,103163813,4583,Active,,,,,Minimum inhibitory concentration required in vitro against Streptococcus D,Other,10397494.0,
681,208740,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the streptococcus agalactiae CMX 508 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
682,208893,6,3,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus aureus H228.,Other,3007757.0,
683,208894,6,3,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus aureus UC-76.,Other,3007757.0,
684,208910,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the streptococcus bovis A 5169 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
685,208946,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Streptococcus pyogenes,Other,3172136.0,
686,209061,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Streptococcus epidermis 8,Other,2342057.0,
687,209067,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Streptococcus faecalis MGH-2,Other,3346869.0,
688,209087,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus faecalis MGH-2,Other,3007757.0,
689,209126,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Streptococcus pyogenes C203,Other,3346869.0,
690,209225,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Streptococcus faecalis 2473,Other,2342057.0,
691,209239,5,3,,103163813,4583,Unspecified,,,,,In vitro minimum inhibitory concentration was determined for antibacterial activity against Staphylococcus faecalis 29212 strain.,Other,,
692,209240,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Streptococcus faecalis,Other,3172136.0,
693,209278,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the streptococcus pyogenes 2548 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
694,209279,6,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against the streptococcus pyogenes EES 61 by 2-fold agar dilution method using brain-heart infusion agar.,Other,2824776.0,
695,209302,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus pyogenes C203.,Other,3007757.0,
696,209462,6,2,,103163813,4583,Unspecified,,,,,In vitro antibacterial activity against Streptococcus pyogenes A65,Other,2342057.0,
697,209730,6,2,,103163813,4583,Unspecified,,,,,Inhibition of growth of Streptococcus pneumonia,Other,3172136.0,
698,209894,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae SV-1,Other,3346869.0,
699,210022,6,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae (SV-1),Other,3005575.0,
700,210196,6,2,,103163813,4583,Unspecified,,,,,Compound was tested for inhibition of the gram-negative organism Streptococcus pneumoniae SV-1,Other,3007757.0,
701,243151,7,2,,103163813,4583,Unspecified,,,1412.54,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
702,271563,3,11,,103163813,4583,Unspecified,125266.0,1459.0,,,Residual activity of human CK2 at 30 uM,Other,17064064.0,
703,271563,3,11,,103163813,4583,Unspecified,54037520.0,1460.0,,,Residual activity of human CK2 at 30 uM,Other,17064064.0,
704,271563,3,11,,103163813,4583,Unspecified,55977123.0,1457.0,,,Residual activity of human CK2 at 30 uM,Other,17064064.0,
705,279817,8,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv in 7H9 broth,Other,17145798.0,
706,279818,8,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv infected in mouse J774A.1 macrophages,Other,17145798.0,
707,279819,3,5,,103163813,4583,Unspecified,,,,,Fraction unbound ligand in mouse plasma at 0.01 to 50 mg/litre,Other,17145798.0,
708,279820,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H3Rv on day 7,Other,17145798.0,
709,279821,3,3,,103163813,4583,Active,,,,,Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 1,Other,17145798.0,
710,279822,3,4,,103163813,4583,Active,,,,,Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 7,Other,17145798.0,
711,279823,3,3,,103163813,4583,Active,,,,,Bactericidal activity in Mycobacterium tuberculosis H37Rv on day 14,Other,17145798.0,
712,279824,6,2,,103163813,4583,Unspecified,,,,,"Cmax in BALB/c mouse at 37.5 to 2400 mg/kg, po",Other,17145798.0,
713,279827,7,2,,103163813,4583,Unspecified,,,,,"AUC(0-infinity) in BALB/c mouse at 37.5 to 2400 mg/kg, po",Other,17145798.0,
714,279830,3,3,,103163813,4583,Unspecified,,,,,"Half life in BALB/c mouse at 37.5 to 2400 mg/kg, po",Other,17145798.0,
715,279837,3,3,,103163813,4583,Unspecified,,,,,Reduction of Mycobacterium tuberculosis H37Rv in orally dosed BALB/c mouse lung,Other,17145798.0,
716,279839,3,5,,103163813,4583,Unspecified,,,,,"Ratio of fraction AUC in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po",Other,17145798.0,
717,279840,3,4,,103163813,4583,Unspecified,,,,,"Ratio of fraction Cmax in Mycobacterium tuberculosis infected BALB/c mouse to MIC in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po",Other,17145798.0,
718,279841,3,3,,103163813,4583,Unspecified,,,,,"Drug level in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po",Other,17145798.0,
719,279842,6,2,,103163813,4583,Unspecified,,,,,"Toxicity in Mycobacterium tuberculosis infected BALB/c mouse model at 225 to 115000 mg/kg, po",Other,17145798.0,
720,283088,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus SA1199B overexpressing NorA at 5 ug by disk diffusion method,Other,17101679.0,
721,285159,8,1,,103163813,4583,Active,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days,Other,17210775.0,
722,285160,8,1,,103163813,4583,Active,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days,Other,17210775.0,
723,285161,8,1,,103163813,4583,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay,Other,17210775.0,
724,285162,8,1,,103163813,4583,Active,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days,Other,17210775.0,
725,285682,9,1,,103163813,4583,Unspecified,,,,,Antimicrobial activity against wild type Pseudomonas aeruginosa PAO1 after 24 hrs,Other,17261620.0,
726,285683,9,1,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa PAO1 with rpoN mutation after 24 hrs,Other,17261620.0,
727,285684,9,1,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa PAO1 with pvdS mutation after 24 hrs,Other,17261620.0,
728,285685,3,3,,103163813,4583,Unspecified,,,,,Increase in pvdS gene expression in Pseudomonas aeruginosa PAO1 with rpoN mutation at 8 ug/ml after 3 hrs relative to wild type,Other,17261620.0,
729,285686,3,3,,103163813,4583,Unspecified,,,,,Increase in vqsR gene expression in Pseudomonas aeruginosa PAO1 with rpoN mutation at 8 ug/ml relative to wild type,Other,17261620.0,
730,285687,3,3,,103163813,4583,Unspecified,,,,,Increase in GFP tagged vqsR protein expression in Pseudomonas aeruginosa PAO1 with rpoN mutation at 8 ug/ml by flow cytometry relative to wild type,Other,17261620.0,
731,287371,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli after 72 hrs by disk diffusion method,Other,17189664.0,
732,287372,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus after 72 hrs by disk diffusion method,Other,17189664.0,
733,287373,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae after 72 hrs by disk diffusion method,Other,17189664.0,
734,287374,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus after 72 hrs by disk diffusion method,Other,17189664.0,
735,287375,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Micrococcus luteus after 72 hrs by disk diffusion method,Other,17189664.0,
736,287376,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Proteus vulgaris after 72 hrs by disk diffusion method,Other,17189664.0,
737,287377,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis after 72 hrs by disk diffusion method,Other,17189664.0,
738,287378,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Listeria monocytogenes after 72 hrs by disk diffusion method,Other,17189664.0,
739,287379,4,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa after 72 hrs by disk diffusion method,Other,17189664.0,
740,293582,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae isolate assessed after 24 hrs by serial dilution method,Other,17223562.0,
741,293583,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa isolate assessed after 24 hrs by serial dilution method,Other,17223562.0,
742,293584,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli isolate assessed after 24 hrs by by serial dilution method,Other,17223562.0,
743,293585,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis isolate assessed after 24 hrs by serial dilution method,Other,17223562.0,
744,293586,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus isolate assessed after 24 hrs by serial dilution method,Other,17223562.0,
745,293587,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae RSHM 574 assessed after 24 hrs by serial dilution method,Other,17223562.0,
746,293588,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 25853 assessed after 24 hrs by serial dilution method,Other,17223562.0,
747,293589,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 assessed after 24 hrs by serial dilution method,Other,17223562.0,
748,293590,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 assessed after 24 hrs by serial dilution method,Other,17223562.0,
749,293591,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed after 24 hrs by serial dilution method,Other,17223562.0,
750,295097,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 11230 at 5 ug after 24 hrs by disk diffusion method,Other,17350734.0,
751,295100,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 6538 at 5 ug after 24 hrs by disk diffusion method,Other,17350734.0,
752,295103,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae UC57 at 5 ug after 24 hrs by disk diffusion method,Other,17350734.0,
753,295106,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 5 ug after 24 hrs by disk diffusion method,Other,17350734.0,
754,295109,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Proteus vulgaris ATCC 8427 at 5 ug after 24 hrs by disk diffusion method,Other,17350734.0,
755,295112,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus ATCC 7064 at 5 ug after 24 hrs by disk diffusion method,Other,17350734.0,
756,295115,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis CCM 2067 at 5 ug after 24 hrs by disk diffusion method,Other,17350734.0,
757,295118,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Listeria monocytogenes ATCC 15313 at 5 ug after 24 hrs by disk diffusion method,Other,17350734.0,
758,295121,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Micrococcus luteus La 2971 at 5 ug by disk diffusion method,Other,17350734.0,
759,295850,3,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Proteus vulgaris A161 by disk diffusion method at 10 ug/disc,Other,17418454.0,
760,295851,3,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Proteus vulgaris KUKEM1329 by disk diffusion method at 10 ug/disc,Other,17418454.0,
761,295852,3,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Streptococcus pyogenes ATCC 176 by disk diffusion method at 10 ug/disc,Other,17418454.0,
762,295853,3,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Streptococcus pyogenes KUKEM676 by disk diffusion method at 10 ug/disc,Other,17418454.0,
763,297186,6,2,,103163813,4583,Inactive,,,,,Antibacterial activity against multidrug resistant Staphylococcus aureus 49589,Other,17665895.0,
764,316444,6,2,,103163813,4583,Unspecified,,,155.3,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,18068979.0,
765,316445,7,1,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,18068979.0,
766,316446,7,1,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis by agar dilution method,Other,18068979.0,
767,316447,7,1,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 by agar dilution method,Other,18068979.0,
768,316449,3,3,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse lungs assessed as viable organisms at 50 mg/kg, ip after 35 days relative to control",Other,18068979.0,
769,316451,3,4,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse spleen assessed as viable organisms at 50 mg/kg, ip after 35 days relative to control",Other,18068979.0,
770,322313,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method,Other,17371815.0,
771,322314,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method,Other,17371815.0,
772,322315,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method,Other,17371815.0,
773,322316,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method,Other,17371815.0,
774,322317,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method,Other,17371815.0,
775,322318,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method,Other,17371815.0,
776,324745,6,4,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling,Other,17325221.0,
777,324746,5,1,,103163813,4583,Unspecified,,,,,Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage,Other,17325221.0,
778,324747,3,5,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days,Other,17325221.0,
779,324749,3,7,,103163813,4583,Unspecified,,,,,Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing at 150 mg/kg/day after 9 months,Other,17325221.0,
780,349880,8,1,,103163813,4583,Unspecified,,,,,Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA,Other,19374444.0,
781,352089,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs,Other,18524419.0,
782,352090,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae after 24 hrs,Other,18524419.0,
783,352091,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs,Other,18524419.0,
784,352092,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Escherichia coli after 24 hrs,Other,18524419.0,
785,352093,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs,Other,18524419.0,
786,352094,11,1,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs,Other,18524419.0,
787,352095,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against ceftriazone-resistant Bacillus subtilis after 24 hrs,Other,18524419.0,
788,352096,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs,Other,18524419.0,
789,352097,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Staphylococcus aureus after 24 hrs,Other,18524419.0,
790,352621,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella Typhimurium NCIM 2501 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
791,352625,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Klebsiella aerogenes NCIM 2239 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
792,352629,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa NCIM 2200 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
793,352633,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli NCIM 2065 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
794,352801,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis NCIM 2063 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
795,352805,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacillus cereus NCIM 2155 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
796,352809,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Vibrio fischeri NCIM 2154 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
797,352813,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Corynebacterium rubrum NCIM 2252 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
798,352817,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus albus NCIM 2178 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
799,352821,3,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Proteus vulgaris NCIM 2027 at 5 ug/disk after 24 hrs by disk diffusion method,Other,18718695.0,
800,352825,3,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Aspergillus niger NCIM 902 at 5 ug/disk after 72 hrs by disk diffusion method,Other,18718695.0,
801,352829,3,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Aspergillus flavus NCIM 902 at 5 ug/disk after 72 hrs by disk diffusion method,Other,18718695.0,
802,352833,3,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Rhodotorula rubra NCIM 3174 at 5 ug/disk after 72 hrs by disk diffusion method,Other,18718695.0,
803,352837,3,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Aspergillus fumigatus NCIM 902 at 5 ug/disk after 72 hrs by disk diffusion method,Other,18718695.0,
804,352841,3,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Aspergillus parasiticus NCIM 904 at 5 ug/disk after 72 hrs by disk diffusion method,Other,18718695.0,
805,352845,3,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Penicillium chrysogenum NCIM 707 at 5 ug/disk after 72 hrs by disk diffusion method,Other,18718695.0,
806,352849,3,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Lipomyces lipofer NCIM 3252 at 5 ug/disk after 72 hrs by disk diffusion method,Other,18718695.0,
807,352853,3,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Trichoderma viride NCIM 1195 at 5 ug/disk after 72 hrs by disk diffusion method,Other,18718695.0,
808,371458,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by disk diffusion method,Other,18023934.0,
809,371459,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus isolate after 24 hrs by disk diffusion method,Other,18023934.0,
810,371460,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs by disk diffusion method,Other,18023934.0,
811,371461,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis isolate after 24 hrs by disk diffusion method,Other,18023934.0,
812,371462,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs by disk diffusion method,Other,18023934.0,
813,371463,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli isolate after 24 hrs by disk diffusion method,Other,18023934.0,
814,371464,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs by disk diffusion method,Other,18023934.0,
815,371465,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae after 24 hrs by disk diffusion method,Other,18023934.0,
816,371466,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs by disk diffusion method,Other,18023934.0,
817,385163,9,1,,103163813,4583,Active,,,,,Antimicrobial activity against Escherichia coli by broth microdilution method,Other,18293903.0,
818,385164,9,1,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Candida albicans by broth microdilution method,Other,18293903.0,
819,385165,9,1,,103163813,4583,Active,,,,,Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method,Other,18293903.0,
820,385166,9,1,,103163813,4583,Active,,,,,Antimicrobial activity against Enterococcus faecalis by broth microdilution method,Other,18293903.0,
821,385167,9,1,,103163813,4583,Active,,,,,Antimicrobial activity against Bacillus cereus by broth microdilution method,Other,18293903.0,
822,385168,9,1,,103163813,4583,Active,,,,,Antimicrobial activity against Staphylococcus aureus by broth microdilution method,Other,18293903.0,
823,386623,4,8,,103163813,4583,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
824,386885,7,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 19433 by cup plate method,Other,18023930.0,
825,386886,7,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against sEscherichia coli ATCC 25922 by cup plate method,Other,18023930.0,
826,386887,7,2,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Candida albicans ATCC 2091 by cup plate method,Other,18023930.0,
827,391975,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth dilution method,Other,17620379.0,
828,391976,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 by broth dilution method,Other,17620379.0,
829,391977,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis JH2-2 by broth microdilution method,Other,17620379.0,
830,391978,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis JH2-2-omega-pG1KT mutant with inactivated qnr gene by broth microdilution method,Other,17620379.0,
831,391979,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis JH2-2-delta-pG1KT mutant by broth microdilution method,Other,17620379.0,
832,391980,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis JH2-2 containing ORI23 promoter by broth microdilution method,Other,17620379.0,
833,391981,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis JH2-2-omega-pG1KT/pORI23::qnr-cat mutant with qnr gene complementation by broth microdilution method,Other,17620379.0,
834,391982,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis JH2-2 containing ORI23::qnr-cat promoter mutant overexpressing qnr by broth microdilution method,Other,17620379.0,
835,391984,3,3,,103163813,4583,Inactive,,,,,Inhibition of Escherichia coli DNA gyrase-mediated Escherichia coli pBR322 DNA supercoiling at 1 ug/mL in presence of 0.9 uM histidine6-tagged Enterococcus faecalis qnr protein preincubated before compound administration by agarose gel electrophoresis,Other,17620379.0,
836,391985,3,3,,103163813,4583,Active,,,,,Inhibition of Escherichia coli DNA gyrase-mediated Escherichia coli pBR322 DNA supercoiling at 1 ug/mL by agarose gel electrophoresis,Other,17620379.0,
837,391986,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus RN4220 by twofold dilution method,Other,17620379.0,
838,391987,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23 promoter by twofold dilution method,Other,17620379.0,
839,391988,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus RN4220 containing ORI23::qnr-cat promoter mutant by twofold dilution method,Other,17620379.0,
840,391989,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Lactococcus lactis IL-1419 by twofold dilution method,Other,17620379.0,
841,392220,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23 promoter by twofold dilution method,Other,17620379.0,
842,395097,6,2,,103163813,4583,Unspecified,,,100.0,IC50,Antitrypanosomal activity against wild type Trypanosoma brucei brucei s427 after 48 hrs by alamar blue assay,Confirmatory,19250832.0,
843,395358,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 11230 at 5 ug after 24 hrs by disk diffusion method,Other,18417256.0,
844,395359,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 6538 at 5 ug after 24 hrs by disk diffusion method,Other,18417256.0,
845,395360,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae UC57 at 5 ug after 24 hrs by disk diffusion method,Other,18417256.0,
846,395361,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 5 ug after 24 hrs by disk diffusion method,Other,18417256.0,
847,395362,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Proteus vulgaris ATCC 8427 at 5 ug after 24 hrs by disk diffusion method,Other,18417256.0,
848,395363,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus ATCC 7064 at 5 ug after 24 hrs by disk diffusion method,Other,18417256.0,
849,395364,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis CCM 2067 at 5 ug after 24 hrs by disk diffusion method,Other,18417256.0,
850,395365,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Listeria monocytogenes ATCC 15313 at 5 ug after 24 hrs by disk diffusion method,Other,18417256.0,
851,395366,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Micrococcus luteus La 2971 at 5 ug after 24 hrs by disk diffusion method,Other,18417256.0,
852,395715,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Lactococcus lactis IL-1419 containing ORI23::qnr-cat promoter mutant by twofold dilution method,Other,17620379.0,
853,395716,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli DH10B by twofold dilution method,Other,17620379.0,
854,395717,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli DH10B containing ORI23 promoter by twofold dilution method,Other,17620379.0,
855,395718,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli DH10B containing ORI23::qnr-cat promoter mutant by twofold dilution method,Other,17620379.0,
856,395772,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae isolate containing extended spectrum beta lactamase after 24 hrs by twofold serial dilution technique,Other,18289735.0,
857,395773,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae RSHM 574 after 24 hrs by twofold serial dilution technique,Other,18289735.0,
858,395774,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa isolate after 24 hrs by twofold serial dilution technique,Other,18289735.0,
859,395775,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hrs by twofold serial dilution technique,Other,18289735.0,
860,395776,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli isolate containing extended spectrum beta lactamase after 24 hrs by twofold serial dilution technique,Other,18289735.0,
861,395777,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by twofold serial dilution technique,Other,18289735.0,
862,395778,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against ceftriaxone-resistant Bacillus subtilis isolate after 24 hrs by twofold serial dilution technique,Other,18289735.0,
863,395779,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by twofold serial dilution technique,Other,18289735.0,
864,395780,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate after 24 hrs by twofold serial dilution technique,Other,18289735.0,
865,395781,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by twofold serial dilution technique,Other,18289735.0,
866,396096,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus K1758-A overexpressing mepA by broth microdilution technique,Other,18358571.0,
867,396097,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus K1758-P by broth microdilution technique,Other,18358571.0,
868,396098,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus K2361 overexpressing norA by broth microdilution technique,Other,18358571.0,
869,396099,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus K1902 by broth microdilution technique,Other,18358571.0,
870,396100,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa K1536 overexpressing mexCD by broth microdilution technique,Other,18358571.0,
871,396101,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa OCR1 overexpressing mexAB by broth microdilution technique,Other,18358571.0,
872,396102,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution technique,Other,18358571.0,
873,396103,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli AG102 overexpressing acrAB by broth microdilution technique,Other,18358571.0,
874,396104,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli AG100 by broth microdilution technique,Other,18358571.0,
875,404304,3,10,,103163813,4583,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
876,405114,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Vibrio splendidus 12B01 expressing plasmid-mediated QnrS-like quinolone resistance determinants,Other,17452482.0,
877,405115,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Vibrio splendidus LGP32 expressing plasmid-mediated QnrS-like quinolone resistance determinants,Other,17452482.0,
878,405116,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 harbouring pVS1 expressing quinolone resistant Vibrio splendidus 12B01 QnrVS1 gene,Other,17452482.0,
879,405117,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 harbouring pVS2 expressing quinolone resistant Vibrio splendidus LGP32 QnrVS2 gene,Other,17452482.0,
880,405118,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 harbouring pS1 plasmid expressing quinolone resistant QnrS1 gene,Other,17452482.0,
881,405119,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 harbouring pS2 plasmid expressing quinolone resistant QnrS2 gene,Other,17452482.0,
882,405120,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 harbouring p0 plasmid expressing pCR-BluntII-TOPO,Other,17452482.0,
883,405121,6,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10,Other,17452482.0,
884,405470,3,3,,103163813,4583,Inactive,,,,,Antibacterial activity against oxacillin-dependent methicillin-resistant Staphylococcus aureus 2884D isolate at 5 ug by disc diffusion method,Other,17470657.0,
885,405477,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 2884 isolate at 5 ug by disc diffusion method,Other,17470657.0,
886,405478,3,3,,103163813,4583,Inactive,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 2884 isolate at 30 ug by disc diffusion method,Other,17470657.0,
887,406844,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 by E-test,Other,17502413.0,
888,406845,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 containing pS1B plasmid expressing quinolone resistance determinant QnrS1 by E-test,Other,17502413.0,
889,406846,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli TOP10 containing pS1A plasmid expressing quinolone resistance determinant QnrB4 by E-test,Other,17502413.0,
890,406847,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterobacter cloacae S1 isolate expressing quinolone resistance determinant QnrB4 by E-test,Other,17502413.0,
891,408340,8,5,,103163813,4583,Unspecified,7531135.0,3757.0,1412.54,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
892,423635,7,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs,Other,19275174.0,
893,424862,3,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate assessed as resistant isolates,Other,17938181.0,
894,424863,3,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates,Other,17938181.0,
895,424879,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Enterobacter cloacae E705 bearing qnrB10 gene with aac(6)-IId-aadA1a integron in presence of IPTG,Other,17938184.0,
896,425069,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae M7943 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG,Other,17938184.0,
897,425070,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Escherichia coli M7943-TC2 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG,Other,17938184.0,
898,425071,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53-AzR in presence of IPTG,Other,17938184.0,
899,425072,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH10B expressing pCRQB10 in presence of IPTG,Other,17938184.0,
900,425073,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH10B expressing pCR2.1 in presence of IPTG,Other,17938184.0,
901,425074,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH10B in presence of IPTG,Other,17938184.0,
902,425652,7,2,,103163813,4583,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
903,425653,7,2,,103163813,4583,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
904,427196,8,1,,103163813,4583,Unspecified,,,,,Membrane permeability by PAMPA-BBB assay,Other,19663388.0,
905,427197,8,1,,103163813,4583,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay,Other,19663388.0,
906,427198,8,1,,103163813,4583,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay,Other,19663388.0,
907,428900,3,3,,103163813,4583,Inactive,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation assessed as complete cell killing at 4 times MIC after 4 hrs by time-kill analysis,Other,17908946.0,
908,428901,3,3,,103163813,4583,Inactive,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation assessed as complete cell killing at 4 times MIC after 4 hrs by time-kill analysis,Other,17908946.0,
909,428977,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate D43 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
910,428978,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate B111 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
911,428979,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate E86 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
912,428980,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate A102 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
913,428981,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate C152 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
914,428982,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT29 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
915,428983,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT61 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
916,428984,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 102 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
917,428985,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 104 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
918,428986,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 107 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
919,428987,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate nar 108 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
920,428988,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate ipt 2 harboring DNA gyrase A D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
921,428989,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 28 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
922,428990,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 45 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
923,428991,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 46 harboring DNA gyrase A D87G mutation by disk diffusion method,Other,17908946.0,
924,428992,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 50 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
925,428993,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 51 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
926,428994,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate ipt 32 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
927,428995,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate ipt 33 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
928,428996,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT118 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
929,428997,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT142 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
930,428998,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
931,428999,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT145 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
932,429001,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT2 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
933,429002,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT3 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
934,429003,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT9 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
935,429004,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT15 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
936,429005,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT18 harboring DNA gyrase A S83F and D87G mutation by disk diffusion method,Other,17908946.0,
937,429006,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT37 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
938,429007,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT40 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
939,429008,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT42 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
940,429009,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT47 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
941,429010,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT48 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
942,429011,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT49 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
943,429012,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT54 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
944,429013,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT60 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
945,429014,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG3 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
946,429015,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG5 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
947,429016,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG6 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
948,429017,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG7 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
949,429018,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG8 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
950,429019,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG15 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
951,429020,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG16 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
952,429021,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG17 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
953,429022,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG152 harboring DNA gyrase A S83F and D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
954,429023,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG168 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
955,429024,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG169 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
956,429025,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG176 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
957,429026,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG182 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
958,429027,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG258 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
959,429028,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG259 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
960,429029,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation by disk diffusion method,Other,17908946.0,
961,429030,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate BL 21801 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
962,429031,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate BL 21095 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
963,429032,7,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate BL 3769 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS,Other,17908946.0,
964,429033,3,3,,103163813,4583,Active,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT76 harboring wild type DNA gyrase A by time-kill analysis,Other,17908946.0,
965,429034,3,3,,103163813,4583,Active,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation assessed as decrease in viable count at 4 times MIC after 4 hrs by time-kill analysis,Other,17908946.0,
966,429035,3,3,,103163813,4583,Active,,,,,Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation assessed as decrease in viable count at 4 times MIC after 4 hrs by time-kill analysis,Other,17908946.0,
967,429036,3,3,,103163813,4583,Inactive,,,,,Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT18 harboring DNA gyrase A S83F and D87G mutation assessed as decrease in viable count at 4 times MIC after 4 hrs by time-kill analysis,Other,17908946.0,
968,433400,7,4,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as DNA supercoiling inhibition,Other,18070975.0,
969,433401,7,4,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae DNA gyrase subunit A G89C mutant assessed as DNA supercoiling inhibition,Other,18070975.0,
970,433402,7,4,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae DNA gyrase subunit A A91V mutant assessed as DNA supercoiling inhibition,Other,18070975.0,
971,433403,7,4,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as DNA supercoiling inhibition,Other,18070975.0,
972,433404,6,1,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as formation of DNA cleavable complex,Other,18070975.0,
973,433578,3,5,,103163813,4583,Inactive,,,,,Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A G89A mutant assessed as formation of DNA cleavable complex,Other,18070975.0,
974,433579,6,1,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A A91V mutant assessed as formation of DNA cleavable complex,Other,18070975.0,
975,433580,6,1,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as formation of DNA cleavable complex,Other,18070975.0,
976,433581,3,5,,103163813,4583,Unspecified,,,,,"Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A G89C mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2",Other,18070975.0,
977,433582,3,5,,103163813,4583,Unspecified,,,,,"Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2",Other,18070975.0,
978,433583,3,5,,103163813,4583,Unspecified,,,,,"Selectivity index, ratio of CC25 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to CC25 for Mycobacterium leprae wild type DNA gyrase A2B2 by DNA cleavage assay",Other,18070975.0,
979,434955,1,2,,56423109,4583,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
980,434959,1,1,,85788436,4583,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
981,434962,1,2,,56423109,4583,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
982,434973,1,3,,56423109,4583,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
983,434989,1,1,,56423109,4583,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
984,435003,1,3,,56423109,4583,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
985,435005,1,1,,56423109,4583,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
986,435022,2,2,,56423109,4583,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
987,435030,1,2,,56423109,4583,Active,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
988,435030,1,2,,56423109,4583,Active,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
989,442657,8,1,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method,Other,19942326.0,
990,442658,8,1,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method,Other,19942326.0,
991,442659,8,2,,103163813,4583,Unspecified,,,155.3,IC50,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Confirmatory,19942326.0,
992,444050,7,1,,103163813,4583,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
993,444051,6,2,,103163813,4583,Unspecified,,,,,Total clearance in human,Other,20070106.0,
994,444052,6,2,,103163813,4583,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
995,444053,6,2,,103163813,4583,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
996,444054,6,1,,103163813,4583,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
997,444055,3,3,,103163813,4583,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
998,444056,3,3,,103163813,4583,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
999,444057,3,3,,103163813,4583,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
1000,444058,6,2,,103163813,4583,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
1001,445445,7,1,,103163813,4583,Unspecified,,,,,Permeability at pH 6.5 by PAMPA method,Other,19947605.0,
1002,445446,3,4,,103163813,4583,Unspecified,,,,,Oral bioavailability in human,Other,19947605.0,
1003,447080,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 11230 at 5 ug after 24 hrs by agar disk diffusion assay,Other,19700225.0,
1004,447081,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 6538 at 5 ug after 24 hrs by agar disk diffusion assay,Other,19700225.0,
1005,447082,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae UC57 at 5 ug after 24 hrs by agar disk diffusion assay,Other,19700225.0,
1006,447083,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus ATCC 7064 at 5 ug after 24 hrs by agar disk diffusion assay,Other,19700225.0,
1007,447215,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Micrococcus luteus La 2971 at 5 ug after 24 hrs by agar disk diffusion assay,Other,19700225.0,
1008,447216,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Proteus vulgaris ATCC 8427 at 5 ug after 24 hrs by agar disk diffusion assay,Other,19700225.0,
1009,447217,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium smegmatis CCM 2067 at 5 ug after 24 hrs by agar disk diffusion assay,Other,19700225.0,
1010,447218,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Listeria monocytogenes ATCC 15313 at 5 ug after 24 hrs by agar disk diffusion assay,Other,19700225.0,
1011,447219,3,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 5 ug after 24 hrs by agar disk diffusion assay,Other,19700225.0,
1012,449435,10,1,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis XDR infected in MDBK by BACTEC analysis,Other,19679378.0,
1013,449728,1,2,,56423109,4583,Active,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1014,449739,1,2,,11533038,4583,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1015,449762,1,2,,56423109,4583,Inconclusive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1016,449763,1,3,,56423109,4583,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1017,449768,1,1,,11533038,4583,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1018,450457,3,4,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus aureus after 24 hrs by twofold serial dilution method,Other,19581101.0,
1019,450458,3,4,,103163813,4583,Active,,,,,Antibacterial activity against Bacillus subtilis after 24 hrs by twofold serial dilution method,Other,19581101.0,
1020,450459,3,4,,103163813,4583,Active,,,,,Antibacterial activity against Serratia marcescens after 24 hrs by twofold serial dilution method,Other,19581101.0,
1021,450460,3,4,,103163813,4583,Active,,,,,Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by twofold serial dilution method,Other,19581101.0,
1022,450461,3,4,,103163813,4583,Active,,,,,Antibacterial activity against Escherichia coli after 24 hrs by twofold serial dilution method,Other,19581101.0,
1023,463073,1,2,,11533038,4583,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1024,463079,1,2,,56423109,4583,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1025,463082,1,1,,56423109,4583,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1026,463096,1,1,,50106760,4583,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1027,463097,1,1,,50106760,4583,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1028,463104,1,2,,56423109,4583,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1029,463106,1,2,,90341488,4583,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1030,463111,1,1,,11533038,4583,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1031,463141,1,2,,56423109,4583,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1032,463165,1,1,,11533038,4583,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1033,463189,1,1,,53778010,4583,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1034,463190,1,2,,56423109,4583,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1035,463195,1,2,,56423109,4583,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1036,463210,1,2,,56423109,4583,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1037,463212,1,1,,56423109,4583,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1038,463254,1,1,,11533038,4583,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1039,467863,6,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 hrs,Other,19902967.0,
1040,469403,5,1,,103163813,4583,Unspecified,,,,,Permeability across PAMPA membrane,Other,19856923.0,
1041,476929,3,3,,103163813,4583,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
1042,481439,3,4,,103163813,4583,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
1043,481442,3,6,,103163813,4583,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
1044,485270,1,1,,56423109,4583,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1045,485272,1,1,,56423109,4583,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1046,485273,2,1,,56423109,4583,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1047,485275,1,3,,56423109,4583,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1048,485281,1,1,,11533038,4583,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1049,485290,1,1,,11533038,4583,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1050,485290,1,1,,26747609,4583,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1051,485290,1,1,,26747610,4583,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1052,485290,1,1,,50106760,4583,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1053,485294,1,1,,11533038,4583,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1054,485295,1,2,,90341488,4583,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1055,485297,1,1,,11533038,4583,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1056,485297,1,1,,90341488,4583,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1057,485298,1,1,,11533038,4583,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1058,485298,1,1,,90341488,4583,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1059,485313,1,2,,11533038,4583,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1060,485313,1,2,,90341488,4583,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1061,485314,1,1,,11533038,4583,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1062,485314,1,1,,50106760,4583,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1063,485317,1,2,,56423109,4583,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1064,485341,1,1,,11533038,4583,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1065,485342,1,2,,90341488,4583,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1066,485344,1,1,,11533038,4583,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1067,485345,1,2,,90341488,4583,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1068,485346,1,1,,56423109,4583,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1069,485346,1,1,,56423109,4583,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1070,485347,1,2,,11533038,4583,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1071,485350,1,2,,92124396,4583,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1072,485350,1,2,,92125279,4583,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1073,485353,2,1,,11533038,4583,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1074,485358,1,1,,11533038,4583,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1075,485364,1,1,,11533038,4583,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1076,485366,1,2,,90341488,4583,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1077,485367,1,2,,11533038,4583,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1078,485368,1,2,,90341488,4583,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1079,488745,1,4,,85231170,4583,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1080,488752,1,4,,85231170,4583,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1081,488772,1,1,,90341488,4583,Inactive,8659577.0,58819.0,23.7781,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1082,488773,1,2,,90341488,4583,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1083,488788,1,1,,11533038,4583,Inactive,6323930.0,855317.0,100.0,AC50_uM,Ras-converting Enzyme/Cell Proliferation Pathway Measured in Biochemical System Using Plate Reader - 2034-01_Inhibitor_Dose_CherryPick,Confirmatory,,
1084,488789,1,1,,11533038,4583,Active,136429.0,,9.264,AC50_uM,Trypsin Inhibition Assay Measured in Biochemical System Using Plate Reader - 2034-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1085,488806,1,2,,11533038,4583,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1086,488815,1,1,,11533038,4583,Active,1015837.0,,1.95,AC50_uM,Ste24 Inhibition Assay Measured in Biochemical System Using Plate Reader - 2034-03_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1087,488816,1,1,,90341488,4583,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1088,488837,1,1,,11533038,4583,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1089,488837,1,1,,90341488,4583,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1090,488839,1,1,,56423109,4583,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1091,488839,1,1,,56423109,4583,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1092,488847,1,3,,56423109,4583,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1093,488862,1,1,,56423109,4583,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1094,488890,1,2,,56423109,4583,Inconclusive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1095,488895,1,2,,56423109,4583,Active,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1096,488896,1,1,,56423109,4583,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1097,488899,1,1,,56423109,4583,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1098,488922,1,2,,11533038,4583,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1099,488942,1,1,,56423109,4583,Active,15645703.0,899625.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
1100,488942,1,1,,56423109,4583,Active,15646160.0,899738.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
1101,488949,1,2,,85231170,4583,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1102,488949,1,2,,90341488,4583,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1103,488953,1,1,,90341488,4583,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1104,488955,1,1,,56423109,4583,Active,16130723.0,947287.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
1105,488955,1,1,,56423109,4583,Active,16130724.0,947286.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
1106,488955,1,1,,56423109,4583,Active,16130726.0,947294.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
1107,488956,1,1,,56423109,4583,Active,,,,,Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of bacterial viability,Screening,,
1108,488965,1,2,,56423109,4583,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1109,488966,1,1,,56423109,4583,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1110,488975,1,2,,56423109,4583,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1111,488977,1,2,,56423109,4583,Active,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1112,488978,1,1,,90341488,4583,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1113,488979,1,1,,50106760,4583,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1114,488980,1,1,,85231170,4583,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1115,488981,1,1,,90341488,4583,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1116,488982,1,1,,90341488,4583,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1117,488983,1,1,,90341488,4583,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1118,489030,2,1,,56423109,4583,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1119,489031,2,1,,56423109,4583,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1120,492947,1,1,,11533038,4583,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1121,492953,1,1,,56423109,4583,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1122,492956,1,1,,56423109,4583,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1123,492967,1,2,,92125279,4583,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1124,492967,1,2,,99301809,4583,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1125,492972,1,1,,56423109,4583,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1126,493005,1,1,,56423109,4583,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1127,493008,1,1,,56423109,4583,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1128,493008,1,1,,56423109,4583,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1129,493008,1,1,,56423109,4583,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1130,493008,1,1,,56423109,4583,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1131,493011,1,1,,56423109,4583,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1132,493012,1,1,,56423109,4583,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1133,493014,1,1,,11533038,4583,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1134,493027,1,2,,56423109,4583,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1135,493027,1,2,,56423109,4583,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1136,493033,1,2,,92124396,4583,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1137,493033,1,2,,92125279,4583,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1138,493035,1,2,,56423109,4583,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1139,493035,1,2,,56423109,4583,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1140,493036,1,2,,56423109,4583,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1141,493056,1,1,,11533038,4583,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1142,493084,1,1,,11533038,4583,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1143,493087,1,1,,56423109,4583,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1144,493091,1,1,,56423109,4583,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1145,493098,1,1,,56423109,4583,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1146,493106,1,1,,90341488,4583,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1147,493107,1,1,,90341488,4583,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1148,493127,1,1,,50106760,4583,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1149,493131,1,1,,56423109,4583,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1150,493140,1,1,,103914061,4583,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1151,493153,1,1,,90341488,4583,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1152,493153,1,1,,90341488,4583,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1153,493160,1,1,,56423109,4583,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1154,493162,1,2,,99301809,4583,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1155,493164,1,2,,90341488,4583,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1156,493164,1,2,,90341488,4583,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1157,493164,1,2,,90341488,4583,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1158,493187,1,2,,56423109,4583,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1159,493189,1,1,,50106760,4583,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1160,493244,1,1,,56423109,4583,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1161,493244,1,1,,56423109,4583,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1162,493244,1,1,,56423109,4583,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1163,493244,1,1,,56423109,4583,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1164,498187,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Stenotrophomonas maltophilia D457 containing chromosomally encoded Smqnr gene by epsilon test,Other,19841154.0,
1165,498188,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Stenotrophomonas maltophilia MBS108 containing both chromosomally and plasmid encoded Smqnr gene by epsilon test,Other,19841154.0,
1166,498189,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Stenotrophomonas maltophilia MBS109 containing chromosomally encoded Smqnr gene by epsilon test,Other,19841154.0,
1167,498190,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Stenotrophomonas maltophilia MBS82 deficient in Smqnr gene by epsilon test,Other,19841154.0,
1168,498191,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Stenotrophomonas maltophilia MBS101 containing plasmid encoded Smqnr gene by epsilon test,Other,19841154.0,
1169,498192,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Stenotrophomonas maltophilia MBS100 deficient in Smqnr gene by epsilon test,Other,19841154.0,
1170,498780,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method,Other,19805559.0,
1171,498781,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method,Other,19805559.0,
1172,498782,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene by agar dilution method,Other,19805559.0,
1173,498785,2,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay,Other,19805559.0,
1174,498786,2,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay,Other,19805559.0,
1175,498787,2,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene at 10 ug by disk diffusion assay,Other,19805559.0,
1176,498872,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method,Other,19884362.0,
1177,504326,1,2,,56423109,4583,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1178,504326,1,2,,56423109,4583,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1179,504327,1,1,,11533038,4583,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1180,504327,1,1,,90341488,4583,Inconclusive,153791535.0,2648.0,19.9526,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1181,504329,1,1,,56423109,4583,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1182,504332,1,1,,11533038,4583,Inconclusive,168985070.0,,8.9125,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1183,504332,1,1,,50106760,4583,Inconclusive,168985070.0,,56.2341,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1184,504332,1,1,,90341488,4583,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1185,504333,1,1,,11533038,4583,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1186,504339,1,1,,56423109,4583,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1187,504357,1,1,,56423109,4583,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1188,504357,1,1,,56423109,4583,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1189,504364,1,1,,85231170,4583,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1190,504406,1,1,,56423109,4583,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1191,504408,2,1,,11533038,4583,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1192,504411,1,1,,56423109,4583,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1193,504414,1,1,,56423109,4583,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1194,504414,1,1,,56423109,4583,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1195,504423,1,1,,56423109,4583,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1196,504441,1,1,,56423109,4583,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1197,504444,1,1,,56423109,4583,Inconclusive,224028257.0,4780.0,32.6427,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1198,504454,1,3,,56423109,4583,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1199,504459,1,3,,11533038,4583,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method from Validation Set,Screening,,
1200,504462,1,1,,56423109,4583,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1201,504490,1,2,,56423109,4583,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1202,504523,1,1,,56423109,4583,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1203,504523,1,1,,56423109,4583,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1204,504536,1,1,,90341488,4583,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1205,504541,1,1,,11533038,4583,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1206,504547,1,1,,90341488,4583,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1207,504548,1,2,,90341488,4583,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1208,504558,1,1,,56423109,4583,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1209,504577,2,2,,56423109,4583,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1210,504582,2,1,,56423109,4583,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1211,504594,1,1,,56423109,4583,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1212,504600,1,2,,11533038,4583,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1213,504621,1,1,,56423109,4583,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1214,504634,1,1,,56423109,4583,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1215,504648,1,1,,56423109,4583,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1216,504651,1,1,,11533038,4583,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1217,504652,1,1,,11533038,4583,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1218,504660,1,1,,11533038,4583,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1219,504690,1,3,,56423109,4583,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1220,504692,2,2,,56423109,4583,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1221,504700,1,1,,56423109,4583,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1222,504700,1,1,,56423109,4583,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1223,504707,1,1,,56423109,4583,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1224,504707,1,1,,56423109,4583,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1225,504720,1,1,,56423109,4583,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1226,504734,1,1,,56423109,4583,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1227,504766,2,1,,56423109,4583,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1228,504770,1,2,,92124396,4583,Active,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1229,504775,1,1,,56423109,4583,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1230,504803,1,1,,56423109,4583,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1231,504810,1,2,,11533038,4583,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1232,504810,1,2,,90341488,4583,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1233,504812,1,2,,11533038,4583,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1234,504812,1,2,,90341488,4583,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1235,504821,1,1,,85231170,4583,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
1236,504833,1,2,,56423109,4583,Active,11141885.0,60482.0,,,Confirmatory screen for compounds that activate the Choline Transporter (CHT),Screening,,
1237,504836,1,2,,90341488,4583,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
1238,504842,1,1,,11533038,4583,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1239,504843,1,1,,56423109,4583,Inconclusive,,,,AC50_uM,Bacterial Growth Inhibition Counterscreen using BacTiter-Glo Measured in Microorganism System Using Plate Reader - 2093-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1240,504845,1,1,,56423109,4583,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1241,504845,1,1,,90341488,4583,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1242,504847,1,1,,56423109,4583,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1243,504847,1,1,,90341488,4583,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1244,504865,1,1,,90341488,4583,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
1245,504884,1,2,,56423109,4583,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1246,504891,1,1,,56423109,4583,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1247,504894,1,1,,56423109,4583,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1248,504937,1,2,,56423109,4583,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1249,504941,1,1,,56423109,4583,Inactive,90111653.0,948321.0,,AC50_uM,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_Dose_CherryPick_Activity_Set2,Confirmatory,,
1250,510156,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 35218 by spectrophotometry,Other,20591538.0,
1251,510157,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against cephalosporin-resistant Acinetobacter baumannii by spectrophotometry,Other,20591538.0,
1252,510158,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Acinetobacter baumannii RSKK 02026 by spectrophotometry,Other,20591538.0,
1253,510159,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against extended spectrum beta lactamase expressing Proteus mirabilis by spectrophotometry,Other,20591538.0,
1254,510161,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Proteus mirabilis ATCC 7002 by spectrophotometry,Other,20591538.0,
1255,510162,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against trimethoprim-sulfamethoxazole and tazobactum-induced Pseudomonas aeruginosa by spectrophotometry,Other,20591538.0,
1256,510163,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa ATCC 10145 by spectrophotometry,Other,20591538.0,
1257,510164,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against extended spectrum beta lactamase expressing Escherichia coli by spectrophotometry,Other,20591538.0,
1258,510166,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli ATCC 35218 by spectrophotometry,Other,20591538.0,
1259,510167,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae RSKK 574 by spectrophotometry,Other,20591538.0,
1260,510168,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against extended spectrum beta lactamase expressing Klebsiella pneumoniae by spectrophotometry,Other,20591538.0,
1261,510169,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus by spectrophotometry,Other,20591538.0,
1262,510170,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Enterococcus faecalis ATCC 29212 by spectrophotometry,Other,20591538.0,
1263,510171,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against cephalosporin-resistant Enterococcus faecalis by spectrophotometry,Other,20591538.0,
1264,515780,5,1,,103163813,4583,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
1265,520423,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU18 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method,Other,18362191.0,
1266,520868,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU28 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method,Other,18362191.0,
1267,520869,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU33 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method,Other,18362191.0,
1268,520870,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU47 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method,Other,18362191.0,
1269,520871,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU57 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method,Other,18362191.0,
1270,520872,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU67 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method,Other,18362191.0,
1271,520873,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU69 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method,Other,18362191.0,
1272,520874,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolate TSU90 isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method,Other,18362191.0,
1273,520875,4,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant mecA-positive Staphylococcus saprophyticus isolates isolated from genitourinary tracts of acute cystitis patient after 24 hrs at 35 degC by agar dilution method,Other,18362191.0,
1274,521220,3,3,,103163813,4583,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
1275,521966,1,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Campylobacter jejuni assessed as resistant isolates by disk diffusion method,Other,20038624.0,
1276,521967,2,5,,103163813,4583,Unspecified,,,,,Antibacterial activity against Campylobacter coli assessed as resistant isolates by disk diffusion method,Other,20038624.0,
1277,521968,4,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Campylobacter sp. assessed as resistance breakpoint by CLSI method,Other,20038624.0,
1278,522870,3,6,,103163813,4583,Active,,,,,Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in human 5637 cells assessed as decrease in intracellular bacterial level at 400 to 700 ug/ml after 12 hrs by serial dilution method,Other,20231390.0,
1279,523001,1,4,,103163813,4583,Unspecified,,,,,Cytotoxicity against human 5637 cells assessed as mild induction of cell death by trypan blue exclusion assay,Other,20231390.0,
1280,523002,1,4,,103163813,4583,Unspecified,,,,,Cytotoxicity against human 5637 cells assessed as mild induction of cell death by LDH release assay,Other,20231390.0,
1281,523004,2,5,,103163813,4583,Active,,,,,Antibacterial activity against uropathogenic Escherichia coli UTI89 assessed as degradation of preexisting biofilm after 24 hrs by microscopy,Other,20231390.0,
1282,524790,7,2,,103163813,4583,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1283,524796,7,1,,103163813,4583,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
1284,524824,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against erythromycin resistant Campylobacter sp. by agar plate dilution method,Other,20038624.0,
1285,524825,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against erythromycin susceptible Campylobacter sp. by agar plate dilution method,Other,20038624.0,
1286,524826,2,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against erythromycin resistant Campylobacter sp. assessed as resistance breakpoint by CLSI method,Other,20038624.0,
1287,524827,2,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against erythromycin susceptible Campylobacter sp. assessed as resistance breakpoint by CLSI method,Other,20038624.0,
1288,529159,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay,Other,18285485.0,
1289,529160,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa 100609 after 20 hrs by broth microdilution assay in presence of 250 ug/ml polyethylenimine,Other,18285485.0,
1290,529161,2,3,,103163813,4583,Unspecified,,,,,"FIC index, ratio of MIC for Pseudomonas aeruginosa 100609 in presence of 250 ug/ml polyethylenimine to MIC for Pseudomonas aeruginosa 100609",Other,18285485.0,
1291,529456,4,2,,103163813,4583,Unspecified,,,,,"Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest",Other,18519712.0,
1292,529457,4,2,,103163813,4583,Unspecified,,,,,"Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest",Other,18519712.0,
1293,529669,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli R4525 expressing gyrA S83L and D87Y and parC S80I and E84G mutant gene by CLSI method,Other,18519717.0,
1294,529670,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 transconjugate by CLSI method,Other,18519717.0,
1295,529671,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 by CLSI method,Other,18519717.0,
1296,530244,2,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli K-12 BW-25113 assessed as survival rate at 5 ug/ml after 6 hrs by time kill analysis,Other,18519731.0,
1297,530245,2,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against apaH deficient Escherichia coli K-12 BW-25113 assessed as survival rate at 5 ug/ml after 6 hrs by time kill analysis,Other,18519731.0,
1298,530246,2,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against surA deficient Escherichia coli K-12 BW-25113 assessed as survival rate at 5 ug/ml after 6 hrs by time kill analysis,Other,18519731.0,
1299,530345,5,2,,103163813,4583,Unspecified,,,,,"Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method",Other,18644958.0,
1300,530346,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method,Other,18644958.0,
1301,530347,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method,Other,18644958.0,
1302,530348,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method,Other,18644958.0,
1303,530349,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method,Other,18644958.0,
1304,530350,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method,Other,18644958.0,
1305,530368,6,2,,103163813,4583,Active,,,28.0,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB,Confirmatory,18426901.0,
1306,530369,4,2,,103163813,4583,Active,,,7.0,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant,Confirmatory,18426901.0,
1307,530370,4,2,,103163813,4583,Active,,,8.0,IC50,"Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A and I85V mutant",Confirmatory,18426901.0,
1308,530371,4,2,,103163813,4583,Active,,,7.0,IC50,"Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A, I85V, F96W and P101M mutant",Confirmatory,18426901.0,
1309,530372,4,2,,103163813,4583,Active,,,25.0,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I mutant,Confirmatory,18426901.0,
1310,530373,4,2,,103163813,4583,Active,,,3.0,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant,Confirmatory,18426901.0,
1311,530374,2,3,,103163813,4583,Inactive,,,,,"Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA S69V, A71G, E72D, T73V, M74I, N76K, A83S, S84A, I85V, F96W and P101M mutant",Other,18426901.0,
1312,530375,4,2,,103163813,4583,Active,,,7.0,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB R447K mutant gene,Confirmatory,18426901.0,
1313,530376,4,2,,103163813,4583,Active,,,20.0,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB N464S mutant gene,Confirmatory,18426901.0,
1314,530377,4,2,,103163813,4583,Active,,,4.0,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA A83S mutant/GyrB R447K mutant gene,Confirmatory,18426901.0,
1315,530378,4,2,,103163813,4583,Active,,,11.0,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA M74I and A83S mutant/GyrB R447K mutant gene,Confirmatory,18426901.0,
1316,530379,6,2,,103163813,4583,Active,,,1.5,IC50,Inhibition of Escherichia coli DNA gyrase GyrA/GyrB,Confirmatory,18426901.0,
1317,530380,2,5,,103163813,4583,Active,,,,,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage,Other,18426901.0,
1318,530381,2,3,,103163813,4583,Active,,,,,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant assessed as concentration required for inducing cleavage,Other,18426901.0,
1319,530382,2,3,,103163813,4583,Active,,,,,"Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A and I85V mutant assessed as concentration required for inducing cleavage",Other,18426901.0,
1320,530383,2,3,,103163813,4583,Active,,,,,"Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S, S84A, I85V, F96W and P101M mutant assessed as concentration required for inducing cleavage",Other,18426901.0,
1321,530384,2,3,,103163813,4583,Inconclusive,,,,,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I mutant assessed as concentration required for inducing cleavage,Other,18426901.0,
1322,530385,2,3,,103163813,4583,Active,,,,,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant assessed as concentration required for inducing cleavage,Other,18426901.0,
1323,530386,2,3,,103163813,4583,Active,,,,,"Inhibition of Mycobacterium tuberculosis DNA gyrase GyrB/GyrA S69V, A71G, E72D, T73V, M74I, N76K, A83S, S84A, I85V, F96W and P101M mutant assessed as concentration required for inducing cleavage",Other,18426901.0,
1324,530387,2,3,,103163813,4583,Inactive,,,,,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB R447K mutant gene assessed as concentration required for inducing cleavage,Other,18426901.0,
1325,530388,2,3,,103163813,4583,Active,,,,,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB N464S mutant gene assessed as concentration required for inducing cleavage,Other,18426901.0,
1326,530389,2,3,,103163813,4583,Inactive,,,,,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA A83S mutant/GyrB R447K mutant gene assessed as concentration required for inducing cleavage,Other,18426901.0,
1327,530390,2,3,,103163813,4583,Inactive,,,,,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA M74I and A83S mutant/GyrB R447K mutant gene assessed as concentration required for inducing cleavage,Other,18426901.0,
1328,530391,2,5,,103163813,4583,Active,,,,,Inhibition of Escherichia coli DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage,Other,18426901.0,
1329,530392,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1330,530393,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Typhimurium harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1331,530394,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Haemophilus influenzae harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1332,530395,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1333,530396,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Klebsiella oxytoca harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1334,530397,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Methylovorus sp. harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1335,530398,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Neisseria gonorrhoeae harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1336,530399,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori 1 harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1337,530400,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori 2 harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1338,530401,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Ehrlichia chaffeensis harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1339,530402,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1340,530403,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Borrelia burgdorferi harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1341,530404,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1342,530405,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1343,530406,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Enterococcus faecalis harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1344,530407,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Streptococcus pneumoniae harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1345,530408,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1346,530409,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1347,530410,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium fortuitum harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1348,530411,2,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Tropheryma whipplei harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1349,530412,2,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Treponema pallidum harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1350,530413,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis harboring DNA gyrase GyrA QRDR,Other,18426901.0,
1351,530414,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1352,530415,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica Typhimurium harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1353,530416,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Haemophilus influenzae harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1354,530417,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1355,530418,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Klebsiella oxytoca harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1356,530419,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Methylovorus sp. harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1357,530420,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Neisseria gonorrhoeae harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1358,530421,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Helicobacter pylori harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1359,530422,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Ehrlichia chaffeensis harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1360,530423,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacteroides fragilis harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1361,530424,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Borrelia burgdorferi harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1362,530425,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Clostridium perfringens harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1363,530426,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1364,530427,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Enterococcus faecalis harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1365,530615,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Streptococcus pneumoniae harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1366,530616,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1367,530617,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1368,530618,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium fortuitum harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1369,530619,2,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Tropheryma whipplei harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1370,530620,2,3,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Treponema pallidum harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1371,530621,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis harboring DNA gyrase GyrB QRDR,Other,18426901.0,
1372,530622,1,3,,103163813,4583,Unspecified,,,,,Ratio of CC25 for Mycobacterium tuberculosis DNA gyrase GyrB/GyrA A83S mutant to CC25 for Escherichia coli DNA gyrase GyrA/GyrB,Other,18426901.0,
1373,530623,1,3,,103163813,4583,Unspecified,,,,,Ratio of CC25 for Mycobacterium tuberculosis DNA gyrase GyrB/GyrA M74I and A83S mutant to CC25 for Escherichia coli DNA gyrase GyrA/GyrB,Other,18426901.0,
1374,531332,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa PAO4290 by agar dilution method,Other,18676884.0,
1375,531333,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa PAO4290 selected after 1.0 ug/ml of azithromycin by agar dilution method,Other,18676884.0,
1376,531334,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa TNP030 by agar dilution method,Other,18676884.0,
1377,531335,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa TNP030 selected after 1.0 ug/ml of azithromycin by agar dilution method,Other,18676884.0,
1378,531336,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 by agar dilution method,Other,18676884.0,
1379,531337,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 selected after 1.0 ug/ml of azithromycin by agar dilution method,Other,18676884.0,
1380,532033,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Citrobacter werkmanii PS012 expressing PMQR determinant qnrB22 gene by Etest,Other,20421404.0,
1381,532034,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Citrobacter freundii S008 expressing PMQR determinant qnrB23 gene by Etest,Other,20421404.0,
1382,532035,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 TrcPS012 harboring PMQR determinant qnrB22 by Etest,Other,20421404.0,
1383,532036,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 TrcS008 harboring PMQR determinant qnrB23 by Etest,Other,20421404.0,
1384,532037,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 by Etest,Other,20421404.0,
1385,532038,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli DH5alpha TrfPS012 harboring PMQR determinant qnrB22 by Etest,Other,20421404.0,
1386,532039,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli DH5alpha TrfS008 harboring PMQR determinant qnrB23 by Etest,Other,20421404.0,
1387,532040,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli DH5alpha by Etest,Other,20421404.0,
1388,532980,5,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5alpha in presence of 10 mM N-Acetylcysteine,Other,20547812.0,
1389,532981,5,3,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5alpha,Other,20547812.0,
1390,532982,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli W3110 in presence of 10 mM N-Acetylcysteine,Other,20547812.0,
1391,532983,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli W3110,Other,20547812.0,
1392,532984,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli MG1655 in presence of 10 mM N-Acetylcysteine,Other,20547812.0,
1393,532985,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli MG1655,Other,20547812.0,
1394,532986,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa NCIM 5029,Other,20547812.0,
1395,532987,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa NCIM 5029 in presence of 10 mM N-Acetylcysteine,Other,20547812.0,
1396,532988,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella aerogenes NCIM 2281,Other,20547812.0,
1397,532989,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella aerogenes NCIM 2281 in presence of 10 mM N-Acetylcysteine,Other,20547812.0,
1398,532990,2,3,,103163813,4583,Active,,,,,Antibacterial activity against Klebsiella pneumoniae NCIM 2883 assessed as growth inhibition in presence of 10 mM N-Acetylcysteine,Other,20547812.0,
1399,534337,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei Bp216 harboring mini-Tn7T after 24 hrs by broth microdilution method,Other,20498323.0,
1400,534338,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei Bp250 harboring mini-Tn7T-bpeA+B+ -oprB+ after 24 hrs by broth microdilution method,Other,20498323.0,
1401,534339,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei 1026b after 24 hrs by broth microdilution method,Other,20498323.0,
1402,534340,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei Bp50 harboring deleted (amrRAB-oprA)::FRT gene after 24 hrs by broth microdilution method,Other,20498323.0,
1403,534341,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei Bp227 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method,Other,20498323.0,
1404,534342,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei Bp58 harboring deleted bpeR::FRT gene after 24 hrs by broth microdilution method,Other,20498323.0,
1405,534343,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei Bp173 harboring mini-Tn7T after 24 hrs by broth microdilution method,Other,20498323.0,
1406,534344,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei Bp174 harboring mini-Tn7T-bpeR+ after 24 hrs by broth microdilution method,Other,20498323.0,
1407,534345,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei Bp175 harboring mini-Tn7T-P1-bpeR+ after 24 hrs by broth microdilution method,Other,20498323.0,
1408,534346,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Burkholderia pseudomallei Bp207 harboring deleted (bpeAB-oprA)::FRT gene after 24 hrs by broth microdilution method,Other,20498323.0,
1409,534418,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG-Russia,Other,18955515.0,
1410,534419,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG-Connaught,Other,18955515.0,
1411,534421,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG-Denmark,Other,18955515.0,
1412,534424,5,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium bovis BCG-Pasteur,Other,18955515.0,
1413,535832,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against wild-type Pseudomonas aeruginosa GP61 after 18 hrs by agar dilution method,Other,18694945.0,
1414,535833,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa GP62KT41 harboring oprD gene after 18 hrs by agar dilution method,Other,18694945.0,
1415,535834,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against wild-type Pseudomonas aeruginosa GP62 after 18 hrs by agar dilution method,Other,18694945.0,
1416,535835,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa GP37KT31 harboring oprD gene after 18 hrs by agar dilution method,Other,18694945.0,
1417,535836,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against wild-type Pseudomonas aeruginosa GP37 after 18 hrs by agar dilution method,Other,18694945.0,
1418,535837,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa GP20KT21 harboring oprD gene after 18 hrs by agar dilution method,Other,18694945.0,
1419,535838,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against wild-type Pseudomonas aeruginosa GP20 after 18 hrs by agar dilution method,Other,18694945.0,
1420,535839,5,2,,103163813,4583,Unspecified,,,,,"Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method",Other,18694945.0,
1421,535840,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa GP4KT111 harboring oprD gene after 18 hrs by agar dilution method,Other,18694945.0,
1422,535841,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against wild-type Pseudomonas aeruginosa GP4 after 18 hrs by agar dilution method,Other,18694945.0,
1423,535842,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa PAO1 SO20 harboring mexAB-oprM gene after 18 hrs by agar dilution method,Other,18694945.0,
1424,535843,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa PAO1 IPM46 harboring oprD gene after 18 hrs by agar dilution method,Other,18694945.0,
1425,535844,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTS harboring mexAB-oprM gene after 18 hrs by agar dilution method,Other,18694945.0,
1426,535845,5,2,,103163813,4583,Unspecified,,,,,"Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL1 harboring oprD, mexAB-oprM gene after 18 hrs by agar dilution method",Other,18694945.0,
1427,535846,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution method,Other,18694945.0,
1428,535847,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa PAO1 KTL harboring oprD gene after 18 hrs by agar dilution method,Other,18694945.0,
1429,535848,5,2,,103163813,4583,Unspecified,,,,,"Antimicrobial activity against Pseudomonas aeruginosa GP61KT51 harboring oprD,mexAB-oprM gene after 18 hrs by agar dilution method",Other,18694945.0,
1430,540209,4,3,,103163813,4583,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1431,540210,4,3,,103163813,4583,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1432,540211,2,5,,103163813,4583,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1433,540212,4,3,,103163813,4583,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1434,540213,4,3,,103163813,4583,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1435,540222,4,3,,103163813,4583,Unspecified,,,,,Clearance in rat after iv administration,Other,16621936.0,
1436,540223,3,2,,103163813,4583,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,16621936.0,
1437,540224,4,3,,103163813,4583,Unspecified,,,,,Clearance in dog after iv administration,Other,16621936.0,
1438,540225,4,3,,103163813,4583,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,16621936.0,
1439,540226,4,3,,103163813,4583,Unspecified,,,,,Clearance in monkey after iv administration,Other,16621936.0,
1440,540227,4,3,,103163813,4583,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,16621936.0,
1441,540228,4,3,,103163813,4583,Unspecified,,,,,Clearance in human after iv administration,Other,16621936.0,
1442,540229,4,3,,103163813,4583,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,16621936.0,
1443,540230,2,5,,103163813,4583,Unspecified,,,,,Dose normalised AUC in rat after po administration,Other,16019946.0,
1444,540231,2,5,,103163813,4583,Unspecified,,,,,Dose normalised AUC in dog after po administration,Other,16019946.0,
1445,540232,2,5,,103163813,4583,Unspecified,,,,,Dose normalised AUC in monkey after po administration,Other,16019946.0,
1446,540233,2,5,,103163813,4583,Unspecified,,,,,Dose normalised AUC in human after po administration,Other,16019946.0,
1447,540234,2,5,,103163813,4583,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
1448,540253,1,1,,56423109,4583,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1449,540253,1,1,,56423109,4583,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1450,540253,1,1,,56423109,4583,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1451,540256,1,2,,50106760,4583,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1452,540256,1,2,,90341488,4583,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1453,540263,1,1,,56423109,4583,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1454,540263,1,1,,56423109,4583,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1455,540267,1,1,,56423109,4583,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1456,540275,1,1,,11533038,4583,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1457,540276,1,2,,11533038,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1458,540276,1,2,,26747609,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1459,540276,1,2,,26747610,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1460,540276,1,2,,26747611,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1461,540276,1,2,,26747612,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1462,540276,1,2,,50106760,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1463,540276,1,2,,50106761,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1464,540276,1,2,,50122908,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1465,540276,1,2,,50122909,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1466,540276,1,2,,85231170,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1467,540276,1,2,,90341488,4583,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1468,540277,1,1,,11533038,4583,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1469,540295,1,1,,56423109,4583,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1470,540299,1,2,,92124396,4583,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1471,540299,1,2,,92125279,4583,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
1472,540303,1,1,,56423109,4583,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1473,540303,1,1,,56423109,4583,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1474,540303,1,1,,56423109,4583,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1475,540308,1,1,,56423109,4583,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1476,540317,1,1,,56423109,4583,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1477,540336,1,1,,56423109,4583,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1478,540336,1,1,,56423109,4583,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1479,540364,1,2,,56423109,4583,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1480,542139,2,3,,103163813,4583,Active,,,,,Antimicrobial activity against Salmonella enterica HN-GSS2006-142 by broth microdilution assay,Other,19029321.0,
1481,542140,2,3,,103163813,4583,Active,,,,,Antimicrobial activity against Salmonella enterica HN-GSS2007-0.033 by broth microdilution assay,Other,19029321.0,
1482,542141,2,3,,103163813,4583,Active,,,,,Antimicrobial activity against Salmonella enterica HN-GSS2007-0.056 by broth microdilution assay,Other,19029321.0,
1483,542142,2,3,,103163813,4583,Active,,,,,Antimicrobial activity against Salmonella enterica HN-GSS-2007-057 by broth microdilution assay,Other,19029321.0,
1484,542143,5,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH10B by broth microdilution assay,Other,19029321.0,
1485,542144,5,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH10B harboring pBR322 by broth microdilution assay,Other,19029321.0,
1486,542145,5,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH10B harboring pBR322 with Salmonella enterica HN-GSS-2007-057 qnrA1 gene by broth microdilution assay,Other,19029321.0,
1487,542146,5,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH10B harboring pBR322 with Salmonella enterica HN-GSS-2007-057 qnrS1 gene by broth microdilution assay,Other,19029321.0,
1488,542147,5,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH10B harboring pBR322 with Salmonella enterica HN-GSS-2007-057 qnrD gene by broth microdilution assay,Other,19029321.0,
1489,542148,5,3,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH10B harboring p2007057 by broth microdilution assay,Other,19029321.0,
1490,550047,4,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus assessed as inhibition of visible growth after 48 hrs by agar dilution method,Other,21130647.0,
1491,550048,4,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli assessed as inhibition of visible growth after 48 hrs by agar dilution method,Other,21130647.0,
1492,550049,4,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae assessed as inhibition of visible growth after 48 hrs by agar dilution method,Other,21130647.0,
1493,557090,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 0.1% alpha-1-acid glycoprotein,Other,19164148.0,
1494,557091,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 4% human serum albumin,Other,19164148.0,
1495,557092,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 50% human serum,Other,19164148.0,
1496,557093,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method,Other,19164148.0,
1497,557094,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus CIP 76.25 by microdilution method in presence of 1.6% gamma globulin,Other,19164148.0,
1498,557095,4,7,,103163813,4583,Active,113576.0,213.0,12.0,Kd,Binding affinity to first site on human serum albumin by SPR,Confirmatory,19164148.0,
1499,557096,2,3,,103163813,4583,Unspecified,,,,,Binding affinity to human alpha-1-acid glycoprotein assessed as compound binding sites level by SPR,Other,19164148.0,
1500,557097,1,4,,103163813,4583,Unspecified,,,,,Protein binding in serum,Other,19164148.0,
1501,557098,2,9,,103163813,4583,Unspecified,113576.0,213.0,,,Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at 18 to 36 ug/ml by SPR,Other,19164148.0,
1502,557099,2,9,,103163813,4583,Unspecified,113576.0,213.0,,,Binding affinity to human serum albumin assessed as fraction of binding sites occupied by compound at >145 ug/ml by SPR,Other,19164148.0,
1503,559358,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1504,559359,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1505,559360,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii Nine-Mile obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1506,559361,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1507,559362,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1508,559363,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii Q212 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1509,559364,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1510,559365,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1511,559366,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP1 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1512,559367,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1513,559368,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1514,559369,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP2 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1515,559370,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1516,559371,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1517,559372,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP3 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1518,559550,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1519,559551,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1520,559552,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP4 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1521,559553,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1522,559554,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1523,559555,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP5 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1524,559556,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1525,559557,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1526,559558,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP6 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1527,559559,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1528,559560,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1529,559561,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP7 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1530,559562,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-resistant Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1531,559563,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-intermediate susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1532,559564,5,4,,103163813,4583,Unspecified,,,,,Antimicrobial activity against compound-susceptible Coxiella burnetii isolate CP8 obtained from patient with acute Q fever infected in african green monkey Vero cells after 24 hrs by shell vial assay,Other,19332671.0,
1533,559576,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Acanthamoeba castellanii amoeba cells,Other,19332673.0,
1534,559578,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Waddlia chondrophila ATCC VR-1470 infected in Vero cells,Other,19332673.0,
1535,559579,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Parachlamydia acanthamoebae infected in Acanthamoeba castellanii amoeba cells,Other,19332673.0,
1536,559580,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis infected in Vero cells,Other,19332673.0,
1537,559581,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydophila pneumoniae infected in Vero cells,Other,19332673.0,
1538,559582,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydophila psittaci infected in Vero cells,Other,19332673.0,
1539,560259,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica serovar Typhimurium STYM61/9 expressing qnrB19 gene variant carried by IncL/M-like plasmid by Etest,Other,19528272.0,
1540,560260,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica serovar Typhimurium transconjugant p61/9T expressing qnrB19 gene variant carried by IncL/M-like plasmid by Etest,Other,19528272.0,
1541,560261,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli CSH26RifR receiving qnrB19 gene variant carried by IncL/M-like plasmid from Salmonella enterica serovar Typhimurium STYM61/9 by Etest,Other,19528272.0,
1542,560590,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method,Other,19349516.0,
1543,560591,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method,Other,19349516.0,
1544,560592,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method,Other,19349516.0,
1545,560593,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method,Other,19349516.0,
1546,560601,4,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa by microdilution method,Other,19349516.0,
1547,562240,5,2,,103163813,4583,Active,,,2.03,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
1548,562241,5,2,,103163813,4583,Active,,,3.13,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
1549,562242,5,2,,103163813,4583,Active,,,1.73,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
1550,562243,5,2,,103163813,4583,Active,,,2.03,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
1551,562244,5,2,,103163813,4583,Active,,,3.13,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
1552,562245,5,2,,103163813,4583,Active,,,1.73,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
1553,562782,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis L2/oflR harboring ompA gene,Other,19687238.0,
1554,562783,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia suis S45/rifR harboring rpoB gene,Other,19687238.0,
1555,562784,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis J/6276/rifR harboring ompA and rpoB genes,Other,19687238.0,
1556,562785,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia muridarum MoPn/oflR harboring ompA gene,Other,19687238.0,
1557,562786,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis L2/oflR-rifR1 harboring ompA and rpoB genes,Other,19687238.0,
1558,562787,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia suis R19/tetR harboring tet(C) allele,Other,19687238.0,
1559,562788,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia muridarum MoPn/rifRoflR harboring ompA and rpoB genes,Other,19687238.0,
1560,562789,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis L2/tetR13 harboring tet(C) allele,Other,19687238.0,
1561,562790,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis J/6276/tetR harboring tet(C) allele,Other,19687238.0,
1562,562791,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis F/70/rifR harboring rpoB gene,Other,19687238.0,
1563,562792,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydophila caviae GPIC/rifR harboring rpoB gene,Other,19687238.0,
1564,562793,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis L2/oflR-rifR2 harboring ampA and rpoB genes,Other,19687238.0,
1565,562794,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis J/6276/oflR-rifR1 harboring ompA and rpoB genes,Other,19687238.0,
1566,562795,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia muridarum MoPn/oflR-rifR harboring ompA and rpoB genes,Other,19687238.0,
1567,562796,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis J/6276/oflR-rifR2 harboring ompA and rpoB genes,Other,19687238.0,
1568,562797,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis L2/tetR1 harboring tet(C) allele,Other,19687238.0,
1569,562798,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia muridarum MoPn/tetR14 harboring tet(C) allele,Other,19687238.0,
1570,562799,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia muridarum MoPn/tetR1 harboring tet(C) allele,Other,19687238.0,
1571,562800,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Chlamydia trachomatis F/70/rifR-tetR harboring rpoB gene and tet(C) allele,Other,19687238.0,
1572,562824,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1573,562825,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1574,562826,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1575,562827,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1576,562828,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1577,562829,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1578,562926,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Clostridium difficile CD196 by broth dilution method,Other,19805572.0,
1579,562927,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Clostridium difficile ATCC 43603-M1 by broth dilution method,Other,19805572.0,
1580,562928,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Clostridium difficile ATCC 43603 by broth dilution method,Other,19805572.0,
1581,562929,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Clostridium difficile CD196 M1 by broth dilution method,Other,19805572.0,
1582,562930,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Clostridium difficile CD07-259 by broth dilution method,Other,19805572.0,
1583,562931,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Clostridium difficile 6269 by broth dilution method,Other,19805572.0,
1584,562932,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Clostridium difficile 6425 by broth dilution method,Other,19805572.0,
1585,562933,2,4,,103163813,4583,Unspecified,,,,,Upregulation of slpA gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1586,562934,2,4,,103163813,4583,Unspecified,,,,,Upregulation of slpA gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1587,562935,2,3,,103163813,4583,Active,,,,,Upregulation of slpA gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis,Other,19805572.0,
1588,562936,2,3,,103163813,4583,Active,,,,,Upregulation of cwp84 gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis,Other,19805572.0,
1589,562937,2,3,,103163813,4583,Active,,,,,Upregulation of cwp84 gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis,Other,19805572.0,
1590,562938,2,3,,103163813,4583,Active,,,,,Upregulation of cwp84 gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis,Other,19805572.0,
1591,562939,2,3,,103163813,4583,Inactive,,,,,Effect on fbp69 gene expression in Clostridium difficile 6425 at 0.5 times MIC by real-time PCR analysis,Other,19805572.0,
1592,562940,2,3,,103163813,4583,Inactive,,,,,Effect on fbp69 gene expression in Clostridium difficile CD07-259 at 0.5 times MIC by real-time PCR analysis,Other,19805572.0,
1593,562941,2,3,,103163813,4583,Inactive,,,,,Effect on fbp69 gene expression in Clostridium difficile 6269 at 0.5 times MIC by real-time PCR analysis,Other,19805572.0,
1594,562942,2,4,,103163813,4583,Unspecified,,,,,Upregulation of cwp84 gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1595,562943,2,4,,103163813,4583,Unspecified,,,,,Upregulation of slpA gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1596,562944,2,4,,103163813,4583,Unspecified,,,,,Upregulation of fbp68 gene expression in Clostridium difficile CD196 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1597,562945,2,4,,103163813,4583,Unspecified,,,,,Upregulation of cwp84 gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1598,562946,2,4,,103163813,4583,Unspecified,,,,,Upregulation of slpA gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1599,563007,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1600,563008,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1601,563009,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1602,563010,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay,Other,19687244.0,
1603,563011,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay,Other,19687244.0,
1604,563012,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay,Other,19687244.0,
1605,563013,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay,Other,19687244.0,
1606,563014,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay,Other,19687244.0,
1607,563015,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay,Other,19687244.0,
1608,563016,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay,Other,19687244.0,
1609,563017,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay,Other,19687244.0,
1610,563018,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene by resazurin microtiter assay,Other,19687244.0,
1611,563019,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay,Other,19687244.0,
1612,563020,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay,Other,19687244.0,
1613,563021,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay,Other,19687244.0,
1614,563022,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene by resazurin microtiter assay,Other,19687244.0,
1615,563023,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene and deletion of codons 678 and 679 in gyrB mutant gene by resazurin microtiter assay,Other,19687244.0,
1616,563024,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene by resazurin microtiter assay,Other,19687244.0,
1617,563025,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene by resazurin microtiter assay,Other,19687244.0,
1618,563026,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by resazurin microtiter assay,Other,19687244.0,
1619,563027,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene by resazurin microtiter assay,Other,19687244.0,
1620,563028,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene by resazurin microtiter assay,Other,19687244.0,
1621,563029,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene by resazurin microtiter assay,Other,19687244.0,
1622,563030,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene by resazurin microtiter assay,Other,19687244.0,
1623,563031,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene by resazurin microtiter assay,Other,19687244.0,
1624,563032,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 by resazurin microtiter assay,Other,19687244.0,
1625,563033,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 by resazurin microtiter assay,Other,19687244.0,
1626,563034,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 by resazurin microtiter assay,Other,19687244.0,
1627,563035,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 by resazurin microtiter assay,Other,19687244.0,
1628,563036,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 by resazurin microtiter assay,Other,19687244.0,
1629,563037,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 by resazurin microtiter assay,Other,19687244.0,
1630,563038,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 by resazurin microtiter assay,Other,19687244.0,
1631,563039,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 by resazurin microtiter assay,Other,19687244.0,
1632,563040,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 by resazurin microtiter assay,Other,19687244.0,
1633,563041,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1634,563042,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1635,563043,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1636,563044,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1637,563045,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1638,563046,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1639,563047,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1640,563048,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1641,563049,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1642,563050,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1643,563051,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1644,563052,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1645,563053,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1646,563054,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1647,563055,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1648,563056,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1649,563057,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1650,563058,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1651,563059,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1652,563101,2,4,,103163813,4583,Unspecified,,,,,Upregulation of fbp68 gene expression in Clostridium difficile CD196 M1 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1653,563208,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1654,563209,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1655,563210,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1656,563211,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene assessed as microbial susceptibility and deletion of codons 678 and 679 in gyrB mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1657,563212,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1658,563213,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1659,563214,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by agar proportion method,Other,19687244.0,
1660,563215,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1661,563216,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1662,563217,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1663,563218,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1664,563219,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1665,563220,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1666,563221,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1667,563222,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1668,563223,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1669,563224,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1670,563225,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1671,563226,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1672,563227,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1673,563228,2,3,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 assessed as microbial susceptibility by agar proportion method,Other,19687244.0,
1674,563330,2,4,,103163813,4583,Unspecified,,,,,Upregulation of cwp84 gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1675,563331,2,4,,103163813,4583,Unspecified,,,,,Upregulation of slpA gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1676,563332,2,4,,103163813,4583,Unspecified,,,,,Upregulation of fbp68 gene expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1677,563333,2,4,,103163813,4583,Unspecified,,,,,Upregulation of cwp84 gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1678,563334,2,4,,103163813,4583,Unspecified,,,,,Upregulation of slpA gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1679,563335,2,4,,103163813,4583,Unspecified,,,,,Upregulation of fbp68 gene expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by real-time PCR analysis relative to control,Other,19805572.0,
1680,563336,2,3,,103163813,4583,Unspecified,,,,,Induction of Cwp84 protease expression in Clostridium difficile 6425 at 0.5 times MIC by immunoblot analysis,Other,19805572.0,
1681,563337,2,3,,103163813,4583,Active,,,,,Induction of Cwp84 protease expression in Clostridium difficile CD196 at 0.5 times MIC by immunoblot analysis,Other,19805572.0,
1682,563338,2,3,,103163813,4583,Active,,,,,Induction of Cwp84 protease expression in Clostridium difficile CD196 M1 at 0.5 times MIC by immunoblot analysis,Other,19805572.0,
1683,563339,2,3,,103163813,4583,Unspecified,,,,,Induction of Cwp84 protease expression in Clostridium difficile ATCC 43603-M1 at 0.5 times MIC by immunoblot analysis,Other,19805572.0,
1684,563340,2,3,,103163813,4583,Inactive,,,,,Effect on Cwp84 protease expression in Clostridium difficile ATCC 43603 at 0.5 times MIC by immunoblot analysis,Other,19805572.0,
1685,563341,2,3,,103163813,4583,Active,,,,,Induction of Cwp84 protease expression in Clostridium difficile 6269 at 0.5 times MIC by immunoblot analysis,Other,19805572.0,
1686,563342,2,3,,103163813,4583,Active,,,,,Induction of Cwp84 protease expression in Clostridium difficile CD07-259 at 0.5 times MIC by immunoblot analysis,Other,19805572.0,
1687,563500,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Serratia marcescens ATCC 13880 by broth dilution method,Other,19752278.0,
1688,563501,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-resistant Serratia marcescens 01 by broth dilution method,Other,19752278.0,
1689,563502,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 71 by broth dilution method,Other,19752278.0,
1690,563503,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against cetylpyridinium chloride-sensitive Serratia marcescens 79 by broth dilution method,Other,19752278.0,
1691,572147,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method,Other,18591276.0,
1692,572150,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method,Other,18591276.0,
1693,572151,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method,Other,18591276.0,
1694,572509,5,2,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Salmonella enterica serovar Typhimurium isolate SL1344 harboring wild type ParC gene by agar dilution method,Other,19596880.0,
1695,572510,5,2,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Salmonella enterica serovar Braenderup isolate s2906 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1696,572511,5,2,,103163813,4583,Inconclusive,,,,,Antimicrobial activity against Salmonella enterica serovar Typhimurium isolate s2878 harboring wild type ParC gene by agar dilution method,Other,19596880.0,
1697,572512,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica serovar Montevideo isolate s2317 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1698,572513,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica serovar Mbandaka isolate s2159 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1699,572514,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica serovar Corvallis isolate s2064 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1700,572515,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Salmonella enterica serovar Stanley isolate s2043 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1701,572516,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrS-positive Salmonella enterica serovar Montevideo isolate s2944 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1702,572517,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrS-positive Salmonella enterica serovar Braenderup isolate s2856 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1703,572518,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrS-positive Salmonella enterica serovar Typhimurium isolate s2705 harboring wild type ParC gene by agar dilution method,Other,19596880.0,
1704,572519,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrS-positive Salmonella enterica serovar Typhimurium isolate s2425 harboring wild type ParC gene by agar dilution method,Other,19596880.0,
1705,572520,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrS-positive Salmonella enterica serovar Virginia isolate s2219 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1706,572521,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrS-positive Salmonella enterica serovar Montevideo isolate s2209 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1707,572522,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrA-positive Salmonella enterica serovar Mbandaka isolate s2093 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1708,572523,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrS-positive Salmonella enterica serovar Corvallis isolate s2052 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1709,572524,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrS-positive Salmonella enterica serovar Stanley isolate s2018 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1710,572525,5,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against qnrS-positive Salmonella enterica serovar Corvallis isolate s2017 harboring ParC QRDR mutant gene by agar dilution method,Other,19596880.0,
1711,574583,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1712,574589,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 obtained from pus of patient at 2 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1713,574784,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2403 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1714,574790,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1715,574796,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1716,574802,2,3,,103163813,4583,Inactive,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 obtained from sputum of patient at 2 ug/ml by Bactec MGIT960 modified proportion method,Other,20713679.0,
1717,574806,5,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 625 horboring rpoB S531L/G566R/I569L, katG S315T/R463L, gyrA A90V/S95T, rrs A1401G by CLSI method",Other,20713679.0,
1718,574807,5,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 761 horboring rpoB S531L/Q510P, katG S315T/R463L, gyrA D94N/S95T, rrs G1484T by CLSI method",Other,20713679.0,
1719,574808,5,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2301 horboring rpoB S531L, katG R463L/E217G, gyrA D94N/S95T, rrs A1401G by CLSI method",Other,20713679.0,
1720,574809,5,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2474 horboring rpoB H526Y, katG D329A/R463L, gyrA D94G/S95T, rrs A1401G by CLSI method",Other,20713679.0,
1721,574810,5,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis isolate 2911 horboring rpoB D516V, katG S315T/R463L, gyrA D94G/S95T/R128S/Y129C, rrs A1401G by CLSI method",Other,20713679.0,
1722,574811,5,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against extensively drug-resistant Mycobacterium tuberculosis H37Rv by CLSI method,Other,20713679.0,
1723,576612,7,5,,103163813,4583,Unspecified,7531135.0,3757.0,1412.54,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
1724,581492,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA A90V mutant gene,Other,19721073.0,
1725,581493,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94A mutant gene,Other,19721073.0,
1726,581494,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94G mutant gene,Other,19721073.0,
1727,581495,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94N mutant gene,Other,19721073.0,
1728,581496,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrA D94Y mutant gene,Other,19721073.0,
1729,581497,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrB D500N mutant gene,Other,19721073.0,
1730,581498,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrB D540D mutant gene,Other,19721073.0,
1731,581499,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying mutation,Other,19721073.0,
1732,581500,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against fluoroquinolone-resistant Mycobacterium tuberculosis Beijing genotype isolates without carrying multiple mutation and harboring gyrB A90V and T539P mutant genes,Other,19721073.0,
1733,581501,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA A90V mutant gene,Other,19721073.0,
1734,581502,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94A mutant gene,Other,19721073.0,
1735,581503,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94G mutant gene,Other,19721073.0,
1736,581504,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94N mutant gene,Other,19721073.0,
1737,581505,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94Y mutant gene,Other,19721073.0,
1738,581506,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA G88A mutant gene,Other,19721073.0,
1739,581507,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB D500N mutant gene,Other,19721073.0,
1740,581508,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB D540D mutant gene,Other,19721073.0,
1741,581509,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing,Other,19721073.0,
1742,581510,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB A90V and D500A mutant genes,Other,19721073.0,
1743,581511,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrB A90V and T539P mutant genes,Other,19721073.0,
1744,581512,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA A90V and D94A mutant genes,Other,19721073.0,
1745,581513,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA A90V and D94G mutant genes,Other,19721073.0,
1746,581514,4,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against mixture of fluoroquinolone-resistant and sensitive Mycobacterium tuberculosis Beijing genotype isolates carrying heteropeaks upon sequencing at mutation site and harboring gyrA D94G and D94A mutant genes,Other,19721073.0,
1747,588208,2,3,,103163813,4583,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
1748,588214,2,3,,103163813,4583,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1749,588215,2,3,,103163813,4583,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1750,588216,2,3,,103163813,4583,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1751,588217,2,3,,103163813,4583,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1752,588218,2,3,,103163813,4583,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1753,588219,2,3,,103163813,4583,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1754,588220,2,3,,103163813,4583,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
1755,588334,1,1,,56423109,4583,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1756,588335,1,1,,56423109,4583,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1757,588342,1,1,,11533038,4583,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
1758,588349,1,1,,90341488,4583,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
1759,588352,1,2,,56423109,4583,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1760,588354,1,1,,56423109,4583,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1761,588358,1,2,,56423109,4583,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1762,588368,1,2,,11533038,4583,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
1763,588378,1,1,,90341488,4583,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
1764,588391,1,1,,56423109,4583,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1765,588405,1,1,,56423109,4583,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1766,588413,1,2,,56423109,4583,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1767,588436,1,1,,56423109,4583,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1768,588453,1,1,,56423109,4583,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1769,588453,1,1,,85231170,4583,Inactive,8659577.0,58819.0,17.7828,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1770,588453,1,1,,90341488,4583,Inactive,8659577.0,58819.0,23.7781,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1771,588456,1,1,,56423109,4583,Inactive,8659577.0,58819.0,79.4328,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1772,588456,1,1,,90341488,4583,Inactive,8659577.0,58819.0,3.9811,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1773,588458,1,1,,56423109,4583,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1774,588459,1,2,,11533038,4583,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
1775,588459,1,2,,11533038,4583,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
1776,588459,1,2,,11533038,4583,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
1777,588460,1,2,,11533038,4583,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
1778,588460,1,2,,11533038,4583,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
1779,588460,1,2,,11533038,4583,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
1780,588461,1,2,,11533038,4583,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
1781,588461,1,2,,11533038,4583,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
1782,588461,1,2,,11533038,4583,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
1783,588473,1,1,,56423109,4583,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1784,588473,1,1,,56423109,4583,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1785,588475,1,2,,56423109,4583,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1786,588475,1,2,,56423109,4583,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1787,588478,1,2,,124801091,4583,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1788,588489,1,1,,56423109,4583,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1789,588492,1,1,,56423109,4583,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1790,588493,1,2,,56423109,4583,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1791,588497,1,2,,56423109,4583,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1792,588497,1,2,,56423109,4583,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1793,588497,1,2,,56423109,4583,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1794,588499,1,3,,56423109,4583,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1795,588499,1,3,,56423109,4583,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1796,588499,1,3,,56423109,4583,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1797,588501,1,2,,56423109,4583,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1798,588501,1,2,,56423109,4583,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1799,588501,1,2,,56423109,4583,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1800,588506,1,2,,11533038,4583,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
1801,588511,1,2,,56423109,4583,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1802,588519,1,2,,92124396,4583,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1803,588519,1,2,,92125279,4583,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1804,588549,1,1,,56423109,4583,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1805,588550,1,1,,11533038,4583,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
1806,588579,1,1,,56423109,4583,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1807,588579,1,1,,90341488,4583,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1808,588579,1,1,,124880995,4583,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1809,588579,1,1,,124880996,4583,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1810,588590,1,1,,50106760,4583,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1811,588590,1,1,,56423109,4583,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1812,588591,1,1,,50106760,4583,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1813,588591,1,1,,56423109,4583,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1814,588621,1,1,,56423109,4583,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1815,588627,1,1,,56423109,4583,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1816,588664,1,2,,56423109,4583,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1817,588664,1,2,,56423109,4583,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1818,588674,1,2,,56423109,4583,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1819,588675,1,1,,56423109,4583,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1820,588676,1,1,,56423109,4583,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1821,588685,1,1,,11533038,4583,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
1822,588689,1,1,,56423109,4583,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1823,588692,2,1,,56423109,4583,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1824,588726,1,2,,56423109,4583,Active,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1825,588727,1,1,,56423109,4583,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1826,588795,1,1,,56423109,4583,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1827,588795,1,1,,90341488,4583,Inconclusive,4758356.0,2237.0,37.6858,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1828,588814,1,3,,56423109,4583,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1829,588819,1,4,,56423109,4583,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1830,588834,2,1,,50106760,4583,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1831,588834,2,1,,144204254,4583,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1832,588849,1,1,,11533038,4583,Inconclusive,73858575.0,9986.0,,AC50_uM,Human Ras-Converting Enzyme Inhibition Assay Measured in Biochemical System Using Plate Reader - 2034-04_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1833,588850,1,1,,56423109,4583,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1834,588852,1,3,,56423109,4583,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1835,588855,1,1,,56423109,4583,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1836,588856,1,1,,56423109,4583,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1837,602123,1,1,,56423109,4583,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1838,602141,1,1,,56423109,4583,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1839,602162,1,1,,56423109,4583,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1840,602163,1,1,,56423109,4583,Active,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1841,602179,1,2,,56423109,4583,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1842,602229,1,1,,56423109,4583,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1843,602233,1,1,,56423109,4583,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1844,602244,1,2,,56423109,4583,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1845,602247,1,2,,56423109,4583,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1846,602248,1,2,,56423109,4583,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1847,602250,1,2,,56423109,4583,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1848,602252,1,1,,56423109,4583,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1849,602252,1,1,,56423109,4583,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1850,602261,1,1,,56423109,4583,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1851,602274,1,2,,56423109,4583,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1852,602281,1,1,,56423109,4583,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1853,602281,1,1,,56423109,4583,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1854,602310,1,2,,56423109,4583,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1855,602313,1,1,,56423109,4583,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1856,602314,1,2,,92124396,4583,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1857,602314,1,2,,92125279,4583,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1858,602329,1,1,,56423109,4583,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1859,602332,1,1,,56423109,4583,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1860,602332,1,1,,90341488,4583,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1861,602332,1,1,,124880995,4583,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1862,602332,1,1,,124880996,4583,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1863,602340,1,2,,56423109,4583,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1864,602342,2,1,,56423109,4583,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1865,602346,1,1,,56423109,4583,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1866,602363,1,1,,56423109,4583,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1867,602393,1,1,,56423109,4583,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1868,602396,1,2,,56423109,4583,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1869,602399,1,2,,56423109,4583,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1870,602405,1,1,,56423109,4583,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1871,602410,1,1,,56423109,4583,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1872,602429,1,1,,56423109,4583,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1873,602438,1,1,,56423109,4583,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1874,602440,1,1,,56423109,4583,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1875,602449,1,2,,56423109,4583,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1876,602481,1,1,,56423109,4583,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1877,623870,1,1,,56423109,4583,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1878,623870,1,1,,56423109,4583,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1879,623877,1,1,,56423109,4583,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1880,623901,1,1,,56423109,4583,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1881,623908,1,1,,56423109,4583,Active,11141885.0,60482.0,,,Counter screen assay of the parental HEK293 cells for compounds that activate the Choline Transporter (CHT),Screening,,
1882,624037,1,3,,56423109,4583,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1883,624038,1,3,,56423109,4583,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1884,624040,1,3,,56423109,4583,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1885,624101,1,2,,85788436,4583,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1886,624125,1,4,,56423109,4583,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1887,624126,1,3,,56423109,4583,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1888,624127,1,2,,56423109,4583,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1889,624146,1,1,,90341488,4583,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
1890,624147,1,1,,90341488,4583,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
1891,624148,1,2,,90341488,4583,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
1892,624149,1,1,,90341488,4583,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
1893,624151,1,1,,85788436,4583,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
1894,624156,1,1,,85788436,4583,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1895,624168,1,1,,56423109,4583,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1896,624169,1,1,,56423109,4583,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1897,624170,1,1,,56423109,4583,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1898,624171,1,1,,56423109,4583,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1899,624172,1,1,,56423109,4583,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1900,624173,1,3,,56423109,4583,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1901,624178,1,1,,56423109,4583,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1902,624202,1,1,,56423109,4583,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1903,624204,1,2,,56423109,4583,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1904,624246,1,1,,56423109,4583,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1905,624256,1,2,,56423109,4583,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1906,624263,1,1,,56423109,4583,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1907,624263,1,1,,56423109,4583,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1908,624267,1,2,,56423109,4583,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1909,624267,1,2,,56423109,4583,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1910,624268,1,3,,56423109,4583,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1911,624288,1,1,,56423109,4583,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1912,624296,1,1,,56423109,4583,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1913,624297,1,1,,56423109,4583,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1914,624304,1,2,,56423109,4583,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1915,624330,1,2,,56423109,4583,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1916,624349,1,2,,92124396,4583,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1917,624349,1,2,,92125279,4583,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1918,624349,1,2,,92307540,4583,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1919,624349,1,2,,92309103,4583,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1920,624349,1,2,,121362467,4583,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1921,624349,1,2,,121362950,4583,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1922,624352,1,1,,56423109,4583,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1923,624354,1,1,,56423109,4583,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1924,624377,1,1,,11533038,4583,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1925,624414,1,1,,56423109,4583,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1926,624415,1,2,,56423109,4583,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1927,624416,1,1,,11533038,4583,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1928,624417,1,1,,56423109,4583,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1929,624418,1,1,,56423109,4583,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1930,624455,1,1,,90341488,4583,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
1931,624463,1,1,,56423109,4583,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1932,624464,1,1,,56423109,4583,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1933,624465,1,1,,56423109,4583,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1934,624466,1,3,,11533038,4583,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1935,624467,1,1,,11533038,4583,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1936,624483,1,1,,56423109,4583,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1937,625144,5,5,,103163813,4583,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1938,625145,4,7,,103163813,4583,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1939,625146,5,5,,103163813,4583,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1940,625147,4,7,,103163813,4583,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1941,625148,4,7,,103163813,4583,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1942,625149,4,7,,103163813,4583,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1943,625150,5,5,,103163813,4583,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1944,625151,4,7,,103163813,4583,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1945,625152,4,7,,103163813,4583,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1946,625153,4,7,,103163813,4583,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1947,625154,4,7,,103163813,4583,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1948,625155,4,7,,103163813,4583,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1949,625156,1,9,,103163813,4583,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1950,625157,6,2,,103163813,4583,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1951,625158,3,4,,103163813,4583,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1952,625159,5,5,,103163813,4583,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1953,625160,1,9,,103163813,4583,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1954,625161,4,7,,103163813,4583,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1955,625162,4,7,,103163813,4583,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1956,625163,4,7,,103163813,4583,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1957,625164,1,6,,103163813,4583,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1958,625165,3,4,,103163813,4583,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1959,625166,3,4,,103163813,4583,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1960,625167,5,5,,103163813,4583,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1961,625168,4,7,,103163813,4583,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1962,625169,1,6,,103163813,4583,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1963,625170,3,4,,103163813,4583,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1964,625171,4,7,,103163813,4583,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1965,625172,4,7,,103163813,4583,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1966,625173,5,5,,103163813,4583,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1967,625174,5,5,,103163813,4583,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1968,625175,5,5,,103163813,4583,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1969,625176,1,9,,103163813,4583,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1970,625177,5,5,,103163813,4583,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1971,625178,5,5,,103163813,4583,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1972,625179,1,9,,103163813,4583,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1973,625180,5,5,,103163813,4583,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1974,625181,5,5,,103163813,4583,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1975,625182,5,5,,103163813,4583,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1976,625183,5,5,,103163813,4583,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1977,625184,5,5,,103163813,4583,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1978,625185,5,5,,103163813,4583,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1979,625186,5,5,,103163813,4583,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1980,625187,5,5,,103163813,4583,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1981,625188,1,9,,103163813,4583,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1982,625189,1,7,,103163813,4583,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1983,625190,4,5,,103163813,4583,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1984,625191,4,7,,103163813,4583,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1985,625192,4,7,,103163813,4583,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1986,625193,5,5,,103163813,4583,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1987,625194,4,7,,103163813,4583,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1988,625195,4,7,,103163813,4583,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1989,625196,5,6,,103163813,4583,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1990,625197,3,4,,103163813,4583,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1991,625198,4,7,,103163813,4583,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1992,625199,4,7,,103163813,4583,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1993,625200,4,7,,103163813,4583,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1994,625201,4,7,,103163813,4583,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1995,625202,4,7,,103163813,4583,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1996,625203,4,7,,103163813,4583,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1997,625204,4,7,,103163813,4583,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1998,625205,4,7,,103163813,4583,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1999,625206,4,7,,103163813,4583,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2000,625207,4,7,,103163813,4583,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2001,625208,5,5,,103163813,4583,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2002,625209,4,7,,103163813,4583,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2003,625210,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2004,625211,1,6,,103163813,4583,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2005,625212,3,4,,103163813,4583,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2006,625213,4,7,,103163813,4583,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2007,625214,1,9,,103163813,4583,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2008,625215,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2009,625216,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2010,625217,4,7,,103163813,4583,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2011,625218,4,7,,103163813,4583,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2012,625219,3,4,,103163813,4583,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2013,625220,4,7,,103163813,4583,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2014,625221,4,7,,103163813,4583,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2015,625222,4,7,,103163813,4583,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2016,625223,4,7,,103163813,4583,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2017,625224,3,4,,103163813,4583,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2018,625225,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2019,625226,4,7,,103163813,4583,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2020,625227,4,7,,103163813,4583,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2021,625228,4,7,,103163813,4583,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2022,625229,5,5,,103163813,4583,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2023,625230,1,6,,103163813,4583,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2024,625231,4,7,,103163813,4583,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2025,625232,1,9,,103163813,4583,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2026,625233,4,7,,103163813,4583,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2027,625234,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2028,625235,4,7,,103163813,4583,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2029,625236,5,5,,103163813,4583,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2030,625237,4,7,,103163813,4583,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2031,625238,4,7,,103163813,4583,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2032,625239,4,7,,103163813,4583,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2033,625240,1,9,,103163813,4583,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2034,625241,4,7,,103163813,4583,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2035,625242,4,7,,103163813,4583,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2036,625243,5,5,,103163813,4583,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2037,625244,5,5,,103163813,4583,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2038,625245,5,5,,103163813,4583,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2039,625246,1,9,,103163813,4583,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2040,625247,5,5,,103163813,4583,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2041,625248,5,5,,103163813,4583,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2042,625249,5,5,,103163813,4583,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2043,625250,5,5,,103163813,4583,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2044,625251,5,5,,103163813,4583,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2045,625252,4,7,,103163813,4583,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2046,625253,4,7,,103163813,4583,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2047,625254,4,7,,103163813,4583,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2048,625255,4,7,,103163813,4583,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2049,625256,4,7,,103163813,4583,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2050,625257,4,7,,103163813,4583,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2051,625258,4,7,,103163813,4583,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2052,625259,4,7,,103163813,4583,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2053,625260,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2054,625261,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2055,625262,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2056,625263,4,7,,103163813,4583,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2057,625264,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2058,625265,1,6,,103163813,4583,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2059,625266,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2060,625267,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2061,625268,4,2,,103163813,4583,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2062,625268,4,2,,103163813,4583,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2063,625268,4,2,,103163813,4583,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2064,625268,4,2,,103163813,4583,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2065,625269,4,7,,103163813,4583,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2066,625270,4,7,,103163813,4583,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2067,625271,5,5,,103163813,4583,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2068,625272,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2069,625273,4,6,,103163813,4583,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2070,625274,1,6,,103163813,4583,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2071,625275,3,4,,103163813,4583,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2072,625279,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2073,625280,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2074,625281,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2075,625282,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2076,625283,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2077,625284,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2078,625285,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2079,625286,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2080,625287,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2081,625288,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2082,625289,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2083,625290,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2084,625291,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2085,625292,1,3,,103163813,4583,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2086,635079,3,1,,103163813,4583,Unspecified,,,,,Permeability of the compound after 2.5 hrs by PAMPA-BBB assay,Other,22100138.0,
2087,637605,3,1,,103163813,4583,Unspecified,,,,,Permeability of the compound by PAMPA,Other,22209418.0,
2088,639368,3,1,,103163813,4583,Unspecified,,,,,Permeability of the compound by PAMPA assay,Other,21420206.0,
2089,651550,1,1,,56423109,4583,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2090,651560,1,1,,56423109,4583,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2091,651572,1,2,,11533038,4583,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2092,651582,1,1,,56423109,4583,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2093,651602,1,1,,11533038,4583,Active,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2094,651602,1,1,,11533038,4583,Active,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2095,651602,1,1,,11533038,4583,Active,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2096,651610,2,1,,11533038,4583,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2097,651631,4,1,,144204254,4583,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2098,651632,4,1,,144204254,4583,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2099,651633,4,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2100,651634,4,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2101,651635,1,3,,56423109,4583,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2102,651635,1,3,,90341488,4583,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2103,651636,1,1,,56423109,4583,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2104,651640,1,1,,11533038,4583,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2105,651644,1,1,,56423109,4583,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2106,651647,1,1,,56423109,4583,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2107,651654,1,1,,56423109,4583,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2108,651658,1,1,,11533038,4583,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2109,651660,1,1,,11533038,4583,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2110,651661,2,1,,11533038,4583,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2111,651687,1,1,,56423109,4583,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2112,651699,1,1,,56423109,4583,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2113,651699,1,1,,56423109,4583,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2114,651702,1,2,,56423109,4583,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2115,651704,2,1,,11533038,4583,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2116,651710,1,1,,11533038,4583,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2117,651711,2,1,,11533038,4583,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2118,651718,1,2,,11533038,4583,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2119,651719,1,2,,11533038,4583,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
2120,651723,1,1,,56423109,4583,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2121,651724,1,1,,56423109,4583,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2122,651725,1,1,,56423109,4583,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2123,651768,1,2,,56423109,4583,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2124,651800,1,1,,11533038,4583,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2125,651819,1,1,,56423109,4583,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2126,651820,1,1,,56423109,4583,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2127,651821,2,4,,11533038,4583,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2128,651828,1,2,,92309103,4583,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2129,651828,1,2,,121361554,4583,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2130,651828,1,2,,121362467,4583,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2131,651957,1,1,,11533038,4583,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2132,651958,1,1,,11533038,4583,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2133,651965,1,1,,56423109,4583,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2134,651982,1,1,,11533038,4583,Active,16130723.0,947287.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
2135,651982,1,1,,11533038,4583,Active,16130724.0,947286.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
2136,651982,1,1,,11533038,4583,Active,16130726.0,947294.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
2137,651983,1,1,,11533038,4583,Active,,,,,Counterscreen for inhibitors of RecBCD: Absorbance-based cell-based high throughput assay to identify inhibitors of bacterial viability,Screening,,
2138,651984,1,1,,11533038,4583,Active,15645703.0,899625.0,,,Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2139,651984,1,1,,11533038,4583,Active,15646160.0,899738.0,,,Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2140,651999,1,1,,56423109,4583,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2141,652010,1,1,,11533038,4583,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2142,652017,1,1,,11533038,4583,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2143,652025,1,1,,56423109,4583,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2144,652039,1,1,,11533038,4583,Active,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2145,652048,1,2,,56423109,4583,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2146,652048,1,2,,144204254,4583,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2147,652051,1,1,,56423109,4583,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2148,652051,1,1,,144204254,4583,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2149,652054,1,1,,56423109,4583,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2150,652067,1,4,,11533038,4583,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2151,652104,1,1,,56423109,4583,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2152,652105,1,1,,56423109,4583,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2153,652106,1,1,,56423109,4583,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2154,652106,1,1,,90341488,4583,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2155,652115,1,1,,11533038,4583,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2156,652126,1,3,,11533038,4583,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2157,652154,1,1,,11533038,4583,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2158,652162,2,1,,11533038,4583,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2159,652163,1,1,,11533038,4583,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2160,652163,1,1,,56423109,4583,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2161,652197,1,1,,11533038,4583,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2162,652257,1,1,,11533038,4583,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2163,656227,2,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2164,656228,2,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2165,656229,2,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2166,656230,2,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, streptomycin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2167,656231,2,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, ethambutol-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2168,656232,2,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2169,656233,2,2,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid-, rifampin-, ofloxacin-, ethambutol-, streptomycin-resistant Mycobacterium tuberculosis after 16 to 24 hrs by alamar blue assay",Other,22418278.0,
2170,659472,1,3,,103163813,4583,Unspecified,,,,,Effective permeability across porcine polar brain lipid after 4 hrs by PAMPA,Other,22257026.0,
2171,665367,1,3,,103163813,4583,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv at 10 ug/mL by radiometric growth assay,Other,22578509.0,
2172,665368,1,3,,103163813,4583,Inactive,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis clinical isolate at 10 ug/mL by radiometric growth assay,Other,22578509.0,
2173,678712,1,8,,103163813,4583,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
2174,678713,1,8,,103163813,4583,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
2175,678714,1,8,,103163813,4583,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2176,678715,1,8,,103163813,4583,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2177,678716,1,8,,103163813,4583,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
2178,678717,1,8,,103163813,4583,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
2179,678721,1,5,,103163813,4583,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
2180,678722,1,5,,103163813,4583,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
2181,679031,1,8,,103163813,4583,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: inhibition of DNP-SG uptakee (DNP-SG: 1 uM, OFLX: 10000 uM) in bile canalicular membrane vesicles from SD rat",Other,9495864.0,
2182,680399,1,8,,103163813,4583,Unspecified,146345508.0,6583.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, OFLX: 1000 uM) in Xenopus laevis oocytes",Other,10215651.0,
2183,681306,1,8,,103163813,4583,Unspecified,296439301.0,4363.0,,,"TP_TRANSPORTER: increase in Vincristine intracellular accumulation (Vincristine: 0.03 uM, Ofloxacin: 21.7 mg/mL) in HL60R cells: flow cytometric analysis",Other,10817732.0,
2184,681771,1,7,,103163813,4583,Unspecified,81886651.0,29509.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 2 uM, OFLX: 2000 uM) in Xenopus laevis oocytes",Other,10411577.0,
2185,682301,1,7,,103163813,4583,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, OFLX: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
2186,686940,1,1,,11533038,4583,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2187,686949,1,1,,11533038,4583,Active,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput confirmation assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2188,686952,1,2,,11533038,4583,Active,,,,,Counterscreen for activators of kallikrein-7 (K7) zymogen: Fluorescence intensity-based biochemical high throughput counterscreen assay for activators that optically interfere with measurement of EDANS-DABCYL fluorescence,Screening,,
2189,686964,1,1,,11533038,4583,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2190,686970,1,2,,56423109,4583,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2191,686971,1,2,,56423109,4583,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2192,686977,2,1,,49699069,4583,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
2193,686978,1,1,,56423109,4583,Inconclusive,79154014.0,55775.0,29.0929,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2194,686978,1,1,,124880995,4583,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2195,686978,1,1,,124880996,4583,Active,79154014.0,55775.0,12.9953,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2196,686978,1,1,,144204254,4583,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2197,686979,1,1,,56423109,4583,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2198,686979,1,1,,124880995,4583,Inconclusive,79154014.0,55775.0,16.3601,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2199,686979,1,1,,124880996,4583,Active,79154014.0,55775.0,20.5962,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2200,686979,1,1,,144204254,4583,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2201,686992,2,1,,11533038,4583,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2202,686996,1,1,,11533038,4583,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2203,687014,1,1,,11533038,4583,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2204,687016,1,1,,11533038,4583,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2205,687035,1,1,,163564858,4583,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2206,687037,1,3,,163564858,4583,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
2207,687493,1,3,,103163813,4583,Unspecified,,,,,Oral bioavailability in rat,Other,22995771.0,
2208,687494,2,3,,103163813,4583,Unspecified,,,,,"Cmax in rat at 10 mg/kg, iv",Other,22995771.0,
2209,687495,3,2,,103163813,4583,Unspecified,,,,,"AUC (0 to infinity) in rat at 10 mg/kg, iv",Other,22995771.0,
2210,687496,1,2,,103163813,4583,Unspecified,,,,,Half life in rat,Other,22995771.0,
2211,687497,2,3,,103163813,4583,Unspecified,,,,,Clearance in rat,Other,22995771.0,
2212,687498,2,3,,103163813,4583,Unspecified,,,,,Volume of distribution in rat,Other,22995771.0,
2213,687499,1,3,,103163813,4583,Unspecified,,,,,Drug excretion in rat urine,Other,22995771.0,
2214,691688,2,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bartonella henselae infected in african green monkey Vero cells by immunofluorescence staining,Other,22995622.0,
2215,694227,2,2,,103163813,4583,Inconclusive,,,,,Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay,Other,23062712.0,
2216,694231,3,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv under anaerobic condition by BACTEC method,Other,23062712.0,
2217,694359,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv under anaerobic condition assessed as growth inhibition at 2 ug/ml by BACTEC method,Other,23062712.0,
2218,694360,3,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis MS-115 under anaerobic condition by BACTEC method,Other,23062712.0,
2219,694367,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis MS-115 under anaerobic condition assessed as growth inhibition at 2 ug/ml by BACTEC method,Other,23062712.0,
2220,696005,3,1,,103163813,4583,Unspecified,,,,,Permeability of the compound after 4 hrs by PAMPA assay,Other,23085773.0,
2221,699539,1,7,,103163813,4583,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2222,699540,1,7,,103163813,4583,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2223,699541,1,7,,103163813,4583,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2224,713895,2,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294,Other,22280816.0,
2225,713896,2,2,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis isolate CIBIN/UMF 15:19,Other,22280816.0,
2226,720504,1,1,,56423109,4583,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2227,720508,1,1,,11533038,4583,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2228,720509,1,1,,11533038,4583,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2229,720511,1,1,,11533038,4583,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2230,720516,2,1,,144204254,4583,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2231,720532,1,1,,124880995,4583,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2232,720532,1,1,,124880996,4583,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2233,720532,1,1,,144204254,4583,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2234,720533,1,1,,124880995,4583,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2235,720533,1,1,,124880996,4583,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2236,720533,1,1,,144204254,4583,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2237,720538,1,2,,90341488,4583,Inactive,220983390.0,410.0,4.2562,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
2238,720542,1,2,,56423109,4583,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2239,720543,1,1,,11533038,4583,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2240,720551,1,2,,56423109,4583,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2241,720552,2,1,,144204254,4583,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2242,720553,1,2,,56423109,4583,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2243,720554,1,3,,121362467,4583,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2244,720559,1,2,,90341488,4583,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
2245,720572,1,2,,90341488,4583,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
2246,720573,1,2,,90341488,4583,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
2247,720579,2,1,,56423109,4583,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2248,720579,2,1,,124880995,4583,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2249,720579,2,1,,124880996,4583,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2250,720580,1,1,,56423109,4583,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2251,720580,1,1,,124880995,4583,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2252,720580,1,1,,124880996,4583,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2253,720582,1,1,,11533038,4583,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2254,720596,1,1,,11533038,4583,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2255,720634,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2256,720635,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2257,720637,2,1,,144204254,4583,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2258,720641,1,2,,92307540,4583,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2259,720641,1,2,,92309103,4583,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2260,720647,1,2,,11533038,4583,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2261,720648,1,1,,11533038,4583,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2262,720674,2,2,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2263,720675,2,2,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2264,720678,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2265,720679,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2266,720680,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2267,720681,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2268,720682,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2269,720683,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2270,720684,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2271,720685,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2272,720686,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2273,720687,2,2,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2274,720691,4,1,,144204254,4583,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2275,720692,3,1,,144204254,4583,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2276,720693,3,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2277,720700,1,4,,11533038,4583,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2278,720702,1,1,,11533038,4583,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2279,720704,1,4,,11533038,4583,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2280,720707,1,2,,56423109,4583,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2281,720708,1,2,,56423109,4583,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2282,720709,1,2,,56423109,4583,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2283,720711,1,2,,56423109,4583,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2284,720717,1,3,,92124396,4583,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2285,720717,1,3,,92125279,4583,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2286,720717,1,3,,92307540,4583,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2287,720717,1,3,,92309103,4583,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2288,720719,2,1,,144204254,4583,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2289,720725,2,1,,144204254,4583,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2290,733004,1,4,,103163813,4583,Inactive,,,,,Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB G89C mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose gel electrophoresis,Other,23294829.0,
2291,733005,3,1,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB A91V mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose gel electrophoresis,Other,23294829.0,
2292,733006,3,1,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose gel electrophoresis,Other,23294829.0,
2293,733007,1,4,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium leprae DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 2 hrs at 30 degC by ethidium bromide based gel electrophoresis,Other,23294829.0,
2294,733008,1,2,,103163813,4583,Unspecified,,,,,Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 1 hr at 37 degC by ethidium bromide based gel electrophoresis,Other,23294829.0,
2295,733009,1,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv assessed as drug concentration causing =<1% reduction in bacterial growth incubated for 21 to 30 days by proportion method,Other,23294829.0,
2296,743012,3,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2297,743014,3,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2298,743015,3,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2299,743033,3,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2300,743035,2,1,,144204254,4583,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2301,743036,2,1,,144204254,4583,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2302,743040,3,1,,144204254,4583,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2303,743041,3,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2304,743042,3,1,,144204254,4583,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2305,743053,2,1,,144204254,4583,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2306,743054,2,1,,144204254,4583,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2307,743063,2,1,,144204254,4583,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2308,743064,3,1,,144204254,4583,Inconclusive,,,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2309,743065,3,1,,144204254,4583,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2310,743066,3,1,,144204254,4583,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2311,743067,2,1,,144204254,4583,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2312,743069,2,1,,144204254,4583,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2313,743074,2,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2314,743075,2,1,,144204254,4583,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2315,743077,2,1,,144204254,4583,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2316,743078,2,1,,144204254,4583,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2317,743079,3,1,,144204254,4583,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2318,743080,3,1,,144204254,4583,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2319,743081,3,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2320,743083,3,1,,144204254,4583,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2321,743084,3,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2322,743085,3,1,,144204254,4583,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2323,743086,3,1,,144204254,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2324,743091,2,1,,144204254,4583,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2325,743094,3,1,,144204254,4583,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2326,743122,2,1,,144204254,4583,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2327,743126,1,1,,11533038,4583,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2328,743139,2,1,,144204254,4583,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2329,743140,2,1,,144204254,4583,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2330,743191,3,1,,170465035,4583,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2331,743194,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2332,743199,2,1,,170465035,4583,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2333,743202,4,1,,170465035,4583,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2334,743203,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2335,743205,1,1,,90341488,4583,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2336,743205,1,1,,90341488,4583,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
2337,743206,1,1,,90341488,4583,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2338,743206,1,1,,90341488,4583,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
2339,743207,1,1,,90341488,4583,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2340,743207,1,1,,90341488,4583,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
2341,743209,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2342,743210,4,1,,170465035,4583,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2343,743211,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2344,743212,3,1,,170465035,4583,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2345,743213,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2346,743215,3,1,,170465035,4583,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2347,743217,3,1,,170465035,4583,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2348,743218,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2349,743219,3,1,,170465035,4583,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2350,743220,3,1,,170465035,4583,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2351,743221,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2352,743222,3,1,,170465035,4583,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2353,743223,3,1,,170465035,4583,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2354,743224,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2355,743225,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2356,743226,2,1,,170465035,4583,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2357,743227,2,1,,170465035,4583,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2358,743228,3,1,,170465035,4583,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2359,743238,1,1,,11533038,4583,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2360,743239,2,1,,170465035,4583,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2361,743240,2,1,,170465035,4583,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2362,743241,2,1,,170465035,4583,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2363,743242,2,1,,170465035,4583,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2364,743244,1,1,,90341488,4583,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2365,743244,1,1,,144204254,4583,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
2366,743247,1,2,,11533038,4583,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2367,743255,1,1,,56423109,4583,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2368,743266,1,2,,56423109,4583,Inactive,296080761.0,5745.0,79.4328,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2369,743268,1,1,,172080589,4583,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2370,743269,1,1,,11533038,4583,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2371,743269,1,1,,11533038,4583,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2372,743270,1,1,,172080589,4583,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2373,743271,1,1,,172080589,4583,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2374,743272,1,1,,172080589,4583,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2375,743279,1,2,,56423109,4583,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2376,743287,1,1,,11533038,4583,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
2377,743344,1,1,,174006255,4583,Inactive,,,14.9502,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2378,743345,1,1,,174006255,4583,Inactive,,,13.3244,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2379,743346,1,1,,174006255,4583,Inactive,,,0.3347,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2380,743347,1,1,,174006255,4583,Inactive,,,0.1677,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2381,743397,1,1,,11533038,4583,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2382,743398,1,1,,11533038,4583,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2383,755684,2,3,,103163813,4583,Unspecified,7531135.0,3757.0,1420.0,IC50,Inhibition of human ERG current by patch clamp assay,Confirmatory,23711922.0,
2384,762019,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli F-50 measured every 24 hrs for 5 days by conventional dilution method,Other,23811259.0,
2385,762020,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus 8035 measured every 24 hrs for 5 days by conventional dilution method,Other,23811259.0,
2386,762021,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus 209p measured every 24 hrs for 5 days by conventional dilution method,Other,23811259.0,
2387,762022,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa 9027 measured every 24 hrs for 5 days by conventional dilution method,Other,23811259.0,
2388,763993,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Shigella flexneri ATCC 15391 after 24 hrs by two-fold serial dilution method,Other,23811090.0,
2389,763994,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by two-fold serial dilution method,Other,23811090.0,
2390,763997,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Shigella flexneri ATCC 15391 assessed as diameter of inhibition zone at 1 mg/ml after 24 hrs by cup diffusion method (Rvb = 17 mm),Other,23811090.0,
2391,763998,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 6538P assessed as diameter of inhibition zone at 1 mg/ml after 24 hrs by cup diffusion method (Rvb = 15 mm),Other,23811090.0,
2392,763999,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 assessed as diameter of inhibition zone at 1 mg/ml after 24 hrs by cup diffusion method (Rvb = 16 mm),Other,23811090.0,
2393,765104,3,1,,103163813,4583,Unspecified,,,,,"Bacteriostatic activity against rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide-resistant Mycobacterium tuberculosis MS-115 assessed as growth inhibition",Other,23891229.0,
2394,765109,1,2,,103163813,4583,Unspecified,,,,,"Bacteriostatic activity against rifampicin, isoniazid, streptomycin, ethambutol and pyrazinamide-resistant Mycobacterium tuberculosis MS-115 assessed as growth inhibition at 2 ug/mL relative to control",Other,23891229.0,
2395,765112,3,1,,103163813,4583,Unspecified,,,,,Bacteriostatic activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition,Other,23891229.0,
2396,781326,1,2,,103163813,4583,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
2397,922237,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020325,Other,,
2398,922238,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020325,Other,,
2399,922239,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020325,Other,,
2400,922240,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020325,Other,,
2401,922241,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020325,Other,,
2402,922242,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020325,Other,,
2403,923113,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020325,Other,,
2404,923114,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020325,Other,,
2405,923115,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020325,Other,,
2406,923116,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020325,Other,,
2407,923117,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020325",Other,,
2408,923118,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020325,Other,,
2409,923119,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020325,Other,,
2410,923120,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020325,Other,,
2411,923121,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020325,Other,,
2412,923122,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020325,Other,,
2413,923123,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020325,Other,,
2414,923124,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020325,Other,,
2415,923125,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020325,Other,,
2416,929205,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020325,Other,,
2417,929206,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020325,Other,,
2418,929207,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020325,Other,,
2419,929208,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020325,Other,,
2420,929209,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020325",Other,,
2421,929210,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020325,Other,,
2422,929211,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020325,Other,,
2423,929212,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020325,Other,,
2424,929300,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020325,Other,,
2425,929301,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020325,Other,,
2426,929302,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020325,Other,,
2427,929303,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020325,Other,,
2428,929304,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020325,Other,,
2429,929305,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020325,Other,,
2430,929306,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020325,Other,,
2431,929307,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020325,Other,,
2432,929308,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020325,Other,,
2433,929309,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020325,Other,,
2434,929310,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020325,Other,,
2435,929311,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020325,Other,,
2436,929842,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020325,Other,,
2437,929843,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020325,Other,,
2438,929844,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020325,Other,,
2439,929845,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020325,Other,,
2440,929846,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020325,Other,,
2441,929847,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020325,Other,,
2442,929848,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020325,Other,,
2443,929849,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020325,Other,,
2444,929850,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020325,Other,,
2445,929851,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020325,Other,,
2446,929852,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020325,Other,,
2447,931326,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020325,Other,,
2448,931327,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020325,Other,,
2449,931328,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020325,Other,,
2450,931329,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020325,Other,,
2451,931330,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020325",Other,,
2452,931331,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020325,Other,,
2453,931332,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020325,Other,,
2454,941099,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020325,Other,,
2455,943119,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020325,Other,,
2456,943120,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020325,Other,,
2457,943121,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020325,Other,,
2458,943122,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020325,Other,,
2459,943123,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020325,Other,,
2460,943754,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020325,Other,,
2461,943755,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020325,Other,,
2462,943756,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020325,Other,,
2463,943757,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020325,Other,,
2464,943758,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020325,Other,,
2465,943759,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020325,Other,,
2466,943760,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020325,Other,,
2467,943761,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020325,Other,,
2468,943762,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020325,Other,,
2469,943763,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020325",Other,,
2470,943764,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020325,Other,,
2471,943765,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020325,Other,,
2472,943766,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020325,Other,,
2473,956090,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020325,Other,,
2474,956091,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020325,Other,,
2475,956092,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020325,Other,,
2476,956093,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020325,Other,,
2477,956094,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020325,Other,,
2478,956095,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020325,Other,,
2479,956096,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020325,Other,,
2480,956097,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020325,Other,,
2481,956098,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020325,Other,,
2482,956099,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020325,Other,,
2483,956666,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020325,Other,,
2484,956667,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020325,Other,,
2485,956668,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020325,Other,,
2486,956669,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020325,Other,,
2487,956670,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020325,Other,,
2488,956671,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020325,Other,,
2489,956672,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020325,Other,,
2490,956673,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020325,Other,,
2491,956674,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020325,Other,,
2492,966511,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020325,Other,,
2493,966512,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020325,Other,,
2494,966513,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020325,Other,,
2495,966514,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020325,Other,,
2496,966515,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020325,Other,,
2497,966516,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020325,Other,,
2498,966517,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020325,Other,,
2499,966518,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020325,Other,,
2500,966519,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020325,Other,,
2501,966520,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020325,Other,,
2502,966521,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020325,Other,,
2503,966522,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020325,Other,,
2504,966523,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020325,Other,,
2505,966524,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020325,Other,,
2506,966525,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020325,Other,,
2507,966526,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020325,Other,,
2508,966527,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020325,Other,,
2509,966528,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020325,Other,,
2510,966529,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020325,Other,,
2511,971872,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020325,Other,,
2512,971873,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020325,Other,,
2513,971874,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020325,Other,,
2514,971875,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020325,Other,,
2515,971876,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020325,Other,,
2516,971877,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020325,Other,,
2517,971878,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020325,Other,,
2518,971879,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020325,Other,,
2519,971880,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020325,Other,,
2520,971881,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020325,Other,,
2521,971882,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020325,Other,,
2522,971883,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020325,Other,,
2523,971884,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020325,Other,,
2524,972515,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020325,Other,,
2525,972516,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020325,Other,,
2526,972517,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020325,Other,,
2527,972518,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020325,Other,,
2528,972519,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020325,Other,,
2529,972520,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020325,Other,,
2530,974826,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020325,Other,,
2531,975458,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020325,Other,,
2532,975459,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020325,Other,,
2533,975460,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020325,Other,,
2534,975461,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020325,Other,,
2535,975462,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020325,Other,,
2536,975463,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020325,Other,,
2537,975464,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020325,Other,,
2538,975465,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020325,Other,,
2539,975466,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020325,Other,,
2540,975467,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020325,Other,,
2541,977489,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020325,Other,,
2542,977490,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020325,Other,,
2543,977491,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020325,Other,,
2544,977492,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020325,Other,,
2545,977493,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020325,Other,,
2546,977494,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020325,Other,,
2547,977495,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020325,Other,,
2548,977496,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020325,Other,,
2549,977599,1,1,,103163813,4583,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2550,977602,1,2,,103163813,4583,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2551,987801,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2552,987802,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2553,988385,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020325",Other,,
2554,988386,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020325",Other,,
2555,988387,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020325",Other,,
2556,988388,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020325",Other,,
2557,988389,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2558,988390,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020325",Other,,
2559,988391,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020325",Other,,
2560,988392,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020325",Other,,
2561,988393,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020325",Other,,
2562,988394,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2563,988395,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020325,Other,,
2564,988396,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020325",Other,,
2565,988397,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020325,Other,,
2566,988398,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020325",Other,,
2567,988399,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020325",Other,,
2568,988400,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020325",Other,,
2569,988401,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020325",Other,,
2570,988402,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2571,988403,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2572,988404,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020325",Other,,
2573,988405,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020325",Other,,
2574,988406,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020325",Other,,
2575,988407,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2576,988408,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2577,988409,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2578,988410,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2579,988411,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020325",Other,,
2580,988412,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2581,988413,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2582,988414,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2583,988415,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020325",Other,,
2584,988416,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2585,988417,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2586,988418,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020325",Other,,
2587,988419,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2588,988420,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020325",Other,,
2589,988421,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020325",Other,,
2590,988422,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020325",Other,,
2591,990871,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020325",Other,,
2592,990872,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020325,Other,,
2593,990873,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020325,Other,,
2594,990874,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020325",Other,,
2595,990875,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2596,990876,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2597,990877,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020325",Other,,
2598,990878,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020325",Other,,
2599,990879,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2600,990880,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2601,990881,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020325",Other,,
2602,990882,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2603,990883,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020325",Other,,
2604,990884,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020325",Other,,
2605,990885,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020325,Other,,
2606,990886,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2607,990887,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2608,990888,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2609,990889,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020325",Other,,
2610,990890,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020325,Other,,
2611,990891,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2612,990892,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020325",Other,,
2613,990893,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2614,990894,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020325",Other,,
2615,990895,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2616,990896,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020325",Other,,
2617,990897,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2618,990898,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020325",Other,,
2619,990899,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020325",Other,,
2620,990900,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2621,990901,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2622,990902,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020325",Other,,
2623,990903,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020325",Other,,
2624,990904,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020325,Other,,
2625,991486,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020325",Other,,
2626,991487,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020325",Other,,
2627,991488,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020325",Other,,
2628,991489,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020325",Other,,
2629,991490,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2630,991491,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2631,993357,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020325",Other,,
2632,993358,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020325",Other,,
2633,993359,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020325,Other,,
2634,993360,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2635,993361,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020325",Other,,
2636,993362,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2637,993363,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2638,993364,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2639,993365,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020325",Other,,
2640,993366,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2641,995898,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020325",Other,,
2642,995899,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2643,995900,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2644,995901,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020325",Other,,
2645,995902,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2646,995903,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2647,995904,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020325",Other,,
2648,995905,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020325",Other,,
2649,995906,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2650,995907,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020325",Other,,
2651,995908,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2652,995909,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2653,997774,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020325",Other,,
2654,997775,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020325",Other,,
2655,997776,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020325",Other,,
2656,997777,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020325",Other,,
2657,997778,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020325",Other,,
2658,997779,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2659,997780,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2660,997781,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020325",Other,,
2661,997782,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2662,997783,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020325",Other,,
2663,997784,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020325",Other,,
2664,997785,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2665,997786,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020325",Other,,
2666,997787,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2667,997788,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2668,997789,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020325",Other,,
2669,997790,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020325",Other,,
2670,997791,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020325",Other,,
2671,997792,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2672,997793,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2673,997794,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020325",Other,,
2674,997795,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020325",Other,,
2675,997796,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2676,1002690,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020325",Other,,
2677,1002691,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2678,1002692,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020325",Other,,
2679,1002693,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020325",Other,,
2680,1002694,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020325",Other,,
2681,1002695,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2682,1002696,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020325",Other,,
2683,1002697,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020325,Other,,
2684,1002698,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020325",Other,,
2685,1002699,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020325,Other,,
2686,1002700,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020325",Other,,
2687,1002701,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020325",Other,,
2688,1002702,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020325",Other,,
2689,1002703,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020325",Other,,
2690,1002704,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2691,1002705,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020325",Other,,
2692,1002706,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2693,1002707,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020325",Other,,
2694,1002708,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020325",Other,,
2695,1002709,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020325",Other,,
2696,1003295,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2697,1003296,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2698,1003297,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020325",Other,,
2699,1003298,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2700,1003299,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2701,1003300,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2702,1003301,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020325",Other,,
2703,1005169,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2704,1005170,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020325",Other,,
2705,1005171,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020325",Other,,
2706,1005172,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2707,1005173,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020325,Other,,
2708,1005174,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020325,Other,,
2709,1005175,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020325",Other,,
2710,1005176,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020325",Other,,
2711,1005177,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2712,1005178,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020325",Other,,
2713,1005179,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020325,Other,,
2714,1005180,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2715,1005181,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2716,1005182,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2717,1005183,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020325",Other,,
2718,1005184,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020325,Other,,
2719,1005185,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020325",Other,,
2720,1005186,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020325",Other,,
2721,1005187,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020325",Other,,
2722,1005188,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020325",Other,,
2723,1005189,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020325",Other,,
2724,1005190,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020325",Other,,
2725,1005191,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020325",Other,,
2726,1005192,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020325,Other,,
2727,1005193,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020325",Other,,
2728,1005194,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020325",Other,,
2729,1005195,1,3,,103163813,4583,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020325,Other,,
2730,1005196,1,3,,103163813,4583,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020325",Other,,
2731,1053175,2,1,,178125532,4583,Active,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
2732,1053188,2,1,,11533038,4583,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2733,1053197,1,1,,11533038,4583,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2734,1055939,3,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 20 hrs,Other,24224794.0,
2735,1055941,3,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 16 hrs,Other,24224794.0,
2736,1055943,3,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 after 16 hrs,Other,24224794.0,
2737,1056992,1,1,,103163813,4583,Unspecified,,,,,Permeability of the compound by PAMPA,Other,24128814.0,
2738,1056993,1,1,,103163813,4583,Unspecified,,,,,Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA,Other,24128814.0,
2739,1071344,1,1,,103163813,4583,Unspecified,,,,,Permeability of the compound by BBB-PAMPA,Other,24389509.0,
2740,1079931,1,1,,103163813,4583,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2741,1079932,1,1,,103163813,4583,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2742,1079933,1,1,,103163813,4583,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2743,1079934,1,1,,103163813,4583,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2744,1079935,1,1,,103163813,4583,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2745,1079936,1,1,,103163813,4583,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2746,1079937,1,1,,103163813,4583,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2747,1079938,1,1,,103163813,4583,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2748,1079939,1,1,,103163813,4583,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2749,1079940,1,1,,103163813,4583,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2750,1079941,1,1,,103163813,4583,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2751,1079942,1,1,,103163813,4583,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2752,1079943,1,1,,103163813,4583,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2753,1079944,1,1,,103163813,4583,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2754,1079945,1,1,,103163813,4583,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2755,1079946,1,1,,103163813,4583,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2756,1079947,1,1,,103163813,4583,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2757,1079948,1,1,,103163813,4583,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2758,1079949,1,1,,103163813,4583,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2759,1083455,1,2,,103163813,4583,Inactive,,,,,Antifungal activity against Candida albicans ATCC 10231 by microdilution method,Other,,
2760,1083456,1,2,,103163813,4583,Inactive,,,,,Antifungal activity against Candida parapsilosis ATCC 22019 by microdilution method,Other,,
2761,1083457,1,2,,103163813,4583,Inactive,,,,,Antibacterial activity against ceftriaxon-resistant Bacillus subtilis by microdilution method,Other,,
2762,1083458,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against cephalosporins and beta-lactam-resistant Enterococcus faecalis by microdilution method,Other,,
2763,1083459,1,2,,103163813,4583,Inactive,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 by microdilution method,Other,,
2764,1083460,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 by microdilution method,Other,,
2765,1083461,1,2,,103163813,4583,Unspecified,,,,,"Antibacterial activity against oxacillin, gentamicin, aztreonam, trimethoprim-sulfamethoxazole-resistant Staphylococcus aureus by microdilution method",Other,,
2766,1083462,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 by microdilution method,Other,,
2767,1083463,1,2,,103163813,4583,Unspecified,,,,,"Antibacterial activity against trimethoprim-sulfamethoxazole, cefepime-resistant Acinetobacter baumannii by microdilution method",Other,,
2768,1083464,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Acinetobacter baumannii RSKK 02026 by microdilution method,Other,,
2769,1083465,1,2,,103163813,4583,Unspecified,,,,,"Antibacterial activity against ESbetaL positive trimethoprim-sulfamethoxazole, amoxicillin clavulonat, cefriaxon, cephepim, aztreonam-resistant Klebsiella pneumoniae by microdilution method",Other,,
2770,1083466,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae RSKK 574 by microdilution method,Other,,
2771,1083467,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Proteus mirabilis ATCC 7002 by microdilution method,Other,,
2772,1083468,1,2,,103163813,4583,Unspecified,,,,,"Antibacterial activity against ESbetaL positive rimethoprim-sulfamethoxazole, cefepime, tazobactam-resistant Proteus mirabilis by microdilution method",Other,,
2773,1083469,1,2,,103163813,4583,Unspecified,,,,,"Antibacterial activity against trimethoprim-sulfamethoxazole, tazobactam-resistant Pseudomonas aeruginosa by microdilution method",Other,,
2774,1083470,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 10145 by microdilution method,Other,,
2775,1083471,1,2,,103163813,4583,Unspecified,,,,,"Antibacterial activity against ESbetaL positive trimethoprim-sulfamethoxazole, cefepime, tazobactam-resistant Escherichia coli isolate by microdilution method",Other,,
2776,1083472,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 35218 by microdilution method,Other,,
2777,1084878,1,2,,103163813,4583,Active,,,,,Antitubercular activity against multidrug-resistant Mycobacterium tuberculosis by NCCLS agar dilution method,Other,,
2778,1084879,1,2,,103163813,4583,Active,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv by NCCLS agar dilution method,Other,,
2779,1084880,1,2,,103163813,4583,Unspecified,,,155.3,CC50,Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 72 hr by MTT assay,Confirmatory,,
2780,1085910,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus at 100 ug/ml after 24 hr by paper disk diffusion method,Other,,
2781,1085911,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus at 50 ug/ml after 24 hr by paper disk diffusion method,Other,,
2782,1085942,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Streptomyces albus NCIM 2178 at 5 ug/disk after 24 hr by disk diffusion method,Other,,
2783,1085945,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus NCIM 2155 at 5 ug/disk after 24 hr by disk diffusion method,Other,,
2784,1085948,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis NCIM 2063 at 5 ug/disk after 24 hr by disk diffusion method,Other,,
2785,1085951,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterobacter aerogenes NCIM 2239 at 5 ug/disk after 24 hr by disk diffusion method,Other,,
2786,1085954,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa NCIM 2200 at 5 ug/disk after 24 hr by disk diffusion method,Other,,
2787,1085957,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli NCIM 2065 at 5 ug/disk after 24 hr by disk diffusion method,Other,,
2788,1086187,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27953 after 16 to 18 hr by NCCLS broth macrodilution method,Other,,
2789,1086188,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 after 16 to 18 hr by NCCLS broth macrodilution method,Other,,
2790,1086189,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 29213 after 16 to 18 hr by NCCLS broth macrodilution method,Other,,
2791,1087044,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus after 24 hr by CLSI broth microdilution method,Other,,
2792,1087045,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against ceftriaxon-resistant Bacillus subtilis after 24 hr by CLSI broth microdilution method,Other,,
2793,1087046,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hr by CLSI broth microdilution method,Other,,
2794,1087047,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hr by CLSI broth microdilution method,Other,,
2795,1087048,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli producing extended spectrum beta lactamase enzyme after 24 hr by CLSI broth microdilution method,Other,,
2796,1087049,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa after 24 hr by CLSI broth microdilution method,Other,,
2797,1087050,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 after 24 hr by CLSI broth microdilution method,Other,,
2798,1087051,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 25853 after 24 hr by CLSI broth microdilution method,Other,,
2799,1087052,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae RSKK 574 after 24 hr by CLSI broth microdilution method,Other,,
2800,1087053,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae producing extended spectrum beta lactamase enzyme after 24 hr by CLSI broth microdilution method,Other,,
2801,1094986,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas oleovorans MTCC 617 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2802,1094987,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa MTCC 741 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2803,1094988,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis MTCC 439 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2804,1094989,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae MTCC 109 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2805,1094990,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli MTCC 1652 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2806,1094991,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Streptococcus pyogenes MTCC 442 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2807,1094992,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus pumilus MTCC 1640 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2808,1094993,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus MTCC 430 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2809,1094994,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis MTCC 2397 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2810,1094995,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus MTCC 737 at 10 ug/well after 24 hr by agar well diffusion method,Other,,
2811,1096794,1,2,,103163813,4583,Unspecified,,,,,Antifungal activity against Candida albicans at 100 ug/ml after 48 hr by two-fold serial dilution method,Other,,
2812,1096795,1,2,,103163813,4583,Unspecified,,,,,Antifungal activity against Candida albicans at 50 ug/ml after 48 hr by two-fold serial dilution method,Other,,
2813,1096796,1,2,,103163813,4583,Unspecified,,,,,Antifungal activity against Candida albicans at 25 ug/ml after 48 hr by two-fold serial dilution method,Other,,
2814,1096797,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa after 24 hr by two-fold serial dilution method,Other,,
2815,1096798,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae after 24 hr by two-fold serial dilution method,Other,,
2816,1096799,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli after 24 hr by two-fold serial dilution method,Other,,
2817,1096800,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis after 24 hr by two-fold serial dilution method,Other,,
2818,1096801,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis after 24 hr by two-fold serial dilution method,Other,,
2819,1096802,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus after 24 hr by two-fold serial dilution method,Other,,
2820,1106486,1,2,,103163813,4583,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis,Other,,
2821,1107102,1,2,,103163813,4583,Inconclusive,,,,IC50,Antiviral activity against Human immunodeficiency virus,Confirmatory,,
2822,1107103,1,2,,103163813,4583,Inconclusive,,,,,Antiviral activity against Human immunodeficiency virus assessed as protection against virus-induced cytopathogenicity,Other,,
2823,1107104,1,2,,103163813,4583,Unspecified,,,,,Antifungal activity against Pichia kudriavzevii G03,Other,,
2824,1107105,1,2,,103163813,4583,Unspecified,,,,,Antifungal activity against Candida glabrata H05,Other,,
2825,1107106,1,2,,103163813,4583,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 10231,Other,,
2826,1107107,1,2,,103163813,4583,Unspecified,,,,,Antifungal activity against Candida albicans,Other,,
2827,1107108,1,2,,103163813,4583,Unspecified,,,,,Antifungal activity against Aspergillus fumigatus,Other,,
2828,1107109,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli 2231,Other,,
2829,1107110,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus 209P,Other,,
2830,1113446,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Salmonella enterica subsp. enterica serovar Typhi assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm),Other,,
2831,1113447,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Proteus vulgaris assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm),Other,,
2832,1113448,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm),Other,,
2833,1113449,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm),Other,,
2834,1113450,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm),Other,,
2835,1113451,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus assessed as growth inhibition at 50 ug/ml by cup-plate method (Rvb = 8 to 10 mm),Other,,
2836,1114128,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa cloinical isolate after 24 hr by two-fold serial dilution method,Other,,
2837,1114129,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hr by two-fold serial dilution method,Other,,
2838,1114130,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli clinical isolate expressing extended spectrum beta-lactamase after 24 hr by two-fold serial dilution method,Other,,
2839,1114131,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 after 24 hr by two-fold serial dilution method,Other,,
2840,1114132,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis clinical isolate after 24 hr by two-fold serial dilution method,Other,,
2841,1114133,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 hr by two-fold serial dilution method,Other,,
2842,1114134,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate after 24 hr by two-fold serial dilution method,Other,,
2843,1114135,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hr by two-fold serial dilution method,Other,,
2844,1115493,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 11774 assessed as growth inhibition at 5 ug/disk after 24 hr by Kirby-Bauer disk diffusion method,Other,,
2845,1115508,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 10662 assessed as growth inhibition at 5 ug/disk after 24 hr by Kirby-Bauer disk diffusion method,Other,,
2846,1115509,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae ATCC 33495 assessed as growth inhibition at 5 ug/disk after 24 hr by Kirby-Bauer disk diffusion method,Other,,
2847,1115510,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 10536 assessed as growth inhibition at 5 ug/disk after 24 hr by Kirby-Bauer disk diffusion method,Other,,
2848,1115511,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC BAA 1026 assessed as growth inhibition at 5 ug/disk after 24 hr by Kirby-Bauer disk diffusion method,Other,,
2849,1115512,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus ATCC 10876 assessed as growth inhibition at 5 ug/disk after 24 hr by Kirby-Bauer disk diffusion method,Other,,
2850,1115893,1,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis ATCC 6633 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2851,1115894,1,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 25923 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2852,1115895,1,2,,103163813,4583,Unspecified,,,,,Antimicrobial activity against Escherichia coli ATCC 25922 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2853,1115896,1,2,,103163813,4583,Inactive,,,,,Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2854,1116920,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Proteus vulgaris NCIM 2027 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2855,1116921,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Proteus mirabilis NCIM 2241 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2856,1116922,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli NCIM 2065 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2857,1116923,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa NCIM 2036 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2858,1116924,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus NCIM 2156 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2859,1116925,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis NCIM 2063 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2860,1116926,1,2,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus NCIM 2079 assessed as growth inhibition after 24 hr by NCCLS broth dilution method,Other,,
2861,1117298,1,2,,170465035,4583,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2862,1117301,1,2,,170465035,4583,Inactive,,,11.2202,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
2863,1117302,1,2,,170465035,4583,Inactive,,,3.9811,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
2864,1117303,1,2,,170465035,4583,Inactive,,,12.59,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
2865,1117304,1,2,,170465035,4583,Inactive,,,10.0,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2866,1117305,1,2,,170465035,4583,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2867,1117310,1,1,,170465035,4583,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2868,1117311,1,1,,170465035,4583,Inactive,,,11.2202,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
2869,1117312,1,1,,170465035,4583,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2870,1117314,1,1,,170465035,4583,Inactive,,,10.0,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2871,1117315,1,1,,170465035,4583,Inactive,,,3.98107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
2872,1117318,1,1,,170465035,4583,Inactive,,,12.5893,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
2873,1117326,1,1,,170465035,4583,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2874,1117329,1,1,,170465035,4583,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2875,1117336,1,1,,170465035,4583,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2876,1117340,1,1,,170465035,4583,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2877,1117341,1,1,,170465035,4583,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2878,1117342,1,1,,170465035,4583,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2879,1117343,1,1,,170465035,4583,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2880,1117346,1,1,,170465035,4583,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2881,1126742,1,1,,103163813,4583,Active,,,,,Antibacterial activity against 1 ug/ml Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay,Other,24684842.0,
2882,1126743,1,1,,103163813,4583,Active,,,,,Antibacterial activity against 0.5 ug/ml Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 7 days by microtiter plate assay,Other,24684842.0,
2883,1129167,1,1,,103163813,4583,Unspecified,,,,,Permeability of the compound by PAMPA,Other,24592867.0,
2884,1138550,1,1,,103163813,4583,Active,,,,,"In vivo antibacterial activity against Staphylococcus aureus in New zealand rabbit keratitis model assessed as suppression of conjuctival congestion, conjuctival chemosis, infiltration, operative ulcer area and depth at 3 mg/ml administered topically every 4 hrs for four doses every day for 10 days starting 24 hrs post-infection by slit lamp biomicroscopy",Other,24588790.0,
2885,1143263,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis Beijing (E-47/94) assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
2886,1143264,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
2887,1143265,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis D-211 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
2888,1143266,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against streptomycin-resistant Mycobacterium tuberculosis 136570 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
2889,1143267,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis 912253 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
2890,1143268,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against rifampin-resistant Mycobacterium tuberculosis 19000 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
2891,1143269,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against ethambutol-resistant Mycobacterium tuberculosis 17003 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
2892,1143270,1,1,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against ofloxacin-resistant Mycobacterium tuberculosis 12119 assessed as growth inhibition after 2 to 3 weeks by turbidometry,Other,24818517.0,
2893,1152758,1,1,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against wild-type Mycobacterium tuberculosis H37Rv ATCC 27294 after 16 to 18 days by BACTEC 7H12B microdilution method,Other,24809953.0,
2894,1152776,1,1,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against 2-oxo-1-(2-(4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino)piperidin-1-yl)ethyl)-1,2-dihydroquinoline-7-carbonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA A74V mutant",Other,24809953.0,
2895,1152777,1,1,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against 5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA D89N mutant",Other,24809953.0,
2896,1152778,1,1,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against moxifloxacin-resistant Mycobacterium tuberculosis harboring DNA gyraseA G88N mutant,Other,24809953.0,
2897,1152780,1,1,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against Mycobacterium tuberculosis clinical isolates after 2 to 4 weeks by BACTEC 460 radiometric assay,Other,24809953.0,
2898,1152781,1,1,,103163813,4583,Unspecified,,,,,"Ratio of MIC for 5-(((3S,4R)-3-Fluoro-1-(2-(7-methoxy-2-oxo-1,5-naphthyridin-1(2H)-yl)ethyl)piperidin-4-ylamino)methyl)-2-methylnicotinonitrile-resistant Mycobacterium tuberculosis harboring DNA gyraseA D89N mutant to MIC for wild-type Mycobacterium tuberculosis H37Rv ATCC 27294",Other,24809953.0,
2899,1159386,1,2,,103163813,4583,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
2900,1159387,1,2,,103163813,4583,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
2901,1159399,1,2,,103163813,4583,Unspecified,,,,,ASTRAZENECA: Most acidic pKa value (pKa A1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Acids: <= 11.,Other,,
2902,1159509,1,1,,170465035,4583,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2903,1159515,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2904,1159516,1,1,,170465035,4583,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2905,1159517,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2906,1159518,1,1,,170465035,4583,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2907,1159519,1,1,,170465035,4583,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2908,1159520,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2909,1159521,1,1,,170465035,4583,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2910,1159523,1,1,,170465035,4583,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2911,1159524,1,1,,56423109,4583,Inconclusive,,,0.3162,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2912,1159524,1,1,,124880995,4583,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2913,1159524,1,1,,124880996,4583,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2914,1159525,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2915,1159526,1,1,,170465035,4583,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2916,1159527,1,1,,170465035,4583,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2917,1159528,1,1,,170465035,4583,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2918,1159529,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2919,1159531,1,1,,170465035,4583,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2920,1159550,3,1,,252402085,4583,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
2921,1159551,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2922,1159552,1,1,,170465035,4583,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2923,1159553,2,1,,170465035,4583,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2924,1159555,1,1,,170465035,4583,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2925,1159580,2,1,,268734871,4583,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2926,1159580,2,1,,273002927,4583,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2927,1159583,2,1,,178125532,4583,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
2928,1159606,1,1,,56423109,4583,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2929,1159607,2,1,,312309657,4583,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2930,1159614,1,2,,170465035,4583,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
2931,1159620,1,1,,103163813,4583,Active,,,,,Summary of drug indications.,Other,,
2932,1161578,1,1,,103163813,4583,Unspecified,,,,,Permeability of the compound by PAMPA-BBB assay,Other,25156301.0,
2933,1163978,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution assay,Other,25218910.0,
2934,1163979,1,1,,103163813,4583,Inconclusive,,,,,Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold serial dilution assay in presence of 8 mg/mL piperine efflux pump inhibitor,Other,25218910.0,
2935,1163980,1,1,,103163813,4583,Active,,,,,"Antimycobacterial activity against isoniazid, rifampicin, ofloxacin and kanamycin-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 clinical isolate after 28 days by two-fold serial dilution assay in presence of 8 mg/mL piperine efflux pump inhibitor",Other,25218910.0,
2936,1163981,1,1,,103163813,4583,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells at 100 uM after 72 hrs by MTT assay,Other,25218910.0,
2937,1163982,1,1,,103163813,4583,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells at 50 uM after 72 hrs by MTT assay,Other,25218910.0,
2938,1167550,1,1,,103163813,4583,Unspecified,,,,,Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay,Other,25282266.0,
2939,1167605,1,1,,103163813,4583,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by two-fold agar dilution method,Other,25282650.0,
2940,1167608,1,1,,103163813,4583,Active,,,,,Antimicrobial activity against extensively drug-resistant Mycobacterium tuberculosis XDR-TB after 28 days by two-fold agar dilution method,Other,25282650.0,
2941,1171213,1,1,,103163813,4583,Active,,,,,Antibacterial activity against tolC-deficient Escherichia coli,Other,25402200.0,
2942,1171215,1,1,,103163813,4583,Active,,,,,Antibacterial activity against wild-type Escherichia coli,Other,25402200.0,
2943,1171217,1,1,,103163813,4583,Active,,,,,Antibacterial activity against wild-type Pseudomonas aeruginosa,Other,25402200.0,
2944,1171218,1,1,,103163813,4583,Active,,,,,Antibacterial activity against MeXABCDXY-deficient Pseudomonas aeruginosa,Other,25402200.0,
2945,1171223,1,1,,103163813,4583,Unspecified,,,,,Ratio of MIC for wild-type Escherichia coli to MIC for tolC-deficient Escherichia coli,Other,25402200.0,
2946,1171224,1,1,,103163813,4583,Unspecified,,,,,Ratio of MIC for wild-type Pseudomonas aeruginosa to MIC for MeXABCDXY-deficient Pseudomonas aeruginosa,Other,25402200.0,
2947,1172969,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli TG1,Other,25453797.0,
2948,1173449,1,1,,103163813,4583,Unspecified,,,,,Effective permeability of the compound by PAMPA assay,Other,25454267.0,
2949,1173783,1,2,,103163813,4583,Inconclusive,152032507.0,,,IC50,Inhibition of purified Mycobacterium smegmatis GyrB at 50 to 100 uM after 100 mins by ATPase assay,Confirmatory,25456076.0,
2950,1173784,1,1,,103163813,4583,Inconclusive,,,,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase using relaxed pBR322 as substrate after 30 mins by supercoiling assay,Confirmatory,25456076.0,
2951,1173785,1,1,,103163813,4583,Active,,,,,Antimicrobial activity against Mycobacterium tuberculosis H37Rv after 7 days by MABA assay,Other,25456076.0,
2952,1173786,1,1,,103163813,4583,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by MTT assay,Other,25456076.0,
2953,1174106,1,1,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol, streptomycin, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
2954,1174107,1,1,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, streptomycin, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
2955,1174108,1,1,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol, ofloxacin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
2956,1174109,1,1,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol, streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
2957,1174110,1,1,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
2958,1174111,1,1,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin, ethambutol-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
2959,1174112,1,1,,103163813,4583,Unspecified,,,,,"Antimycobacterial activity against isoniazid, rifampin-resistant Mycobacterium tuberculosis after 7 days by microplate Alamar blue assay",Other,25462220.0,
2960,1177574,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by microdilution method,Other,25098388.0,
2961,1177575,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 hrs by microdilution method,Other,25098388.0,
2962,1177576,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Micrococcus luteus ATCC 9341 after 18 hrs by microdilution method,Other,25098388.0,
2963,1177577,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 hrs by microdilution method,Other,25098388.0,
2964,1183278,1,1,,103163813,4583,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25016233.0,
2965,1188153,1,2,,103163813,4583,Inconclusive,152032507.0,,,IC50,Inhibition of 6-His-tagged Mycobacterium smegmatis GyrB expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 100 mins in presence of ATP by malachite green dye based ATP assay,Confirmatory,25129171.0,
2966,1188154,1,1,,103163813,4583,Inconclusive,,,,IC50,Inhibition of Mycobacterium tuberculosis DNA gyrase supercoiling activity using relaxed pBR322 substrate incubated for 30 mins by ethidium bromide staining method,Confirmatory,25129171.0,
2967,1188155,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv after 7 days by microplate alamar blue assay method,Other,25129171.0,
2968,1188156,1,1,,103163813,4583,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell viability at 100 uM after 48 hrs by MTT assay,Other,25129171.0,
2969,1193920,1,1,,103163813,4583,Inconclusive,,,,IC50,Inhibition of Mycobacterium tuberculosis DNA GyrA/B heterotetramer assessed as inhibition of pBR322 supercoiling after 30 mins by gel electrophoresis,Confirmatory,25766629.0,
2970,1193921,1,2,,103163813,4583,Inconclusive,152032507.0,,,IC50,Inhibition of Mycobacterium smegmatis DNA GyrB domain assessed as inhibition of inorganic phosphate release after 100 mins at room temperature by ATPase assay,Confirmatory,25766629.0,
2971,1193922,1,1,,103163813,4583,Active,,,,,Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis H37Rv ATCC 27294 after 28 days by agar dilution method,Other,25766629.0,
2972,1193923,1,1,,103163813,4583,Inconclusive,,,,,Cytotoxicity against mouse RAW264.7 cells at 100 uM after 48 hrs by MTT assay,Other,25766629.0,
2973,1201746,1,1,,103163813,4583,Unspecified,,,,,Permeability of the compound after 16 hrs by PAMPA,Other,25812965.0,
2974,1201747,1,1,,103163813,4583,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25812965.0,
2975,1224517,1,1,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 234/2005 after 7 days by micromethod,Other,24927053.0,
2976,1224519,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 9449/2007 after 7 days by micromethod,Other,24927053.0,
2977,1224521,1,1,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 8666/2010 after 7 days by micromethod,Other,24927053.0,
2978,1224523,1,1,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 1 after 7 days by micromethod,Other,24927053.0,
2979,1224525,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 4 after 7 days by micromethod,Other,24927053.0,
2980,1224527,1,1,,103163813,4583,Active,,,,,Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis Praha 131 after 7 days by micromethod,Other,24927053.0,
2981,1224818,1,1,,312345028,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
2982,1224819,1,1,,312345028,4583,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
2983,1224820,1,1,,312345028,4583,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
2984,1224821,1,1,,312345028,4583,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
2985,1224822,1,1,,312345028,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
2986,1224823,1,1,,312345028,4583,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
2987,1224824,1,1,,174006255,4583,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
2988,1224825,1,1,,174006255,4583,Inactive,,,2.6351,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
2989,1224834,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2990,1224835,1,1,,170465035,4583,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2991,1224836,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2992,1224837,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2993,1224838,1,1,,170465035,4583,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2994,1224839,1,1,,170465035,4583,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2995,1224840,3,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2996,1224841,3,1,,170465035,4583,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2997,1224842,3,1,,170465035,4583,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2998,1224843,1,1,,170465035,4583,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2999,1224844,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3000,1224845,1,1,,170465035,4583,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3001,1224846,1,1,,170465035,4583,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3002,1224847,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3003,1224848,3,1,,170465035,4583,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3004,1224849,3,1,,170465035,4583,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3005,1224857,2,1,,170465035,4583,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3006,1224857,2,1,,174006255,4583,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3007,1224857,2,1,,312345028,4583,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3008,1224859,2,1,,90341488,4583,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3009,1224859,2,1,,170465035,4583,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3010,1224859,2,1,,174006255,4583,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3011,1224863,1,1,,176484424,4583,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3012,1224863,1,1,,176485002,4583,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3013,1224863,1,1,,316920229,4583,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3014,1224864,1,2,,316934657,4583,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
3015,1224865,1,2,,56423109,4583,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3016,1224867,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3017,1224868,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3018,1224869,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3019,1224870,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3020,1224871,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3021,1224872,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3022,1224873,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3023,1224874,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3024,1224875,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3025,1224876,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3026,1224877,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3027,1224878,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3028,1224879,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3029,1224880,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3030,1224881,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3031,1224882,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3032,1224883,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3033,1224884,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3034,1224885,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3035,1224886,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3036,1224887,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3037,1224888,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3038,1224889,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3039,1224890,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3040,1224892,1,1,,170465035,4583,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3041,1224893,1,1,,170465035,4583,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3042,1224894,1,1,,170465035,4583,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3043,1224895,1,1,,170465035,4583,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3044,1224896,1,1,,170465035,4583,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3045,1224905,2,1,,92309103,4583,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3046,1224905,2,1,,92309103,4583,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3047,1224905,2,1,,121361554,4583,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3048,1224905,2,1,,121361554,4583,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3049,1227981,1,1,,103163813,4583,Unspecified,,,,,Antimycobacterial activity against GFP expressing Mycobacterium tuberculosis H37Ra assessed as microbial growth inhibition incubated at 37 degC for 7 days by fluorescence based assay,Other,25734623.0,
3050,1230205,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Bacillus cereus CIP 6624 after 18 hrs by agar dilution method,Other,26034885.0,
3051,1230206,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Bacillus cereus N190 after 18 hrs by agar dilution method,Other,26034885.0,
3052,1230207,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Bacillus cereus N258 after 18 hrs by agar dilution method,Other,26034885.0,
3053,1230208,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Bacillus cereus N349 after 18 hrs by agar dilution method,Other,26034885.0,
3054,1230209,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 hrs by agar dilution method,Other,26034885.0,
3055,1230210,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Corynebacterium striatum N840 after 18 hrs by agar dilution method,Other,26034885.0,
3056,1230211,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus avium CIP 104053 after 18 hrs by agar dilution method,Other,26034885.0,
3057,1230212,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus casseliflavus N487 after 18 hrs by agar dilution method,Other,26034885.0,
3058,1230213,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus casseliflavus CIP 103018 after 18 hrs by agar dilution method,Other,26034885.0,
3059,1230214,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus durans CIP 104999 after 18 hrs by agar dilution method,Other,26034885.0,
3060,1230215,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus faecalis CIP 103214 after 18 hrs by agar dilution method,Other,26034885.0,
3061,1230216,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus faecalis CIP 104676 after 18 hrs by agar dilution method,Other,26034885.0,
3062,1230217,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus faecalis N491 after 18 hrs by agar dilution method,Other,26034885.0,
3063,1230218,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus faecalis N518 after 18 hrs by agar dilution method,Other,26034885.0,
3064,1230219,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis N520 after 18 hrs by agar dilution method,Other,26034885.0,
3065,1230220,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus faecium CIP 103014 after 18 hrs by agar dilution method,Other,26034885.0,
3066,1230221,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecium CIP 107387 after 18 hrs by agar dilution method,Other,26034885.0,
3067,1230222,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus faecium N490 after 18 hrs by agar dilution method,Other,26034885.0,
3068,1230223,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecium N507 after 18 hrs by agar dilution method,Other,26034885.0,
3069,1230224,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecium N733 after 18 hrs by agar dilution method,Other,26034885.0,
3070,1230225,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Enterococcus faecium N823 after 18 hrs by agar dilution method,Other,26034885.0,
3071,1230226,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus gallinarum CIP 105985 after 18 hrs by agar dilution method,Other,26034885.0,
3072,1230227,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus gallinarum N489 after 18 hrs by agar dilution method,Other,26034885.0,
3073,1230228,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus gallinarum N492 after 18 hrs by agar dilution method,Other,26034885.0,
3074,1230229,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Enterococcus hirae CIP 5855 after 18 hrs by agar dilution method,Other,26034885.0,
3075,1230230,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Listeria innocua E044 after 18 hrs by agar dilution method,Other,26034885.0,
3076,1230231,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Listeria monocytogenes CIP 103575 after 18 hrs by agar dilution method,Other,26034885.0,
3077,1230232,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Listeria monocytogenes N783 after 18 hrs by agar dilution method,Other,26034885.0,
3078,1230233,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Listeria monocytogenes N836 after 18 hrs by agar dilution method,Other,26034885.0,
3079,1230234,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Listeria monocytogenes N851 after 18 hrs by agar dilution method,Other,26034885.0,
3080,1230235,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by agar dilution method,Other,26034885.0,
3081,1230236,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus aureus ATCC 9144 oxford after 18 hrs by agar dilution method,Other,26034885.0,
3082,1230237,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus aureus CIP 483 after 18 hrs by agar dilution method,Other,26034885.0,
3083,1230238,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus aureus CIP 53154 after 18 hrs by agar dilution method,Other,26034885.0,
3084,1230239,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus aureus CIP 53156 after 18 hrs by agar dilution method,Other,26034885.0,
3085,1230240,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus aureus CIP 5710 after 18 hrs by agar dilution method,Other,26034885.0,
3086,1230241,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus aureus CIP 7625 after 18 hrs by agar dilution method,Other,26034885.0,
3087,1230242,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus CRBIP 2121 after 18 hrs by agar dilution method,Other,26034885.0,
3088,1230243,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus epidermidis CIP 53124 after 18 hrs by agar dilution method,Other,26034885.0,
3089,1230244,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus haemolyticus CIP 8156 after 18 hrs by agar dilution method,Other,26034885.0,
3090,1230245,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus intermedius N987 after 18 hrs by agar dilution method,Other,26034885.0,
3091,1230246,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus lugdunensis ATCC 43809 after 18 hrs by agar dilution method,Other,26034885.0,
3092,1230247,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus saprophyticus CIP 76125 after 18 hrs by agar dilution method,Other,26034885.0,
3093,1230248,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus saprophyticus E260 after 18 hrs by agar dilution method,Other,26034885.0,
3094,1230249,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Staphylococcus sciuri N993 after 18 hrs by agar dilution method,Other,26034885.0,
3095,1230250,1,1,,103163813,4583,Active,,,,,Antibacterial activity against Streptococcus agalactiae CIP 103227 after 18 hrs by agar dilution method,Other,26034885.0,
3096,1231418,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Bacillus cereus ATCC 14579 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method,Other,25891984.0,
3097,1231419,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method,Other,25891984.0,
3098,1231420,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 35218 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method,Other,25891984.0,
3099,1231421,1,1,,103163813,4583,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition at 5 ug after 24 hrs by disc agar diffusion method,Other,25891984.0,
3100,1259241,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3101,1259242,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3102,1259243,1,1,,170465035,4583,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3103,1259244,1,1,,170465035,4583,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3104,1259247,1,1,,170465035,4583,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3105,1259248,1,1,,170465035,4583,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3106,1259252,1,1,,174006255,4583,Inconclusive,169655958.0,,20.930999999999997,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3107,1259253,1,1,,174006255,4583,Inconclusive,169655958.0,,20.930999999999997,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3108,1259255,1,1,,174006255,4583,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3109,1259256,1,1,,174006255,4583,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3110,1259309,1,1,,178125532,4583,Active,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3111,1259310,1,1,,104169964,4583,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3112,1259310,1,1,,321942383,4583,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3113,1259310,1,1,,332950316,4583,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3114,1259310,1,1,,332950373,4583,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3115,1259311,1,1,,178125532,4583,Active,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3116,1259313,1,1,,56423109,4583,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3117,1259318,1,1,,11533038,4583,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3118,1259325,1,2,,336954396,4583,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3119,1259344,1,1,,144204254,4583,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3120,1259354,1,1,,348405922,4583,Inconclusive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
3121,1259355,1,1,,144204254,4583,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3122,1259356,1,1,,144204254,4583,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3123,1259364,1,1,,170465035,4583,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3124,1259365,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3125,1259366,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3126,1259367,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3127,1259368,1,1,,170465035,4583,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3128,1259369,1,1,,170465035,4583,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3129,1259370,2,2,,124637052,4583,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3130,1259370,2,2,,124637052,4583,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3131,1259370,2,2,,124637052,4583,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3132,1259377,1,1,,170465035,4583,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3133,1259378,1,1,,170465035,4583,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3134,1259379,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3135,1259380,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3136,1259381,1,1,,170465035,4583,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3137,1259382,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3138,1259383,1,1,,170465035,4583,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3139,1259384,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3140,1259385,1,1,,170465035,4583,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3141,1259386,1,1,,170465035,4583,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3142,1259387,1,1,,170465035,4583,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3143,1259388,1,1,,170465035,4583,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3144,1259389,1,1,,124637052,4583,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3145,1259390,1,1,,170465035,4583,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3146,1259391,1,1,,170465035,4583,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3147,1259392,1,1,,170465035,4583,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3148,1259393,1,1,,170465035,4583,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3149,1259394,1,1,,170465035,4583,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3150,1259395,1,1,,170465035,4583,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3151,1259396,1,1,,170465035,4583,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3152,1259400,1,1,,170465035,4583,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3153,1259401,1,1,,170465035,4583,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3154,1259402,1,1,,170465035,4583,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3155,1259403,1,1,,170465035,4583,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3156,1259404,1,1,,170465035,4583,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3157,1259406,1,1,,363920309,4583,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3158,1259406,1,1,1.0,363920309,4583,Inactive,26638650.0,3778.0,0.018342599999999997,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3159,1259406,1,1,2.0,363920309,4583,Inactive,4758626.0,3779.0,-0.00500707,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3160,1259406,1,1,3.0,363920309,4583,Inactive,5031823.0,10242.0,0.0472476,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3161,1259406,1,1,4.0,363920309,4583,Inactive,26051275.0,27345.0,0.00670131,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3162,1259406,1,1,5.0,363920309,4583,Inactive,160410009.0,389816.0,0.00974401,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3163,1259406,1,1,6.0,363920309,4583,Inactive,26638650.0,3778.0,0.0249083,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3164,1259406,1,1,7.0,363920309,4583,Inactive,4758626.0,3779.0,-0.0199984,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3165,1259406,1,1,8.0,363920309,4583,Inactive,5031823.0,10242.0,-0.030048099999999998,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3166,1259406,1,1,9.0,363920309,4583,Inactive,26051275.0,27345.0,0.011155799999999999,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3167,1259406,1,1,10.0,363920309,4583,Inactive,5031823.0,10242.0,0.030794,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
3168,1259407,1,1,,363903183,4583,Inactive,,,,,CCRIS mutagenicity studies,Other,,
3169,1259413,1,2,,104169964,4583,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
3170,1259415,1,1,,11533038,4583,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3171,1259416,1,2,,11533038,4583,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3172,1259416,1,2,,340082230,4583,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3173,1259416,1,2,,375177881,4583,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3174,1259421,1,1,,340082230,4583,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3175,1259421,1,1,,375177881,4583,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3176,1259423,1,2,,354775491,4583,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3177,1259423,1,2,,354797364,4583,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3178,1259423,1,2,,354925998,4583,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3179,1259423,1,2,,354970461,4583,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
